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In clinical trials, we often compare two treatment groups using repeated binary measures over 
time. In such trials, we may encounter missing observations, adverse side effects, or non-
responsiveness to therapy which for ethical reasons, may result in increased medical intervention 
beyond the protocol therapy. We developed a family of statistical tests based on the Wilcoxon 
statistic which orders the vectors of repeated binary observations and events where the ordering 
is determined by ‘clinical relevance’. For some scenarios, clinically meaningful ordering of the 
vectors may be defined by a natural algorithm, while for other scenarios the ordering is obtained 
from a group of clinicians. We present the statistical development of the proposed method, 
effects of the variability of rankings among clinicians, examples of the application of the 
proposed method using data from a clinical trial on otitis media, and simulation studies 
comparing the statistical power of the proposed method to more traditional methods of analysis. 
Our simulation studies indicate that the proposed method is competitive with and, for some 
scenarios, is preferable to the traditional methods. Although the proposed method is not 
applicable to every situation, we believe that for some diseases and scenarios, this simple method 
is noteworthy in the sense that it can be adjusted to extremely complex situations if vectors can 
be hierarchically ordered in a reasonable fashion, it can be focused on alternatives that have high 
clinical relevance, and it can be readily adapted to accommodate non-protocol ‘outcomes’ and 
A WILCOXON-TYPE STATISTIC FOR REPEATED BINARY MEASURES WITH 
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Okan Umit Elci, PhD 
University of Pittsburgh, 2010 
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missing data. The public health relevance of this study is that clinically meaningful results can be 
targeted in clinical trials.  
 
Keywords: Longitudinal data, binary outcomes, Wilcoxon test statistic, ordering, and natural 
algorithm.
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1.0  INTRODUCTION 
Longitudinal studies where measurements are taken repeatedly on the same subjects throughout a 
period of time are commonly used in the health sciences, biological, biomedical, and 
epidemiological areas. Since repeated observations are taken from the same subject, they are 
expected to be correlated with each other over time. These longitudinal serial correlations among 
the measurements made on the same subject should be taken into account in the analysis of the 
data. In such studies, the response at each point in time may be continuous, categorical, or binary 
(e.g., yes/no, success/failure, positive/negative, and presence/absence). In particular, binary 
outcomes are sometimes collected in clinical trials when the purpose is to examine the effect of a 
treatment over time. In some studies, continuous outcomes are dichotomized by a threshold 
value and methods for analyzing binary outcomes are applied. In this work, our main interest 
will be dichotomous outcomes collected in a study with repeated measures over time. As 
motivating examples, we use a group of clinical trials that have been conducted to evaluate the 
efficacy of treatment for otitis media. 
Numerous statistical techniques have been developed for analysis of longitudinal binary 
data. One of the earlier methods used to analyze longitudinal binary data is to sum the repeated 
binary observations for each individual over time and to compare the proportion of responses 
between treatment groups using t-test. Random effects models (mixed effects logistic regression 
models) (Molenberghs and Verbeke 2005) and marginal models (logistic regression models 
using generalized estimating equations (GEE)) (Liang and Zeger 1986) are two commonly used 
alternatives in modeling longitudinal binary data. The former permits heterogeneity across the 
subjects, so the regression coefficients are different between subjects. Thus, random effects 
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models are called subject-specific models. The random intercept logistic regression model is the 
simplest form of this modeling for analysis of longitudinal binary measurements. Marginal 
models are relevant methods for analyzing repeated binary measures, when the main objective of 
a study is to examine the effect of covariates on the population mean. These models assume that 
the regression coefficients are the same for all of the subjects and regression coefficients are 
interpreted for the population level not at the individual level. Hence, they are called population-
averaged models. A logistic regression model using GEE, which is regarded as a marginal 
model, is the longitudinal extension of a logistic regression model for binary responses. Random 
effects models and marginal models consider correlation among the observations obtained from 
the same subjects. 
In some clinical trials, measurements from subjects are collected at specified time points 
for each treatment group (e.g. drug and placebo) during the treatment period and the main 
interest is to examine the efficacy of a new treatment over placebo. Data measured at the last 
time point may be used for primary efficacy assessment.  For example, proportions of positive 
responses to treatment groups based on binary outcomes are compared to evaluate the efficacy of 
a new treatment. In this situation, the comparison is based on the measurements at the last time 
point. Standard statistical methods such as, Fisher’s exact test, chi-squared test of independence, 
t-test, and binary logistic regression can be used to compare two treatment groups (Ali and 
Talukder 2005).   
Interest may be focused primarily on understanding the time trend of a treatment, such as 
the effect of a drug during the early or late stage of the treatment.  Another interest is to establish 
the overall treatment efficacy rather than a time trend of a regimen. A binary logistic regression 
model using GEE or a logistic regression model with random effects, mentioned above, are two 
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approaches to evaluate the time trend and the overall efficacy of a treatment. These approaches 
use the entire longitudinal data collected at each time point.  
Methods using comparisons between pairs of subjects and ranking scores have been used 
to evaluate the differences between two treatment groups. As proposed by Gehan (1965), data 
from pairs of subjects are compared for analysis of time to the occurrence of a particular event in 
clinical trials. Moye et al. (1992) recommended comparing each of the subjects in one group 
(placebo) with each of the subjects in another group (treatment) by integrating additional 
measurements or variables taken over time in the analysis of time-to-event data. Follmann et al. 
(1992) subjectively ranked the patients in clinical trials with multiple outcomes using clinically 
meaningful information based on the subjective strategy of ordering the patients. A group of 
people who are experts in the area of study was asked to rank the patients with several outcomes 
measured over time based on the clinically relevant importance in the analysis of time-to-event 
data from a cardiovascular clinical trial and then techniques using the ranking scores were 
applied to assess the treatment effect.  
Our main purpose in this study is to introduce a novel statistical method in situations 
where we wish to compare two treatments using all of the time points, the outcome is binary, and 
the time points are pre-specified. Our proposed method is based on ordering the entire vector of 
repeated observations rather than considering the individual components of the vector. Ideally, 
vectors can be ordered based on clinical relevance. The two treatment groups are then compared 
by applying statistical techniques handling ranked measurements such as Wilcoxon rank-sum 
test (Wilcoxon 1945) or Mann-Whitney U test (Mann and Whitney 1947) and regression methods 
using the ranked scores. This can be extended to missing data and multiple outcomes.  
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1.1 MISSING DATA ISSUES 
It is uncommon that observations from study subjects at all specified time points will be obtained 
in longitudinal studies. Thus, missing data frequently occur in these studies. The presence of 
missing data can cause misleading inferences and incorrect decisions such as biased and 
inefficient estimates and poor confidence intervals. Missing data can also reduce statistical 
power.  
Ignoring the missing data violates the strict principle of “intention-to-treat” analysis 
comparing the treatment groups to which they were randomly assigned regardless of the 
treatment they actually received (Houck et al. 2004; Bubbar et al. 2006; Li et al. 2006; and Liu et 
al. 2006). Intention-to-treat analyses includes all subjects irrespective of whether they received 
the treatment or they violate the study protocol (e.g., subjects drop out of the study or have 
inadequate adherence). When the missing data are not handled in an appropriate way, one may 
obtain erroneous conclusions. 
Therefore, it is important to examine and account for the reasons for the missing data 
prior to choosing an appropriate statistical method to analyze data. It is crucial to understand the 
patterns of missing data and the mechanisms that result in the data being missing in order to 
handle missing data in the analysis. 
1.1.1 Missing Data Mechanisms  
According to the terminology of Little and Rubin (Little and Rubin 2002), there are three types 
of missing data mechanisms. A missing data process is called missing completely at random 
(MCAR) when the missingness is not associated with either observed or unobserved outcomes 
and is not related to any variables. When the data are MCAR and all available data are used in 
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the analysis, valid inferences can be obtained. It should be emphasized that MCAR is a strong 
assumption and is usually difficult to satisfy in practice.  
Data are said to be missing at random (MAR) if the missingness is related to the observed 
data but does not depend on the potentially unobserved data. MAR is a less restrictive type of 
missing data and more often, but not always, a reasonable assumption in many applications. 
When different withdrawal rates for each treatment groups are assumed, data are more likely to 
be MAR, rather than MCAR (Liu and Gould 2002). When unequal drop-out rates in the 
treatment groups are assumed, missingness depends on the treatment groups. It is considered as 
covariate-dependent dropout. MCAR and MAR are considered as ignorable missingness.  
When the missing data are not random and depend on the unobserved data, missing data 
are called missing not at random (MNAR). One almost always obtains biased estimates and/or 
invalid results using methods which do not take into account the missing values in the analysis 
when the missing data process is MNAR. Results produced by standard methods of analyzing 
longitudinal data are not valid when missing data are MNAR. Special care is needed to analyze 
the data with MNAR. It is required that observed and missing data are jointly modeled to avoid 
misleading inferences. MNAR is considered as non-ignorable missing data. Second paragraph. 
1.1.2 Approaches For Handling Missing Data 
Performing analyses using the methods accounting for missing data are of importance in the 
analysis of data with missing observations. There are different ways to deal with missing data. 
One of the popular choices is a “complete case” (CC) analysis including only subjects with 
complete data. Subjects with missing values are excluded from the analysis. Advantage of CC 
analysis is that any standard statistical methods can be performed on the complete cases. 
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However, CC analysis produces biased estimates unless the strong MCAR assumption is 
satisfied (Little and Rubin 2002). Even though the stringent MCAR assumption holds, one 
disadvantage of CC analysis is that excluding the subjects with missing observations reduces the 
sample size leading to the loss of efficiency. Moreover, excluding the subjects with incomplete 
data violates the principle of intention-to-treat when assessing treatment efficacy or 
effectiveness. 
Another commonly used method to handle missing data in longitudinal studies is the last 
observation carried forward (LOCF) approach, where the last observed value is replaced for all 
of that subject’s subsequent values that are not obtained. The LOCF approach is a simple data 
imputation method and satisfies the intention-to-treat principle by including all subjects 
regardless of missing data. However, the LOCF method makes the very strong and unrealistic 
assumption about missing data (i.e., subject’s response profile remains unchanged at the time of 
the last observed value prior to dropout). It can produce very biased results and tends to decrease 
variability which influences the plausibility of parameter estimates due to the assumption of no 
further change in the profile (Tang et al. 2005). Furthermore, the method is typically applied to 
dropouts and does not address subjects with only intermittent missing data.  
For longitudinal data with binary responses, another approach might be the worst and 
best case analysis which is simple and easy to apply for the imputation of missing data. For 
example, subjects in placebo groups are likely to withdraw from the study because of lack of 
treatment improvement and thus, missing observations for these subjects may be imputed as 
worst response. If subjects who have sufficient benefit from the treatment discontinue the study, 
missing observations for these subjects may be imputed as best response. When subjects in the 
treatment group drop out from the study as a result of an adverse effect or lack of any beneficial 
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treatment effect, best response to all missing responses in the placebo group and worst response 
to all missing responses in the treatment group can be assigned but such an extreme analysis 
would eliminate the beneficial effect of the treatment. It is usually recommended for sensitivity 
analysis to evaluate the effect of treating missing data in different ways regarding the robustness 
of the results.  (Minini et al. 2004) 
GEE analysis using all available observations from subjects requires the MCAR 
assumption. GEE yields valid and consistent estimates under a strong MCAR. Complete case 
and GEE analyses produce invalid estimates when missing data are MAR but not MCAR. 
Likelihood-based methods (random-effects models) also use all available data obtained from 
subjects and yield unbiased results when the less restrictive assumption of MAR is satisfied. 
Gould (1980) proposed a statistical method for analysis of longitudinal data comparing 
two treatment groups based on the observations taken at the last time point from clinical trials in 
the presence of missing data. The main idea in Gould’s method is to consider the information 
about the reasons for withdrawals in the analysis. Response outcomes obtained at the last 
planned occasion and the reasons for withdrawals from two treatment groups are plausibly 
ordered and then statistical methods handling the ranked observations (i.e., Mann Whitney test) 
are performed in comparison of two treatment groups.     
One method to handle missing data is the generalized Wilcoxon test for time-to-event 
data proposed by Gehan (1965). In clinical studies where the outcome of interest is the time to an 
event, patients may not complete the study and are censored before the time to occurrence of an 
event. The relative rank of a censored and non-censored observation is only known if the time to 
event for a subject who is censored or lost to follow-up is greater than the time of event for the 
non-censored subject. Gehan’s generalization of the Wilcoxon statistic is a widely used approach 
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and is useful for comparing two survival curves for randomly right-censored data. All pairs of 
subjects in the two groups are compared in terms of the pattern of events and censored 
measurements.  
Multiple imputation (Rubin 1987) provides a modern and simulation-based approach for 
handling missing data. In multiple imputation, several full data sets are generated in which 
randomly selected observed values are selected from an appropriately defined subset and 
substituted for missing data. These completed data sets are separately analyzed and results from 
each generated data set are combined to yield an overall result. A multiple imputation procedure 
assumes that missing data are MAR. The assumption of MAR is required to produce valid 
inferences. Statistical methods requiring complete data can be used by a multiple imputation 
approach. Popularity of using multiple imputation method increases as developments in 
computer and technology advance.  
1.2 ISSUES OF CLINICAL INTERVENTIONS WHICH ALTER OUTCOMES 
In some clinical trials, two treatment groups are compared to assess the effect of therapy and 
comparison is usually made based on one single primary outcome of interest. In such studies, 
unplanned occurrences may arise and it is common to give non-protocol clinical interventions to 
the patients due to development of illness or the results of the therapy such as drug allergy, 
serious adverse experience, and inadequate effectiveness of treatment. Serious adverse effect of a 
drug in some patients may prevent safe use of treatment which might necessitate change of 
treatment. Unsatisfactory effect of treatment may also require another intervention. Moreover, 
giving another therapy might cause ethical issues and violates the study protocol. This necessity 
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of giving another therapy may result in a dramatic change in the primary outcome or 
inappropriate outcome and interfere with results of the analysis. To assess the effects of therapy, 
it may be important to include such events in the analysis. Applying analyses without 
considering these occurrences may fail to reflect the overall effects of treatment. 
For example, in a clinical trial to compare an antibiotic with placebo in children with 
chronic effusion (fluid in the ear), tube insertion might be needed because of lack of therapeutic 
effect of the treatment. This non-protocol intervention impacts on the primary outcome. Tube 
insertion reduces the occurrence of effusion. If tube insertion is performed on a substantial 
number of children in the placebo group, chronic effusion will be eliminated and the overall 
response will be satisfactory for these children. The placebo group could actually have a lower 
average number of days of chronic effusion than the treatment group because of a large number 
of inserted tubes. Yet clinically this is not considered a good outcome.  
In such cases, it is difficult to accommodate these occurrences in the analysis. 
Incorporating such occurrences into the analysis of data from clinical trials in a way that 
preserves the clinical relevance of the outcomes would be an important contribution.  
1.3 SPECIFIC AIMS 
The primary purpose of this methodological research is to develop a new method of analyzing 
repeated binary data by extending the Wilcoxon test statistic to the vectors of the repeated 
observations. The performance of the proposed method was compared with existing methods in 
the analysis of longitudinal binary outcomes. Since most clinical trials compare two 
interventions or medications and there are natural extensions to more than two groups, we 
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considered comparison of two treatment groups in this study. Analysis of longitudinal 
categorical outcomes and comparing more than two groups can be regarded for future areas of 
research. The following specific aims were considered in this study. 
1.3.1 Comparison of Methods for Longitudinal Binary Responses with Complete Data 
 We first formalized the method for selected orderings of the set of vectors. We contrasted our 
proposed method against three existing methods in the absence of missing data. We validated the 
Type I error and compared the statistical power of the four statistical methods using computer 
simulations. Even though most clinical trials have missing data and the case of a complete data 
set might be considered unrealistic, we felt this is an important first step in our evaluation. It is 
also regarded as beneficial to consider complete data because full data sets are provided when 
multiple imputation approach is used to handle missing data. Moreover, complete data sets are 
analyzed when complete case analysis or LOCF approaches are chosen to handle missing data 
even though they have disadvantages and can produce invalid results under particular 
circumstances. 
1.3.2 Comparison of Methods for Longitudinal Binary Responses with Missing Data  
Missing data occur frequently in longitudinal studies. Statistical methods can produce unrealistic 
and invalid results provided that the missingness has not been properly examined or handled in 
the analysis of the data. Biased and inefficient estimates may be obtained when the statistical 
procedures accounting for missing data are not performed. The proposed procedure has several 
natural extensions which incorporate missing data including a generalized Gehan’s Wilcoxon 
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test statistic (Gehan, E. A. 1965) which has been used for analysis of censored data in clinical 
trials.  
We modified Gould’s idea to account for missing data by ranking withdrawals due to 
outcome related reasons such as lack of efficacy, adverse experiences, recovery or dramatic 
improvement of the treatment.   
Thus, we evaluated the performance of the proposed method and compared it to the other 
traditional methods for longitudinal data with binary responses in the presence of missing data 
with a simulation study. We considered both the MCAR and the MAR missing data process in 
the comparison of the four statistical procedures. 
1.3.3 Development of General Framework for Summarizing Methods of Ranking Vectors 
of Observations 
We developed a general framework for summarizing methods of ranking vectors of observations. 
These were developed based on selection of mathematical functions to mimic standard 
approaches and ranking selected by physicians. If many clinicians are available to order the 
vectors of binary responses with multiple outcomes and adverse effects and homogeneity among 
their rankings is not obtained, it might be difficult to interpret the results and to apply the 
proposed method to the data to be analyzed. We examined the effects of the variability of 
rankings among clinicians and presented a statistical approach to efficiently use this 
heterogeneity in the analysis of the data. If a sufficient number of clinicians were not available to 
reach reasonable agreement of rankings, we developed strategies to use the information available 
from a small group of clinicians to employ the proposed method. 
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1.3.4 Consideration of Clinical Interventions Which Alter Outcomes 
Often in clinical trials, we encounter unpleasant side effects or non-responsiveness to therapy 
which for ethical reasons, may lead to increased medical intervention beyond the protocol 
therapy. Therefore, it is necessary to give non-protocol therapy because of a poor clinical 
outcome with protocol therapy. This may result in patients for whom the primary outcome is 
drastically altered or for which the primary outcome is no longer appropriate or meaningful. 
Standard techniques have difficulty incorporating these occurrences. Our proposed method 
addresses such a problem as long as the ‘need for intervention’ can be clinically ranked relative 
to the original vector of outcomes. We developed necessary statistics in order that the proposed 
method can be applied to such ‘interventions’ and evaluated the effect on the overall analysis.  
  13 
2.0  LONGITUDINAL BINARY RESPONSES WITH COMPLETE DATA 
Our proposed method is to compare the overall evaluation of treatment between two groups by 
transforming the information on the entire vector of repeated outcomes into a ranking of vectors 
in terms of clinical relevance and then applying an appropriate statistical procedure dealing with 
ranked measurements such as Wilcoxon rank-sum test or Mann-Whitney U test or the regression 
methods based on ranks. Our approach requires a rank ordering of all the subjects in both groups 
based on the input from the clinicians. The agreement among the clinicians is an important 
consideration in the analysis of the method.  
2.1 PROPOSED METHODOLOGY 
Suppose that we have two treatment groups of subjects, A and B, to be compared. Assume that 
nA and nB  subjects are assigned to treatment A (Trt-A) and treatment B (Trt-B), respectively and 
measurements are taken from all N = n𝐴+ nB subjects over time in longitudinal study with 𝑘  
time points. Let 𝑥𝑖𝑡 denote the response from the 𝑖𝑡ℎ subject within the Trt-A and 𝑦jt denote the 
response from the 𝑗𝑡ℎ subject within the Trt-B at time 𝑡 (𝑡 = 1, 2, … , 𝑘;  𝑖 = 1,2, … ,𝑛𝐴;  𝑗 =1,2, … ,𝑛𝐵). First, we assume that all measurements are observed from all subjects that is, there 
are no missing data. Without loss of generality, let 1 indicate presence of disease and 0 indicate 
absence of disease.  Thus,  
𝑿𝑖= (𝑥𝑖1, 𝑥𝑖2 , … , 𝑥𝑖𝑘 )1𝑥𝑘 is the sequence of observed outcomes regarding the 𝑖𝑡ℎ subject within 
the Trt-A with  
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𝑥𝑖𝑡 = � 1       𝑖𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒         0      𝑖𝑓 𝑛𝑜 𝑑𝑖𝑠𝑒𝑎𝑠𝑒    𝑖 = 1,2, … ,𝑛𝐴,  𝑡 = 1,2, … ,𝑘 
𝒀𝑗= �𝑦𝑗1, 𝑦𝑗2 , … ,𝑦𝑗𝑘 �1𝑥𝑘 is the sequence of observed outcomes regarding the 𝑗𝑡ℎ subject within 
the Trt-B with  
𝑦𝑗𝑡 = �  1       𝑖𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒          0       𝑖𝑓 𝑛𝑜 𝑑𝑖𝑠𝑒𝑎𝑠𝑒    𝑗 = 1,2, … ,𝑛𝐵 ,  𝑡 = 1,2, … , 𝑘 
Since 𝑘 repeated binary responses are measured, there are 2𝑘 possible response profiles 
over time. The proposed method is based on the assumption that the vectors can be ordered 
depending on their clinical relevance. We define a matrix with 2𝑘 rows and 𝑘 columns. Each row 
of this matrix represents one of the 2𝑘 possible response profiles. It should be noted that some of 
the rows might share the same ranked score depending on their clinical importance. We 
designate this matrix as S. Let S(m) indicate the m𝑡ℎ row of S and Rank (S(m)) denotes the 
assigned score to S(m). Define  
𝛿𝑖 = 𝑅𝑎𝑛𝑘(𝑆(r)) if 𝑿i ≡ 𝑆(r) , 𝑖 = 1, . . . ,𝑛𝐴;  𝑟 = 1, … , 2𝑘 
𝜉𝑗 = 𝑅𝑎𝑛𝑘(𝑆(s)) if 𝒀j ≡ 𝑆(s) , 𝑗 = 1, . . . ,𝑛𝐵;  𝑠 = 1, … , 2𝑘 
Hence, 𝛿1, … , 𝛿𝑛𝐴 are values of the subjects in Trt-A and 𝜉1, … , 𝜉𝑛𝐵 are values of the 
subjects in Trt-B. The Mann Whitney form of the test can be defined as  
𝑈𝑖𝑗 =
⎩
⎪
⎨
⎪
⎧
      0     𝑖𝑓 𝑿𝑖 < 𝒀𝑗  or 𝛿𝑖 < 𝜉𝑗   0.5     𝑖𝑓 𝑿𝑖 = 𝒀𝑗  or 𝛿𝑖 = 𝜉𝑗      1      𝑖𝑓 𝑿𝑖 > 𝒀𝑗  or 𝛿𝑖 > 𝜉𝑗
  
It can be more convenient to work with the following form of the Mann Whitney test.  
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𝑈𝑖𝑗
∗ =
⎩
⎪
⎨
⎪
⎧
  −1   𝑖𝑓 𝑿𝑖 < 𝒀𝑗  or 𝛿𝑖 < 𝜉𝑗   0     𝑖𝑓 𝑿𝑖 = 𝒀𝑗  or 𝛿𝑖 = 𝜉𝑗   1    𝑖𝑓 𝑿𝑖 > 𝒀𝑗  or 𝛿𝑖 > 𝜉𝑗
  
It is easy to see that 𝑈𝑖𝑗∗ = 2𝑈𝑖𝑗 − 1 and we can calculate the statistic 𝑈 or 𝑈∗. 
We can calculate the Wilcoxon (1945) test statistic 𝑊. 𝛿1, … , 𝛿𝑛𝐴 , 𝜉1, … , 𝜉𝑛𝐵 can be 
ordered from lowest to highest score and the Wilcoxon statistic 𝑊 is the sum of the ranks of the 
𝛿’s in the combined ordered arrangement of 𝛿’s and 𝜉’s. When ties are present, ties can be 
replaced by the average of ranks that the set of tied values would have been assigned if the 
values were distinct.  
W = �𝑅𝑎𝑛𝑘(𝛿𝑖) = ����𝐼�𝛿𝑖>𝜉𝑗� + 0.5 𝐼�𝛿𝑖=𝜉𝑗��𝑛𝐵
𝑗=1
+ ��𝐼�𝛿𝑖>𝛿𝑗� + 0.5 𝐼�𝛿𝑖=𝛿𝒋��𝑛𝐴
𝑗=1
�
𝑛𝐴
𝑖=1
𝑛𝐴
𝑖=1
 
Each subject (or vectors of binary responses) in Trt-A can be compared with each subject 
in Trt-B. The Mann-Whitney (1947) statistic, 𝑈, is the number of times a 𝜉𝑗 (1 ≤ j  ≤  nB) in the 
Trt-B precedes a 𝛿𝑖 (1 ≤  i  ≤  nA) in the Trt-A in the combined ranking of the two treatment 
groups. 
𝑈 = ��𝑈𝑖𝑗𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
= ���𝐼�𝛿𝑖>𝜉𝑗� + 0.5𝐼�𝛿𝑖=𝜉𝑗��𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
 
or 
𝑈∗ = ��𝑈𝑖𝑗∗𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
= ���𝐼�𝛿𝑖>𝜉𝑗� − 𝐼�𝛿𝑖<𝜉𝑗��𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
 
where 𝐼{𝑣<0} is a set indicator with 𝐼{𝑣<0} = 1 if 𝑣 < 0 and 0 otherwise. 
When there are no ties, the 𝑈∗ statistic is related to the Wilcoxon statistic 𝑊 and Mann-
Whitney statistic 𝑈. It can be shown that  
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𝑈∗ = 2𝑊 − 𝑛𝐴(𝑛𝐴 + 𝑛𝐵 + 1) 
𝑈∗ = 2𝑈 − 𝑛𝐴𝑛𝐵 
Large values of 𝑈 or 𝑈∗ indicate that there is a difference between treatment groups.  
2.2 SIMULATION STUDY 
We conducted a simulation study to assess the empirical performance of the proposed method 
versus three commonly used methods for analysis of repeated binary measures: 1) Two-sample t-
test comparing the average of the proportion of negative (positive) responses over time between 
two treatment groups; 2) logistic regression modeling using GEE (GEE); and 3) mixed effects 
logistic regression model with random intercept (MERI). Since often investigators are interested 
in a consistent treatment effect across time between two treatment groups, we first did not 
include treatment by time interaction term in the fitting models with GEE and MERI in our 
simulation study. For completeness, we also compared the proposed method with GEE and 
MERI when the interaction term of treatment by time is considered.   
2.2.1 Statistical Models 
We now describe the three approaches applied to each of the simulated longitudinal binary 
responses in this section. Suppose that a total of N subjects are randomized to one of the two 
treatment groups (A and B). Assume that the number of subjects in Trt-A (𝑛𝐴) and Trt-B (𝑛𝐵) are 
equal and that observations from each subject are taken at four time points.  
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Let 𝑌𝑖𝑡 = 1 if the measurement taken from ith subject at time point t is positive (presence 
of disease) response and 𝑌𝑖𝑡 = 0 otherwise; 𝑖 = 1, … ,𝑁 = 𝑛𝐴 + 𝑛𝐵 and 𝑡 = 1, 2, 3, 4. Define a 
treatment indicator as 𝑇𝑟𝑡𝑖 = 0 if subject i is randomized to the Trt-A and 𝑇𝑟𝑡𝑖 = 1 if subject i 
randomized to the Trt-B. To simplify notation, we assume that subjects 𝑖 = 1, … ,𝑛𝐴 are 
randomized to Trt-A and subjects 𝑖 = 𝑛𝐴 + 1, … ,𝑛𝐴 + 𝑛𝐵 are randomized to Trt-B. 
Two-sample t-test comparing the mean of the proportions of negative responses 
The repeated binary outcomes for each subject over time are summarized as a proportion of 
positive responses and two treatment groups are compared based on the proportion of positive 
responses using the two-sample t-test. Let 𝑝𝐴𝑖 and 𝑝𝐵𝑖 be the proportion of positive responses for 
the 𝑖𝑡ℎ subject in Trt-A and Trt-B over the four time points, respectively. The mean of the 
proportions of positive responses for subjects in Trt-A is  
𝑝𝐴 = ∑ 𝑝𝐴𝑖𝑛𝐴𝑖=1𝑛𝐴  
and the mean of the proportions of positive responses for subjects in Trt-B is 
𝑝𝐵 = ∑ 𝑝𝐵𝑖𝑁𝑖=𝑛𝐴+1𝑛𝐵  
The null hypothesis of no treatment effect can be tested to compare two treatment groups 
in terms of average proportion of positive responses over time using the two-sample t-test: 
𝐻0: 𝑝𝐴 = 𝑝𝐵 
Logistic Regression Model using GEE 
The marginal probability of positive response for the 𝑖𝑡ℎ subject at a given time point t (𝑝𝑖𝑡) was 
modeled as a logistic function of time and treatment group assuming no treatment by time 
interaction, that is,  
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𝑙𝑛 �
𝑝𝑖𝑡1 − 𝑝𝑖𝑡� = 𝛽0 + 𝛽1𝑇𝑖𝑚𝑒𝑖𝑡 + 𝛽2𝑇𝑟𝑡𝑖 
where 
𝑇𝑖𝑚𝑒𝑖𝑡 = 1, 2, 3, 4 for the four time points, 
𝑇𝑟𝑡𝑖 is the treatment indicator which equals to 0 for Trt-A and 1  for Trt-B, and  
𝑝𝑖𝑡 = 𝑃 𝑟(𝑌𝑖𝑡 = 1|𝑇𝑟𝑡𝑖). 
𝛽0 and 𝛽1 represent the logit of 𝑝𝑖𝑡 for Trt-A and the linear changes in the logit of positive 
response over time, respectively, and 𝛽2 indicates the difference between treatment groups over 
time. Since the objective is to evaluate the overall treatment effect, 𝛽2 is of primary interest in 
the simulation study. When a logistic regression model using GEE was applied to each simulated 
dataset, different working correlation structures, such as independent, exchangeable, auto-
regressive, and unstructured correlation structures were used. We tested the null hypothesis of no 
treatment difference, that is, 𝐻0: 𝛽2 = 0 
Mixed Effects Logistic Regression Model with Random Intercept 
Mixed-effects logistic regression models with a random intercept were considered for modeling 
each simulated binary data, that is,  
𝑙𝑛 �
𝑝𝑖𝑡1 − 𝑝𝑖𝑡� = 𝛽0 + 𝛽1𝑇𝑖𝑚𝑒𝑖𝑡 + 𝛽2𝑇𝑟𝑡𝑖 + 𝜁𝑖 
where the random subject effects 𝜁𝑖 are distributed as 𝑁�0,𝜎𝜁2� and 𝜁𝑖 independent across 
subjects i, given a random intercept and  𝑝𝑖𝑡 = 𝑃𝑟(𝑌𝑖𝑡 = 1|𝑇𝑟𝑡𝑖 , 𝜁𝑖), and 𝛽0, 𝛽1, and 𝛽2 represent 
the same parameters as  in logistic regression model using GEE above. We assumed that 𝑌𝑖𝑡 are 
independently distributed given 𝑝𝑖𝑡 as 𝑌𝑖𝑡|𝑝𝑖𝑡~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(1,𝑝𝑖𝑡). 
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Similar to logistic regression model using GEE, our interest is to test the null hypothesis 
of no treatment effect over time. We tested the null hypothesis of no treatment difference, that is,  
𝐻0: 𝛽2 = 0 
2.2.2 Simulation Design 
The power and type I error rates of the four statistical procedures were compared through 
computer simulations under a range of scenarios including different marginal probabilities of 
positive response and different correlation structures among the binary observations.  
The type I empirical rates were computed as the proportion of time the null hypothesis of 
no treatment effect was rejected at the two-sided nominal α=0.05. If the empirical type I error 
was close to the nominal error (α=0.05), the test was considered valid. The statistical power for 
selected alternative hypotheses (i.e., treatment effect) was calculated as the proportion of 
rejections of the false null hypothesis of no treatment effect assuming a two-sided type I error of 
0.05.  
2.2.3 Data Generation 
Correlated binary outcomes were generated given the marginal probabilities and correlation 
structure using the method of Park et al. (1996). This method creates correlated binary data from 
correlated Poisson variables with no requirement of a complex numerical procedure to be solved. 
The only limitation of this technique is that negatively correlated binary random variables cannot 
be generated. However, it is not unusual to assume nonnegative correlations among binary 
observations taken repeatedly from the same subject over time. Demirtas (2004) presented an R 
routine for generating correlated binary variables using an algorithm developed by Park et al. 
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(1996). 2000 simulated data sets from a hypothetical longitudinal binary data of different sets of 
parameters were generated using the R function written by Demirtas (2004). In these 
simulations, we restricted attention to four time points. The response at each time point was 
either positive (=1) or negative (=0). In each simulation, correlated binary outcomes with 4 
repeated measurements were generated for the specified number of subjects for each of the two 
treatment groups separately given the marginal expectations (i.e., marginal probabilities of 
positive response at four time points are pA= �pA1, pA2, pA3, pA4� and pB= �pB1, pB2, pB3, pB4� for 
Trt-A and Trt-B, respectively) and the correlation structures among responses. The number of 
subjects was equal for both treatment groups with n = 60 subjects for each group.  
Six sets of marginal expectations of positive responses at four time points were used for 
comparing statistical power: (1) no change over time for placebo group while there is an 
improvement for drug group (pA= (.6, .6, .6, .6) and pB= (.6, .5, .4, .3)); (2) no change at the 
beginning of the study for both groups but the placebo group worsens while the drug group gets 
better later  in the study (pA= (.7, .7, .8, .9) and pB= (.7, .7, .6, .5)); (3) placebo group gradually 
worsens but the drug group gets better over time (pA= (.5, .6, .6, .7) and pB= (.5, .4, .4, .3)); (4) 
both groups show good progress but the drug group shows faster improvement (pA= (.8, .7, .7, .6) 
and pB= (.8, .6, .5, .4)); (5) placebo group gets worse while the drug group does not show any 
change over time (pA= (.4, .5, .6, .7) and pB= (.4, .4, .4, .4)); and (6) no change over time for the 
placebo group while the effect of drug is immediate and is maintained over time 
(pA= (.7, .7, .7, .7) and pB= (.5, .5, .5, .5)).  
A within-subject independent correlation structure (no correlation among the 
observations, i.e., repeated measurements may be taken at long time intervals resulting in 
negligible correlations among the measurements) for weakly dependent binary responses, 
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exchangeable correlation structure (constant correlation among the observations) with correlation 
coefficient being 0.3 for moderately dependent binary responses, and a first-order auto-
regressive, AR(1), correlation structure with correlation coefficient being 0.6 for strongly 
dependent binary responses  
i.e., 
𝐶𝑜𝑟𝑟 �𝑌𝑗 , 𝑌𝑘� = 0.6 𝑓𝑜𝑟 |𝑗 − 𝑘| = 1,
𝐶𝑜𝑟𝑟 �𝑌𝑗 ,𝑌𝑘� =  0.36 𝑓𝑜𝑟 |𝑗 − 𝑘| = 2,  and 𝐶𝑜𝑟𝑟 �𝑌𝑗 ,  𝑌𝑘� = 0.216 𝑓𝑜𝑟 |𝑗 − 𝑘| = 3were 
assumed for the association among the responses. No missing values were generated for this 
simulation study. Thus, the correlation structures were as follows: 
Independent correlation structure: 
𝑅 = �1 0 0 00 1 0 00 0 1 00 0 0 1�,        
Exchangeable correlation structure: 
𝑅 = � 1 0.3 0.3 0.30.3 1 0.3 0.30.3 0.3 1 0.30.3 0.3 0.3 1 �,     
AR(1) correlation structure: 
𝑅 = � 1 0.6 0.36 0.2160.6 1 0.6 0.360.36 0.6 1 0.60.216 0.36 0.6 1 �. 
2.2.4 Strategies for Ordering Vectors of Binary Responses 
Since four repeated binary responses were generated, there are 24 = 16 possible response profiles 
over time. For each simulated data set, we ordered the vectors based on both the number of 
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positive responses (1 = disease), and the time to first/last appearance of disease. Although we 
will eventually obtain input from clinicians on some real life examples, for now we considered 
two different strategies for ordering the observed vectors. For the first ordering strategy to rank 
vectors of observations of subjects (strategy I), we have used a ranking which gives priority to 
the number of disease episodes and then breaks ties by ranking as a  poorer outcome those with 
the earliest episode. For the second ordering strategy (strategy II), we have used a ranking which 
gives priority to the number of disease episodes, as for strategy I, but then breaks ties by ranking 
as a poorer outcome those with the latest episode (Table 2.1). For both ordering strategies, a 
vector of four positive responses at all time points receives the lowest ranked score and a vector 
of four positive responses at all time points receives the highest ranked score. We compared two 
treatment groups with regard to the ordered vectors using the Wilcoxon rank-sum test.  
2.2.5 Simulation Results   
 The results for the type I error rates are presented in Table 2.2 and the results for the power are 
presented in Table 2.3.  
Type I Error Rate 
Table 2.2 presents the percentages of the type I error rates for each procedure when the marginal 
probabilities of positive response (undesirable outcome i.e., having disease) are the same and 
different at all four time points for both treatment groups using different correlation structures. 
Table 1 was produced under three different correlation structures: (1) no correlation between the 
repeated binary responses, (2) exchangeable correlation structure with correlation coefficients 
being 0.3, and (3) AR(1) correlation structure with correlation coefficient being 0.6. Simulation 
results showed that none of the procedures yielded high type I error rates and all procedures 
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produced type I error rates around the nominal value (α=0.05) when independent correlation 
structure was adopted. All methods were comparable with respect to type I error rate in the 
absence of correlation among the repeated binary responses.  
The proposed method using strategies I and II, t-test, and GEE with different correlation 
structures preserved the type I error well under the null hypothesis whereas MERI tended to 
produce slightly higher type I error rate when exchangeable correlation structure was occupied. 
GEE with unstructured correlation structure yielded a little higher type I error rate for the 
situation where the marginal probabilities of positive response were the same at the four time 
points (Patterns 1, 3, and 4) compared to the proposed method, t-test and GEE with other 
correlation structures.    
We did not detect apparent difference with respect to type I error rates over the methods 
when the AR(1) correlation structure with correlation coefficient being 0.6 was used. However, 
MERI model produced slightly higher type I error rates than the proposed method, t-test, and 
GEE with different correlation structures except unstructured (incorrect) correlation structure 
which yielded slightly higher type I error rates for some scenarios such as patterns 1, 4, 6, and 8. 
The reason of obtaining higher type I error rate with MERI can be explained by the fact that an 
increase in the correlation among the observations inflates the type I error rate. (Hedeker and 
Gibbons 2006; Liu and Wu 2008). Diggle et al. (2002) also showed that positive correlation 
increases the type I error rate for repeated binary responses. 
Overall, the proposed method yielded desirable Type I error rates around the nominal 5 
percent and performed well under different scenarios (different marginal probabilities and 
correlation structures).  
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Statistical Power 
Statistical power of the competing methods from simulations are reported in Table 2.3 when the 
correlation structures are independent, exchangeable, and AR(1) with different marginal 
probabilities of positive response at four time points for each treatment group. 
Table 2.1: Ordering of 16 possible vectors based on the two different strategies 
STRATEGY I 
Number of disease episodes 
0 1 2 3 4 
R Profile R Profile R Profile R Profile R Profile 
16 [0 0 0 0] 12 [1 0 0 0] 6 [1 1 0 0] 2 [1 1 1 0] 1 [1 1 1 1] 
  13 [0 1 0 0] 7 [1 0 1 0] 3 [1 1 0 1]   
  14 [0 0 1 0] 8 [1 0 0 1] 4 [1 0 1 1]   
  15 [0 0 0 1] 9 [0 1 1 0] 5 [0 1 1 1]   
    10 [0 1 0 1]     
    11 [0 0 1 1]     
Algorithm: 
1. Rank first by number of disease episodes 
2. Break ties by considering earlier disease as poorer outcome  
STRATEGY II 
Number of disease episodes 
0 1 2 3 4 
 Profile  Profile  Profile  Profile  Profile 
16 [0 0 0 0] 15 [1 0 0 0] 11 [1 1 0 0] 5 [1 1 1 0] 1 [1 1 1 1] 
  14 [0 1 0 0] 10 [1 0 1 0] 4 [1 1 0 1]   
  13 [0 0 1 0] 9 [1 0 0 1] 3 [1 0 1 1]   
  12 [0 0 0 1] 8 [0 1 1 0] 2 [0 1 1 1]   
     [0 1 0 1]     
     [0 0 1 1]     
Algorithm: 
1. Rank first by number of disease episodes 
2. Break ties by considering later disease as poorer outcome  
(1=positive, 0=negative), R=Rank score.  Lower rank score is poorer outcome. 
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  When the marginal expectations of positive response are pA= (.4, .4, .4, .4) and 
pB= (.3, .3, .3, .3), the proposed method had slightly lower power than the other methods in the 
case of no correlation among observations. The proposed method yielded statistical power 
comparable to other procedures except MERI, which kept a little higher power than the other 
methods, in the presence of correlation among the responses (exchangeable and AR-1 correlation 
structures).  
When the marginal expectations of positive response are pA= (.8, .8, .8, .8) and pB= (.7, .7, .7, .7), 
our proposed method with two different ordering schemes had slightly lower statistical power 
than the other methods under the scenario of assuming no correlation among the responses. 
However, our proposed method yielded similar power compared with MERI and higher power 
than the t-test and GEE when we adapted the exchangeable correlation structure. The proposed 
method showed slightly higher or similar power in detecting treatment differences under the 
alternative hypothesis compared with the t-test and GEE, with correct or incorrect correlation 
structures for the scenario of applying AR(1).  
Under the scenario of no change over time for the placebo group but fast and constant 
improvement for treatment group (i.e., pA= (.7, .7, .7, .7) and pB= (.5, .5, .5, .5) or 
pA= (.5, .5, .5, .5) and pB= (.3, .3, .3, .3)), all procedures produced similar power regardless of 
assuming different correlation structures. 
In some clinical trials, placebo-treated subjects are expected to worsen over time and no 
improvement is observed for subjects randomized to drug group. In order to demonstrate this 
situation in our simulation study, we chose scenarios where the marginal expectations of positive 
response for placebo and drug groups are pA= (.4, .5, .6, .7) and pB = (.4, .4, .4, .4) or 
pA= (.6, .7, .8, .9) and pB= (.6, .6, .6, .6), respectively. Under these scenarios, the proposed 
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method with strategy II had higher statistical power than the competitive methods in the absence 
of correlation among the responses but the proposed method with strategy I had the lowest 
power. When we assumed that repeated measurers are correlated, the proposed method with 
strategy II had still higher power than the other procedures and loss in power was higher for 
other procedures than the proposed method with strategy II. 
When the marginal probabilities of positive response difference between two treatment 
groups is high at the beginning of the trial and this difference gradually decreases over time and 
equalize at the last time points (i.e., pA= (.7, .6, .5, .4) and pB = (.4, .4, .4, .4)), the proposed 
method with strategy I produced statistical power higher than the other procedures and the 
proposed method with strategy II produced the lowest power in the absence or presence of 
correlation among the responses. Note that our proposed method produces different power 
depending on the ordering strategy of the vectors. 
For pA= (.3, .5, .6, .8) and pB = (.8, .6, .5, .3) using different correlation structures, our 
proposed method with strategy I and strategy II had noticeably higher statistical power compared 
to other methods. Other procedures yielded power around the nominal 5 percent. It should be 
noted that GEE and MERI methods were not designed to be sensitive to interactions.  
Under the scenario pA= (.6, .6, .6, .6) and pB = (.6, .5, .4, .3), the proposed method with 
strategy II yielded higher power than the other procedures regardless of employing different 
assumptions of correlation among the repeated observations. Statistical power produced by the 
proposed method with strategy I was lower than that produced by the other procedures. 
Although our proposed method with strategy I had lower power than the other procedures, the 
method with strategy II yielded higher power compared to other procedures under the scenario 
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where the marginal probabilities are pA= (.8, .7, .7, .6) and pB = (.8, .6, .5, .4),   pA= (.5, .6, .6, .7) 
and pB = (.5, .4, .4, .3) or pA= (.7, .7, .8, .9) and pB = (.7, .7, .6, .5). 
 
Table 2.2: Type I Error Rate (%): Simulation results for comparing the methods with full data 
 Placebo Drug PROPOSED t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 5.2 4.7 4.6 4.6 4.6 4.6 5.2 4.2 
2 .4 .4 .4 .4 .4 .4 .4 .4 5.2 5.4 5.2 5.4 5.4 5.2 5.7 5.0 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.8 4.5 4.8 4.9 4.9 5.0 5.1 4.5 
4 .7 .7 .7 .7 .7 .7 .7 .7 4.2 5.0 4.2 4.2 4.4 4.2 4.9 4.1 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.3 5.0 5.4 5.8 5.8 5.7 5.7 4.9 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.8 5.7 5.2 5.4 5.4 5.3 5.8 5.0 
7 .6 .7 .8 .9 .6 .7 .8 .9 5.3 5.5 5.4 5.4 5.5 5.6 5.8 5.0 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.0 5.2 4.8 5.1 5.1 5.0 5.4 4.8 
9 .6 .6 .4 .4 .6 .6 .4 .4 5.0 5.1 4.8 5.0 5.0 5.0 5.2 4.2 
Exchangeable Correlation Structure 
1 .3 .3 .3 .3 .3 .3 .3 .3 5.1 5.4 5.0 5.0 5.1 5.2 5.7 6.1 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.9 5.8 5.5 5.5 5.5 5.6 6.0 6.4 
3 .5 .5 .5 .5 .5 .5 .5 .5 5.4 5.8 5.7 5.8 5.8 5.8 6.2 6.8 
4 .7 .7 .7 .7 .7 .7 .7 .7 4.9 5.4 4.9 5.4 5.4 5.7 5.8 6.4 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.8 4.8 4.6 4.6 4.6 4.6 5.1 5.4 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.7 5.4 5.6 5.8 5.8 5.6 6.0 6.4 
7 .6 .7 .8 .9 .6 .7 .8 .9 5.8 4.7 4.8 5.2 5.6 5.2 5.6 6.2 
8 .7 .6 .5 .4 .7 .6 .5 .4 4.9 5.2 5.0 5.1 5.1 5.3 5.4 6.0 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.7 4.4 4.6 4.7 4.7 5.2 5.3 6.0 
AR(1) Correlation  Structure 
1 .3 .3 .3 .3 .3 .3 .3 .3 5.0 5.4 4.7 4.7 5.0 5.4 5.8 6.0 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.7 5.2 5.0 5.0 5.2 5.2 5.8 6.3 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.4 4.7 4.9 5.0 5.0 5.2 5.4 5.6 
4 .7 .7 .7 .7 .7 .7 .7 .7 5.4 5.0 5.4 5.5 5.6 5.4 6.0 6.4 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.2 5.4 5.1 5.2 5.1 5.1 5.4 6.1 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.9 4.5 5.2 5.2 5.2 5.1 5.7 5.8 
7 .6 .7 .8 .9 .6 .7 .8 .9 5.4 4.8 5.0 5.2 5.2 5.4 5.6 6.1 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.4 5.4 5.1 5.4 5.3 5.5 6.0 6.1 
9 .6 .6 .4 .4 .6 .6 .4 .4 5.0 5.4 5.2 5.2 5.4 5.2 5.5 6.4 
Abbreviations: PROPOSED, proposed method based on the ordering of strategy I and II in Table 2.1; t-test, t-
test comparing the means of the proportions of positive responses between the two groups; GEE, logistic 
regression model using GEE; MERI, mixed effects logistic regression model with random intercept; IND, 
independent correlation structure; EX, exchangeable correlation structure; AR(1), first-order auto-regressive 
correlation structure; UN, unstructured correlation structure; pt, marginal probability of positive response at 
time t, t = 1, 2, 3, 4.  
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We also compared our proposed method with GEE and MERI when the time by 
treatment interaction term was considered. We reported the simulation results for this 
comparison in Table 2.4. As expected, GEE and MERI methods gained power in some scenarios 
(i.e., pA= (.3, .5, .6, .8) and pB = (.8, .6, .5, .3), pA= (.4, .5, .6, .7) and pB = (.4, .4, .4, .4), 
pA= (.6, .6, .6, .6) and pB = (.6, .5, .4, .3)) compared to results in Table 2.3. Under these 
scenarios, powers of these methods are comparable with the proposed method when independent 
correlation structure is used and are higher than that of the proposed method in the presence of 
correlation among observations. For some scenarios (i.e., pA= (.4, .4, .4, .4) and 
pB = (.3, .3, .3, .3), pA= (.8, .8, .8, .8) and pB = (.7, .7, .7, .7), pA= (.7, .7, .7, .7) and 
pB = (.5, .5, .5, .5)), there is a decrease in power for GEE and MERI methods. Under these 
scenarios, the proposed method yielded higher power than these methods. 
In summary, the proposed method is competitive with and, for some scenarios, is 
preferable to the traditional methods. As the simulation study showed, different ordering 
strategies of the vectors of binary response give different results. 
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Table 2.3: Power (%): Simulation results for comparing the methods without missing data 
 Placebo Drug  PROPOSED t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II  IND EX AR(1) UN  
Independent Correlation Structure    
1 .3 .5 .6 .8 .8 .6 .5 .3 56.9 54.4 5.0 5.2 5.2 5.2 7.8 3.6 
2 .4 .6 .7. 8 .4 .4 .4 .4 96.9 100 100 100 100 100 100 99.0 
3 .4 .5 .6 .7 .4 .4 .4 .4 69.4 97.7 92.0 92.2 92.2 92.2 92.7 91.5 
4 .7 .6 .5 .4 .4 .4 .4 .4 97.2 69.6 91.6 91.8 91.6 91.7 91.8 91.2 
5 .6 .7 .8 .9 .6 .6 .6 .6 96.9 100 100 100 100 100 100 99.9 
6 .8 .7 .7. 6 .8 .6 .5 .4 48.4 73.2 64.8 65.2 65.2 65.4 66.0 63.9 
7 .5 .6 .6. 7 .5 .4 .4 .3 92.3 99.9 99.4 99.4 99.4 99.4 99.2 99.4 
8 .7 .7 .8 .9 .7 .7 .6 .5 40.1 81.2 68.0 68.7 68.8 68.4 69.3 66.9 
9 .6 .6 .6 .6 .6 .5 .4. 3 70.0 97.0 91.4 91.7 91.7 91.7 91.8 91.0 
10 .4 .4 .4 .4 .3 .3 .3 .3 58.8 58.6 63.8 64.4 64.4 64.8 65.1 63.1 
11 .8 .8 .8 .8 .7 .7 .7 .7 64.8 66.2 70.6 71.3 71.4 71.4 71.4 70.2 
12 .7 .7 .7 .7 .5 .5 .5 .5 99.0 99.2 99.6 99.6 99.6 99.6 99.4 99.6 
13 .5 .5 .5 .5 .3 .3 .3 .3 99.0 99.0 99.7 99.7 99.7 99.7 99.7 99.7 
Exchangeable Correlation Structure    
1 .3 .5 .6 .8 .8 .6 .5 .3 30.6 31.4 4.8 5.0 5.0 5.0 8.5 5.8 
2 .4 .6 .7. 8 .4 .4 .4 .4 83.4 98.9 96.3 96.2 96.3 95.6 96.2 97.2 
3 .4 .5 .6 .7 .4 .4 .4 .4 47.1 81.2 69.4 69.6 70.2 69.3 70.8 73.2 
4 .7 .6 .5 .4 .4 .4 .4 .4 81.2 48.4 69.4 69.7 70.2 69.2 71.4 72.8 
5 .6 .7 .8 .9 .6 .6 .6 .6 49.4 88.0 73.5 74.3 69.6 73.3 71.8 78.3 
6 .8 .7 .7. 6 .8 .6 .5 .4 50.8 69.4 56.1 56.2 61.4 54.2 61.8 59.6 
7 .5 .6 .6. 7 .5 .4 .4 .3 71.4 95.3 88.2 88.4 88.4 87.1 89.2 89.2 
8 .7 .7 .8 .9 .7 .7 .6 .5 52.6 92.2 74.8 74.8 74.2 79.4 79.8 78.8 
9 .6 .6 .6 .6 .6 .5 .4. 3 53.2 83.4 68.0 68.2 68.7 68.1 69.3 69.6 
10 .4 .4 .4 .4 .3 .3 .3 .3 35.2 35.0 36.3 36.8 36.6 36.6 37.8 39.3 
11 .8 .8 .8 .8 .7 .7 .7 .7 51.8 51.8 46.0 46.3 46.2 45.2 46.4 52.6 
12 .7 .7 .7 .7 .5 .5 .5 .5 91.6 91.4 89.6 89.6 89.6 89.1 89.6 92.0 
13 .5 .5 .5 .5 .3 .3 .3 .3 89.4 90.4 91.4 91.6 91.6 90.2 91.4 92.2 
AR(1) Correlation Structure    
1 .3 .5 .6 .8 .8 .6 .5 .3 32.6 32.0 5.4 5.6 5.5 5.4 9.8 6.2 
2 .4 .6 .7. 8 .4 .4 .4 .4 71.2 96.0 89.2 89.4 90.2 89.7 89.6 90.7 
3 .4 .5 .6 .7 .4 .4 .4 .4 33.5 74.4 54.0 54.5 56.8 58.8 58.9 58.8 
4 .7 .6 .5 .4 .4 .4 .4 .4 68.8 38.2 53.3 53.4 55.4 57.4 60.0 56.5 
5 .6 .7 .8 .9 .6 .6 .6 .6 34.5 71.9 57.6 58.4 52.2 60.6 61.1 60.4 
6 .8 .7 .7. 6 .8 .6 .5 .4 62.6 76.4 69.4 69.3 72.2 65.1 69.0 71.4 
7 .5 .6 .6. 7 .5 .4 .4 .3 74.4 96.4 90.8 90.8 90.8 89.8 91.2 92.0 
8 .7 .7 .8 .9 .7 .7 .6 .5 41.2 87.1 72.0 72.4 72.0 79.5 81.4 74.7 
9 .6 .6 .6 .6 .6 .5 .4. 3 64.1 87.4 79.8 80.0 79.8 76.4 78.0 81.7 
10 .4 .4 .4 .4 .3 .3 .3 .3 36.0 36.0 36.8 37.0 36.8 36.5 38.0 40.4 
11 .8 .8 .8 .8 .7 .7 .7 .7 44.1 43.4 43.0 43.4 43.2 42.4 43.8 48.2 
12 .7 .7 .7 .7 .5 .5 .5 .5 91.4 90.0 90.6 90.8 90.8 90.5 91.1 92.4 
13 .5 .5 .5 .5 .3 .3 .3 .3 87.3 87.6 88.6 88.7 88.5 88.4 89.3 89.9 
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Table 2.4: Power (%): Simulation results for comparing the methods without missing data when treatment by 
time interaction is considered 
 Placebo Drug PROPOSED t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 55.4 54.8 5.3 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 97.4 100 99.8 100 100 100 100 100 
3 .4 .5 .6 .7 .4 .4 .4 .4 71.5 97.3 91.4 97.6 97.6 97.6 97.6 97.6 
4 .7 .6 .5 .4 .4 .4 .4 .4 96.8 69.4 90.0 96.3 96.3 96.2 96.4 96.6 
5 .6 .7 .8 .9 .6 .6 .6 .6 72.2 98.9 95.4 99.2 99.2 99.3 99.2 99.3 
6 .8 .7 .7. 6 .8 .6 .5 .4 66.8 88.2 82.8 84.6 84.6 84.6 85.0 84.7 
7 .5 .6 .6. 7 .5 .4 .4 .3 92.0 100 99.2 99.8 99.8 99.8 99.8 99.8 
8 .7 .7 .8 .9 .7 .7 .6 .5 67.0 99.4 95.0 99.8 99.8 99.8 99.8 99.8 
9 .6 .6 .6 .6 .6 .5 .4. 3 68.8 97.3 91.7 96.8 96.8 96.8 97.0 96.8 
10 .4 .4 .4 .4 .3 .3 .3 .3 58.6 58.1 63.7 55.4 55.4 55.6 56.1 53.6 
11 .8 .8 .8 .8 .7 .7 .7 .7 67.4 66.4 71.4 61.6 61.6 61.4 61.6 60.2 
12 .7 .7 .7 .7 .5 .5 .5 .5 98.8 98.7 99.2 98.4 98.4 98.4 98.4 98.4 
13 .5 .5 .5 .5 .3 .3 .3 .3 98.6 98.9 99.2 98.5 98.5 98.5 98.6 98.4 
Exchangeable Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 32.2 32.8 5.8 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 82.2 98.9 96.8 100 100 100 100 100 
3 .4 .5 .6 .7 .4 .4 .4 .4 49.0 81.8 69.2 93.4 93.4 93.4 93.4 94.7 
4 .7 .6 .5 .4 .4 .4 .4 .4 80.6 48.4 68.8 92.5 92.5 91.8 92.1 93.6 
5 .6 .7 .8 .9 .6 .6 .6 .6 49.5 88.2 74.8 98.0 97.9 98.0 98.2 98.6 
6 .8 .7 .7. 6 .8 .6 .5 .4 51.7 69.4 57.0 71.3 72.0 65.8 70.7 71.6 
7 .5 .6 .6. 7 .5 .4 .4 .3 71.0 95.5 88.6 98.9 98.9 99.2 99.0 99.0 
8 .7 .7 .8 .9 .7 .7 .6 .5 49.2 91.3 72.6 99.8 99.8 99.7 99.8 99.8 
9 .6 .6 .6 .6 .6 .5 .4. 3 53.6 83.6 66.7 92.6 92.6 90.9 92.6 92.8 
10 .4 .4 .4 .4 .3 .3 .3 .3 36.1 36.0 37.6 30.1 30.1 30.0 31.4 33.2 
11 .8 .8 .8 .8 .7 .7 .7 .7 50.6 50.6 45.0 33.1 33.2 32.0 33.8 40.0 
12 .7 .7 .7 .7 .5 .5 .5 .5 93.1 92.2 91.2 83.0 83.0 82.1 83.6 86.1 
13 .5 .5 .5 .5 .3 .3 .3 .3 89.4 89.8 91.0 84.0 84.0 82.6 84.0 85.4 
Auto Regressive Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 33.9 31.0 5.0 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 71.9 95.8 90.0 99.9 99.8 99.7 99.8 99.9 
3 .4 .5 .6 .7 .4 .4 .4 .4 33.4 70.6 52.4 93.1 92.8 90.5 91.0 95.2 
4 .7 .6 .5 .4 .4 .4 .4 .4 67.0 37.4 51.8 85.5 85.4 87.2 85.4 89.0 
5 .6 .7 .8 .9 .6 .6 .6 .6 34.0 71.8 56.6 97.4 97.4 96.1 96.6 98.5 
6 .8 .7 .7. 6 .8 .6 .5 .4 61.2 76.2 68.8 75.4 77.6 71.0 74.2 81.2 
7 .5 .6 .6. 7 .5 .4 .4 .3 72.4 96.4 89.4 99.6 99.6 99.6 99.6 99.8 
8 .7 .7 .8 .9 .7 .7 .6 .5 42.8 87.7 72.0 99.8 99.8 99.7 99.8 99.8 
9 .6 .6 .6 .6 .6 .5 .4. 3 63.6 87.6 79.5 94.0 94.1 93.6 94.2 96.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 35.2 35.1 35.8 27.6 27.6 28.1 29.0 33.8 
11 .8 .8 .8 .8 .7 .7 .7 .7 48.8 46.7 47.6 36.3 36.3 36.2 37.6 44.9 
12 .7 .7 .7 .7 .5 .5 .5 .5 90.6 90.2 90.9 83.9 83.8 82.8 84.0 87.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 89.2 89.2 90.2 83.8 83.8 82.8 84.2 87.0 
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2.3 POWER CALCULATION OF THE PROPOSED METHOD 
The proposed method uses a Wilcoxon-type test statistic applied to vectors of observations and 
as the number of replicates increases, there is no clear concept of an increase in effective sample 
size as exists for many of the tests for repeated measures. Therefore it is not clear that the power 
of the Wilcoxon test statistic will be competitive with standard techniques. We believe that it is 
important to examine the relationship of the power of the proposed method to the number of 
repeated measurements.  
We consider power calculations for a clinical trial that is designed to compare two 
treatment groups (treatment A and treatment B) on a binary response of disease that will be 
assessed longitudinally over time. We give an illustration under a scenario where the marginal 
probability of disease is the same at all time points but different for each group and repeated 
observations taken from each subject are not correlated (independent correlation structure).  
The Wilcoxon test statistic can be viewed as a test based on stochastic dominance or the 
probability that the rank of a randomly selected subject assigned to treatment A will be lower 
than that of a randomly selected subject assigned to treatment B. For simplicity, lower rank 
indicates worse outcome. We calculate the exact probability that a subject assigned to treatment 
A has a worse rank score than a subject assigned to treatment B for specified marginal 
probabilities and assuming independence as a function of the number of replicates. Let 𝑟 = the 
number of repeated measurements taken from each subject. We assume that the probability of 
observing disease at each time point is 𝑝𝐴 =  0.8 and 𝑝𝐵 =  0.7 for treatment A and B, 
respectively. For 𝑟 =  1, the probability that the rank of randomly chosen subject from treatment 
A is lower than that of randomly chosen from treatment B is the product of the probability that a 
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subject assigned to treatment A has disease and the probability that a subject assigned to 
treatment B does not have disease  
𝑃𝑟(𝐴 <  𝐵)  =  (0.8)(0.3)  =  0.24 
We consider the ordering of vectors based on the strategy I given in Section 2.2.4 to 
calculate the probability 𝑃𝑟(𝐴 <  𝐵) for 𝑟 > 1. Based on this strategy, more time points with 
disease is worse outcome and rank of a subject who has disease earlier is lower than that of a 
subject who has disease later if the subjects have the same number of time points with disease. 
For 𝑟 =  2, for example, a subject who had disease at both time points ([1, 1]) has the lowest 
rank and a subject who had no diseases at all time points ([0, 0]) is the highest rank. A subject 
whose profile is [1, 0] has lower rank score than a subject whose profile is [0, 1]. As 
pA= (0.8, 0.8) andpB= (0.7, 0.7)  for treatment A and B, respectively, for 𝑟 =  2,  
𝑃𝑟(𝐴 <  𝐵)  =  𝑃𝑟([1,1])𝑃𝑟([1,0])  +  𝑃𝑟([1,1])𝑃𝑟([0,1])  +  𝑃𝑟([1,1])𝑃𝑟([0,0])  +                                𝑃𝑟([1,0])𝑃𝑟([0,0])  +  𝑃𝑟 ([0,1])𝑃𝑟( [0,0])  +  𝑃𝑟 ([1,0])𝑃𝑟( [0,1])  
𝑃𝑟 (𝐴 < 𝐵) =  (0.64)(0.21) +  (0.64)(0.21) +  (0.64)(0.09) + (0.16)(0.09) + (0.16)(0.09)+ (0.16)(0.21) = 0.3888 
We calculated 𝑃𝑟(𝐴 <  𝐵) for 𝑟 =  3, 4, 5 by writing a simple program in R package 
and present the results in Table 2.5. The probability that a subject in treatment A has lower rank 
than a subject in treatment B increases as the number of repeated measurements increases as 
shown in Table 2.5. It indicates that the power for testing treatment differences with the 
proposed method which uses a Wilcoxon test statistic increases with the increasing of the 
number of repeated measures. 
The power of the Wilcoxon test statistic was computed using the PROC POWER in SAS 
9.2 for different values of 𝑟. PROC POWER uses the O’Brien-Castelloe approximation to 
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calculate the power for an equal number of subjects of 60 per group (nA = nB = 60) and one-tailed 
alpha level of 0.025. We also estimated the power for the given sample sizes and one-sided Type 
I error of 0.025 through simulation study using 2000 simulation data sets. For each simulation, 
independent binary outcomes were generated given the marginal probabilities (e.g., 
pA= (0.8, 0.8) and pB= (0.7, 0.7) for 𝑟 =  2 and pA= (0.8, 0.8, 0.8) and pB= (0.7, 0.7, 0.7,) for 
𝑟 =  3) for 𝑟 repeated measurements as demonstrated in Section 2.2.3. The power estimates 
computed using SAS 9.2 and using the simulation study are compared in Table 2.5. Table 2.5 
examines the relationship between the power of the Wilcoxon test statistic and the number of 
repeated observations and shows that power estimates increases as the number of repeated 
measurements taken from each subject increases. 
 
Table 2.5: Statistical power calculation for a study with r repeated binary measures for an equal sample size 
of 60 per group and one-tailed alpha=0.025 
 Number of repeated binary measurements 
 2 3 4 5 
Pr (A < B) 0.39 0.48 0.55 0.59 
Power (%) 40.9 54.9 66.8 6.3 
Simulation (%) 39.4 57.1 66.2 75.8 
 
2.4 CONCLUSION 
 
We conducted simulation studies to compare the performance of our proposed method to that of 
commonly used methods for analysis of longitudinal binary data when there are no missing data. 
Simulation studies indicated that none of the approaches are uniformly better than the others. 
The type I error for all methods is reasonably close to the nominal value except MERI method 
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which produced higher type I error rates under the assumption of exchangeable and AR(1) 
correlation structures. There are some situations where our approach performs better/worse in 
terms of statistical power than the other approaches depending on the strategy for ordering 
vectors and the difference in the alternative hypotheses. In most situations, power for testing 
treatment differences with the proposed method versus the other standard methods is comparable 
and our proposed method is competitive with other methods. Note that our proposed method in 
the strategies of ranking we employed detects some types of interaction. Therefore, when 
interaction terms are not included in the GEE or MERI models, the proposed method tends to 
have slightly higher statistical power for alternatives that are different only for main effects but 
are very much inferior if the differences are due to an interaction. When an interaction term is 
included in these models, they lose statistical power for main effects and the proposed test often 
has superior power for main effect. We believe that our approach is feasible and it will readily be 
adaptable to missing data and multiple outcomes (intervention with other treatments). It is also 
more adjustable in distinguishing ‘clinically relevant difference’. 
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3.0  LONGITUDINAL BINARY RESPONSES WITH MISSING DATA 
Although many longitudinal studies are conducted to obtain measurements from all subjects at 
each of several time points, occurrence of missing data is common in such studies. In practice, 
all measurements from all subjects at pre-specified time points are not entirely observed. 
Withdrawal and loss to follow-up of subjects are one of the main concerns in longitudinal 
research. It is important to examine the missing data in order to draw valid and realistic results in 
the analysis of the data. As mentioned in Section 1.1, there are different methods of handling 
missing data in the analysis of repeated binary responses. Our proposed method allows several 
routes to be followed to incorporate missing data in the analysis of longitudinal binary outcomes. 
We restrict attention here to settings in which the pattern of missing data is monotone even 
though the proposed methodology can be applied to dataset in the presence of intermittent 
missing values. The motivation for the monotone missing data pattern is that it is more 
straightforward to address the dropouts compared to intermittent missing data.   
3.1 SET-UP AND NOTATION  
We introduce notations to be used throughout this chapter. We assume that 𝑛𝐴 and 𝑛𝐵 subjects 
are assigned to Trt-A and Trt-B, respectively and binary measurements are taken from all 
𝑁 = 𝑛𝐴+𝑛𝐵 subjects over time in longitudinal study with 𝑘 time points. To simplify notation, we 
assume that the design plan was to observe all subjects at the same number of time points. Let 
𝑿𝑖= (𝑥𝑖1, 𝑥𝑖2 , … , 𝑥𝑖𝑘 ) and 𝒀𝑗= (𝑦𝑗1, 𝑦𝑗2 , … ,𝑦𝑗𝑘) denote the 1𝑥𝑘 complete vectors of repeated 
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binary responses for subject 𝑖 in the Trt-A and subject 𝑗 in the Trt-B, respectively (i.e., outcomes 
that would have been observed if there were no missing data), with 𝑥𝑖𝑡 representing the binary 
response observed for the 𝑖𝑡ℎ subject in the Trt-A and 𝑦𝑗𝑡 representing the binary responses 
observed for the 𝑗𝑡ℎ subject in the Trt-B at time 𝑡 (t = 1,2,…, k,  i = 1,2,…, nA, j=1,2,…,nB). 
When some of the observations from subjects are not observed, we partition the vectors 𝑿𝑖 and 
𝒀𝑗 into 𝑿𝑖= (𝑿𝑖O(𝑡−1),𝑿𝑖M(𝑡)) and 𝒀𝑗= (𝒀𝑗O(𝑡−1),𝒀𝑗M(𝑡)), respectively, where 𝑿𝑖O(𝑡−1) =(𝑥𝑖1, 𝑥𝑖2 , … , 𝑥𝑖,𝑡−1)  denotes the observed part of 𝑿𝑖 before time 𝑡 at which dropout occurs and 
𝑿𝑖
M(𝑡) = (𝑥𝑖𝑡 , 𝑥𝑖,𝑡+1, … , 𝑥𝑖𝑘) denotes the unobserved missing part of 𝑿𝑖 after occurrence of 
dropout at time 𝑡; similarly, 𝒀𝑗
O(𝑡−1) = (𝑦𝑗1, 𝑦𝑗2 , … ,𝑦𝑗,𝑡−1)   denotes the observed part of 𝒀𝑗 
before time 𝑡 at which dropout occurs and 𝒀𝑗
M(𝑡) = (𝑦𝑗𝑡 ,𝑦𝑗,𝑡+1, … ,𝑦𝑖𝑘)   denotes the unobserved 
missing part of 𝒀𝑗 after occurrence of dropout at time 𝑡. Without loss of generality, 1 represents 
the presence of disease, 0 represents the absence of disease, and  ·  indicates a missing 
observation. If the measurement is observed it takes a value 0 or 1 and if the measurement is not 
observed, it is considered as missing. In this situation,  
𝑥𝑖𝑠 = �  1 ,     𝑖𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒                 0 ,     𝑖𝑓 𝑛𝑜 𝑑𝑖𝑠𝑒𝑎𝑠𝑒         
 · ,     𝑚𝑖𝑠𝑠𝑖𝑛𝑔                    𝑖 = 1,2, … ,𝑛𝐴;  𝑠 = 1,2, … , 𝑘 
𝑦𝑗𝑠 = �   1 ,     𝑖𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒                  0 ,     𝑖𝑓 𝑛𝑜 𝑑𝑖𝑠𝑒𝑎𝑠𝑒         
  ·  ,      𝑚𝑖𝑠𝑠𝑖𝑛𝑔                    𝑗 = 1,2, … ,𝑛𝐵;  𝑠 = 1,2, … , 𝑘 
When we restrict the missingness to dropouts, there are 𝑘 possible points at which a 
dropout can occur. Hence, there are 2𝑘 − 1 possible response profiles in case of the occurrence 
of dropout. If we assume that no dropout occurs at the 1𝑠𝑡 time point, there are 2𝑘 − 2 possible 
missingness profiles over time.  
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Since there are 2𝑘 possible response profiles over time for a complete sequence and 2𝑘 − 2 possible profiles over time for an incomplete sequence, there are 2𝑘+1 − 2 possible 
vectors for complete and incomplete sequences together. In other words, the maximum number 
of binary vectors to be obtained cannot exceed 2𝑘+1 − 2. We define a scalar dropout indicator 
𝐷𝑠 = 𝑡 representing the time 𝑡 at which dropout occurs between time 𝑡 and (𝑡 + 1) for 𝑡 =2, … ,𝑘 for 𝑠𝑡ℎ vector. For an incomplete vector of binary responses,  𝐷𝑠 denotes the time at 
which dropout occurs. For a complete vector of binary responses, 𝐷𝑠 = 𝑘 + 1 indicates no 
dropout (i.e. all measurements are observed). 
We define a matrix with (2𝑘+1 − 2) rows and 𝑘 columns. Each row of this matrix 
represents one of the possible response profiles with or without missing data and a ranked score 
will be assigned to each row. We designate this matrix as 𝒁. We will give details about how to 
create the  𝒁 matrix when missing data are encountered. 
For 𝑘 time points, 𝒁𝑠 = �𝑧𝑠1, 𝑧𝑠2, … , 𝑧𝑠𝑘� with 𝑠 =  1,2, … , 2𝑘+1 − 2 denoting one of the 
possible 2𝑘+1 − 2 binary representations for longitudinal binary outcomes in the presence or 
absence of missing data.   
If some responses are not observed, we partition 𝒁𝑠 into two sub-vectors such that 
𝐙𝑠
  O(𝑡−1) represents the sub-vector of observed measurements before time 𝑡 at which loss to 
follow-up occurs and 𝒁𝑠
  M(𝑡) represents the sub-vector of unobserved measurements after 
occurrence of dropout at time 𝑡. 
𝒁𝑠 = �𝒁𝑠  O(𝑡−1),  𝒁𝑠  M(𝑡)�                         (3.1) 
where 
𝒁𝑠
  O(𝑡−1) = �𝑧𝑠1, … , 𝑧𝑠,𝑡−1�  
                                                          𝑡 = 2, … ,𝑘 
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𝒁𝑠
  M(𝑡) = (𝑧𝑠𝑡, … , 𝑧𝑠𝑘)   
Let 𝐂  be a matrix with 2𝑘 rows and 𝑘 columns consisting of all 𝐂𝑠 , 𝑠 =  1, … , 2𝑘. Each 
row of 𝐂  represents one of the possible response profiles without missing observations as shown 
below (𝐂𝑠 denotes 𝑠𝑡ℎ
 row of 𝐂  with 𝑘 binary outcomes and 𝐂𝑠,𝑝 denotes the element of the 𝑠𝑡ℎ 
row and 𝑝𝑡ℎ column of 𝐂): 
𝐂 = � 𝐂1⋮
𝐂2𝑘
�                        (3.2) 
with 
𝑪𝑠,𝑝= � 1,       (ℎ − 1)2𝑘−𝑝  <  𝑠 < ℎ2𝑘−𝑝     ℎ = 1,3, … , 2𝑝 − 1;   𝑠 = 1,2, … , 2𝑘; 𝑝 = 1,2, … , 𝑘0,       𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                                                                                                                               
Let 𝑴 be a matrix with 2𝑘 − 2 rows and 𝑘 columns consisting of response sequences 
including at least one missing observation. Each row of 𝑴 denotes one of the possible response 
profiles with the occurrence of loss to follow-up as shown below: 
𝑴 = � 𝑴1      ⋮        𝑴2𝑘−2�                          (3.3) 
with 
𝑴𝑠,𝑝=
⎩
⎪
⎨
⎪
⎧
1,                  𝐺 + (ℎ − 1)2𝑘−𝑑−𝑝  <  𝑠  ≤  𝐺 + ℎ2𝑘−𝑑−𝑝                          0,                  𝐺 + ℎ2𝑘−𝑑−𝑝 <  𝑠  ≤  𝐺 + (ℎ + 1)2𝑘−𝑑−𝑝                            ∙ ,                  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                                                                              
𝑑 = 1,2, … , 𝑘 − 1
𝑝 = 1,2, … , 𝑘 − 𝑑
ℎ = 1,2, … , 2𝑝 − 1
𝑠 = 1,2, … , 2𝑘 − 2  
where 
𝐺 = 2𝑘�2−1 + 2−2 + ⋯2−(𝑑−1)�𝐼(𝑑≥2) with indicator function 𝐼  
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The rows of the matrix 𝑴  with 2𝑘 − 2 rows and 𝑘 columns are added after the rows of 𝑪  
matrix with 2𝑘 rows and 𝑘 columns to obtain 𝒁 matrix with 2𝑘+1 − 2 rows and 𝑘 columns such 
as  
𝒁(2𝑘+1−2)𝑥𝑘 = � 𝑪2𝑘𝑥𝑘  𝑴2𝑘−2𝑥𝑘�                                                     (3.4) 
As an illustration for 𝑘 = 4, 𝑪 matrix with 24  =  16 rows and 4 columns, 𝑴 matrix with 24 −  2 =  14 rows and 4 columns, and 𝒁 matrix with 24+1 − 2 = 30 rows and 4 columns 
would be  
𝑪 =
⎝
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎛
1 1 1 11 1 1 01 1 0 11 1 0 01 0 1 11 0 1 01 0 0 11 0 0 00 1 1 10 1 1 00 1 0 10 1 0 00 0 1 10 0 1 00 0 0 10 0 0 0⎠⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎞
  𝑴 =
⎝
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎜
⎛
1 1 1 ·1 1 0 ·1 0 1 ·1 0 0 ·0 1 1 ·0 1 0 ·0 0 1 ·0 0 0 ·1 1 · ·1 0 · ·0 1 · ·0 0 · ·1 · · ·0 · · ·⎠⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎟
⎞
       𝒁 = �𝑪
𝑴
�                (3.5) 
3.2 SCORE ASSIGNMENT TO THE VECTORS WITH MISSING DATA 
We assume that ranked scores are determined by a natural algorithm or obtained from a group of 
clinicians for all possible response profiles in the situation where no lost to follow-up has 
occurred. In other words, a group of clinicians ordered the complete sequences of binary 
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responses. We did not ask them to consider vectors with missing data in the ordering of the 
binary outcomes. Hence, we only have ranked scores of fully observed repeated responses from 
clinicians. We also do not incorporate the reasons of withdrawals from the study when assigning 
a score to the vectors including missing data. We basically use the matrix 𝑪 which is obtained 
based on subjective agreement of a group of clinicians as a reference to assign a score to each 
row of the 𝑴 matrix. We indicate a ranked score of a vector of binary responses, 𝑪𝑖 as 𝑅𝑎𝑛𝑘{𝑪𝑖} 
or 𝑅{𝑪𝑖}.  
The idea is to assign scores to the first 2𝑘−1 rows of 𝑴  using the assigned scores of each 
row of  𝑪  and sequentially assign scores to the other rows of 𝑴  using the scores assigned to the 
first 2𝑘−1 rows of 𝑴 calculated by using the scores of the rows of 𝑪. In order to apply this 
procedure, we need to calculate probabilities or weights in the following equation. 
Dropout at 𝑘 − 1   
𝑅{𝑴𝑠} = 𝑃𝑟[𝑴𝑠 = 𝑪2𝑠−1]𝑅{𝑪2𝑠−1} + 𝑃𝑟[𝑴𝑠 = 𝑪2𝑠]𝑅{𝑪2𝑠} ,         𝑠 = 1,2, … , 2𝑘−1         (3.6) 
Dropout at 𝑘 − 𝑑   
𝑅{𝑴𝐹} = 𝑃𝑟[𝑴F = 𝑴𝐿]𝑅{𝑴𝐿} + 𝑃𝑟[𝑴𝐹 = 𝑴𝑇]𝑅{𝑴𝑇}                                                     (3.7) 
where F  =  �2𝑘�2−1  +  2−2  +  …  + 2−(𝑑−1)�I(d≥2) + s�                                              
𝐿 =  �2𝑘(2−1  +  2−2  +  …  + 2−(𝑑−2))𝐼(𝑑−1≥2)  +  2𝑠 − 1�              
 
𝑇 = �2𝑘(2−1  +  2−2  +  …  + 2−(𝑑−2))𝐼(𝑑−1≥2) +  2𝑠�                       𝑤𝑖𝑡ℎ        
𝑑 =  2, 3, … ,𝑘 − 1
𝑠 =  1, 2, … ,  2𝑘−𝑑  
In the above equation (3.7), 𝑘 represents the number of replicates, 𝑑 represents the 
number of missing observations in the vector, and 𝑘 − 𝑑 indicates the time lost to follow-up. 
In Section 3.2.1, we describe two techniques to assign a score to a vector of binary 
responses with missing data (row of 𝑴) using the scores assigned to the vectors of binary 
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responses without missing data (rows of 𝑪). Score of a vector with missing value can be assigned 
by estimating the probability that a response was positive (negative) if it had not been missing. In 
other words, if the probabilities in equations (3.6) and  (3.7) are estimated, score to be assigned 
to a vector with missing data can be calculated.  
In Section 3.2.2, we briefly discuss Gehan’s Wilcoxon statistic which had been proposed 
to analyze time to event data and Gould’s method which incorporates information about reason 
of withdrawals in the analysis. We modified these two approaches to apply the proposed method 
to assign score to the vectors with dropouts.  
3.2.1 Stochastic Approach 
We provide strategies for calculating the probabilities in (3.6) and (3.7) to estimate the scores of 
the vectors with dropouts.     
3.2.1.1 Crude Substitution  
One approach to assign a score to the vector of outcomes with missing values is to form a 
weighted average of the ranks that could theoretically have occurred if there were no missing 
data. Probabilities or weights in (3.6) and (3.7) can be determined based on a priori set 
probabilities.  
 The outcome at any time point may not be obtained from the subjects for different reasons. 
If the missing response was observed, it would have the value 0 or 1. We illustrate this approach 
in the case of four observations collected from each subject over time. For example, we assume 
that missingness occurs at the last time point. The score to be assigned to a vector with a missing 
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observation at the 4𝑡ℎ time point would be one of the two scores from the two possibly observed 
vectors of responses if the observation at the last time point would have been observed as 
outcome is binary taking one of the two outcomes. Therefore, we can assign a score to this 
vector between the two scores. Let [1, 0, 0, •] denotes the 1𝑥4 vector of incomplete binary data 
for a given subject with missing value occurring at the last time point (• indicates missing value). 
If the last observation from this subject was not missing, the complete outcome vector for this 
subject would be [1, 0, 0, 0] or [1, 0, 0, 1]. If 1 indicates a positive (undesirable or disease) 
outcome and a higher score is better, the score to be assigned to the vector with missing 
observation could be higher than the score assigned to [1, 0, 0, 1] and lower than the one 
assigned to  [1, 0, 0, 0]. This approach simply uses the fact that outcome is dichotomous and 
does not take into account the reasons of withdrawals. A score to be assigned to [1, 0, 0, •] would 
be a simple weighted average of the scores assigned to [1, 0, 0, 0] and [1, 0, 0, 1]. We could, for 
example, assign equal weights to the occurrence of a 0 or 1. A modification of the technique 
would be to give priority to the outcomes that previously occurred in this individual. We refer to 
this approach as the “crude substitution approach”. 
When ties are present, previous responses could be used to break the tied values. We 
illustrate a situation where ties can occur by extending the above example. Suppose we ordered 
the vectors of complete binary responses observed at all time points based on the information 
from clinicians or a nested set of criteria and assigned a score to [0, 1, 1, 0] which is higher than 
the score assigned to [1, 0, 0, 1] and lower than the one assigned to [1, 0, 0, 0]. Assume that 
applying the above method results in tied rank for the two vectors, [1, 0, 0, •] and [0, 1, 1, 0]. We 
can break the tied values by comparing these two vectors based on the observations measured in 
the first three time points. As 1 indicates positive response, [1, 0, 0] which is the first three 
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observations of [1, 0, 0, •] would be better result than the [0, 1, 1] which is the first three 
observations of [0, 1, 1, 0]. Therefore, we can assign a higher score to [1, 0, 0, •] than [0, 1, 1, 0].  
Moreover, we actually applied equal weight to the vectors ([1, 0, 0, 0] and [1, 0, 0, 1]) to 
assign a score to the vector with missing data in the first example above. In this hypothetical 
example, we assumed that the occurrence of 1 and that of 0 at the last time point are equal 
regardless of the previously observed responses.  
We illustrate how to assign scores to the vectors with missing data, rows of the 𝑴 matrix in (3.5), by using the assigned scores to the rows of 𝑪 based on strategy I in Table 2.1. We first 
assign scores to the first eight rows of 𝑴 by using equation (3.6) and scores assigned to the rows 
of 𝑪 and then assign scores to the other rows of 𝑴 by using equation (3.7). In the same way, 
scores can be assigned based on strategy II. 
The first row of 𝑴, 𝑴1 = (1 1 1 •), would have been 𝑪1 = (1 1 1 1) or 𝑪2 = (1 1 1 0) if a 
missing observation had been observed. The rank of this vector would be  
𝑅{𝑴1} = 𝑃𝑟[ 𝑴1=(1 1 1 1) ]𝑅{𝑪1} + 𝑃𝑟[𝑴1=(1 1 1 0)]𝑅{𝑪2}    
The last observation is more likely to be a 1 rather than 0 based on the previous responses 
in this vector and therefore, 𝑃𝑟[ 𝑴1= (1 1 1 1) ] would be higher than 𝑃𝑟[ 𝑴1= (1 1 1 0) ]. We 
assigned a score of 1 to 𝑪1 and 2 to 𝑪2 based on the strategy I in Table 2.1 If we assume that 
𝑃𝑟[ 𝑪1= (1 1 1 1) ] = 0.6 which is higher than 𝑃𝑟[ 𝑴1= (1 1 1 0) ] = 0.4, the rank of 𝑴1 is  
𝑅{𝑴1} = 0.6*1 + 0.4*2 = 1.4    
The second row of 𝑴, 𝑴2 = (1 1 0 •), would have been 𝑪3 = (1 1 0 1) or 𝑪4 = (1 1 0 0) if 
a missing observation had been observed. Based on the previous responses, we can assign equal 
weights to the vectors. As 𝑃𝑟[ 𝑴2= (1 1 0 1) ] = 𝑃𝑟[ 𝑴2= (1 1 0 0) ] = 0.5 and assigned scores to 
𝑪3 and 𝑪4 are 3 and 6, respectively, rank of 𝑴2 is  
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𝑅{𝑴2} = 𝑃𝑟[ 𝑴2 = (1 1 0 1) ]𝑅{𝑪3} + 𝑃𝑟[𝑴2=(1 1 0 0)]𝑅{𝑪4} = 0.5*3 + 0.5*6 = 4.5    
Similarly, we assigned scores to the other vectors with one missing value (rows 3-8 of 𝑴) 
below.  
𝑅{𝑴3=(1 0 1 •)} = 𝑃𝑟[𝑴3=(1 0 1 1)]𝑅{𝑪5}  + 𝑃𝑟[𝑴3=(1 0 1 0)]𝑅{𝑪6} =0.5*4    + 0.5*7 = 5.5    
𝑅{𝑴4=(1 0 0 •)} = 𝑃𝑟[𝑴4=(1 0 0 1)]𝑅{𝑪7}  + 𝑃𝑟[𝑴4=(1 0 0 0)]𝑅{𝑪8} =0.4*8    + 0.6*12=10.4    
𝑅{𝑴5=(0 1 1 •)} = 𝑃𝑟[𝑴5=(0 1 1 1)]𝑅{𝑪9}  + 𝑃𝑟[𝑴5=(0 1 1 0)]𝑅{𝑪10}=0.6*5    + 0.4*9=6.6    
𝑅{𝑴6=(0 1 0 •)} = 𝑃𝑟[𝑴6=(0 1 0 1)]𝑅{𝑪11} + 𝑃𝑟[𝑴6=(0 1 0 0)]𝑅{𝑪12}=0.5*10 + 0.5*13=11.5    
𝑅{𝑴7=(0 0 1 •)} = 𝑃𝑟[𝑴7=(0 0 1 1)]𝑅{𝑪13} + 𝑃𝑟[𝑴7=(0 0 1 0)]𝑅{𝑪14}=0.5*11 + 0.5*14 = 12.5    
𝑅{𝑴8=(0 0 0 •)} = 𝑃𝑟[𝑴8=(0 0 0 1)]𝑅{𝑪15} + 𝑃𝑟[𝑴8=(0 0 0 0)]𝑅{𝑪16}=0.4*15 +  0.6*16=15.6    
By using (3.7) and the ranks of first eight rows of 𝑴, we assigned scores to the last six 
rows of 𝑴 as follows. 
𝑅{𝑴9=(1 1 • •)} = 𝑃𝑟[𝑴9=(1 1 1 •)]𝑅{𝑴1}    + 𝑃𝑟[𝑴9= (1 1 0 •)]𝑅{𝑴2}=0.6*1.4 + 0.4*4.5=2.6    
𝑅{𝑴10=(1 0 • •)} = 𝑃𝑟[𝑴10=(1 0 1 •)]𝑅{𝑴3}  + 𝑃𝑟[𝑴10=(1 0 0 •)]𝑅{𝑴4}=0.5*(5.5+10.4)=7.95    
𝑅{𝑴11=(0 1 • •)} = 𝑃𝑟[𝑴11=(0 1 1 •)]𝑅{𝑴5}  + 𝑃𝑟[𝑴11=(0 1 0 •)]𝑅{𝑴6}=0.5*(6.6+11.5)=9.1    
𝑅{𝑴12=(0 0 • •)} = 𝑃𝑟[𝑴12=(0 0 1 •)]𝑅{𝑴7}   + 𝑃𝑟[𝑴12=(0 0 0 •)]𝑅{𝑴8}=0.4*12.5+0.6*15.6=14.4    
𝑅{𝑴13=(1 • • •)} = 𝑃𝑟[𝑴13=(1 1 • •) ]𝑅{𝑴9} + 𝑃𝑟[𝑴13=(1 0 • •)]𝑅{𝑴10}=0.5*(2.6+7.95)=5.3    
𝑅{𝑴14=(0 • • •)} =
𝑃𝑟[𝑴14=(0 1 • •) ]𝑅{𝑴11}+𝑃𝑟[𝑴14=(0 0 • •)]𝑅{𝑴12}=0.5*(9.1+14.4)=11.75     
3.2.1.2 Logistic Regression Substitution 
In this section, we describe another strategy to assign scores to the vectors with missing data 
using the observed data and scores assigned to the possible vectors without missing data. We 
estimate the probability that a response is positive (negative) at a given time point by applying a 
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conditional logistic regression model given the previous responses and treatment variable. We fit 
conditional logistic regression models based on the non-missing data to predict expected values 
for response being positive (disease) at each time point separately.  
Consider a situation in which a binary response is obtained at each visit of 𝑡 = 1, … ,4 and  
𝒀𝑖 = (𝑌𝑖1, 𝑌𝑖2 , 𝑌𝑖3,  𝑌𝑖4). 𝑌𝑖𝑡 indicates the response variable for the 𝑖𝑡ℎ subject at time 𝑡 (𝑖 =1, … ,𝑁). A measurement 𝑌𝑖𝑡 in a longitudinal sequence is described as a function of previous 
outcomes, 𝑌𝑖
  𝑂(𝑡−1) = �𝑌𝑖1, … ,𝑌𝑖,𝑡−1�. Missing values occurring after the first time point can be 
predicted by conditional estimates of the probability that the unobserved value would be equal to 
1 or 0 if it was observed. To compute these probabilities, we assume that the probability of a 
positive response is determined by previously observed responses and a treatment indicator. For 
example, a standard logistic regression model based on the available data at time 𝑡 = 2 given the 
non-missing data at time 𝑡 = 1 and treatment indicator can be fitted to estimate the probability of 
positive response at time 𝑡 = 2. Therefore, we fit the following logistic regression models to 
estimate the probabilities of positive response at points where missing data occurred given the 
treatment indicator and the previous response,  
𝑙𝑜𝑔𝑖𝑡(𝑃𝑟(𝑌𝑖2 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖1)) = 𝛽0 + 𝛽1𝑇𝑟𝑡𝑖 + 𝛽2𝑦𝑖1 
𝑙𝑜𝑔𝑖𝑡(𝑃𝑟(𝑌𝑖3 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖2)) = 𝛼0 + 𝛼1𝑇𝑟𝑡𝑖 + 𝛼2𝑦𝑖2 
𝑙𝑜𝑔𝑖𝑡(𝑃𝑟(𝑌𝑖4 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖3)) = 𝛾0 + 𝛾1𝑇𝑟𝑡𝑖 + 𝛾2𝑦𝑖3. 
Then  
𝑃𝑟(𝑌𝑖2 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖1) = 𝑒𝛽0+𝛽1𝑇𝑟𝑡𝑖+𝛽2𝑦𝑖11 + 𝑒𝛽0+𝛽1𝑇𝑟𝑡𝑖+𝛽2𝑦𝑖1 
𝑃𝑟(𝑌𝑖3 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖2) = 𝑒𝛼0+𝛼1𝑇𝑟𝑡𝑖+𝛼2𝑦𝑖21 + 𝑒𝛼0+𝛼1𝑇𝑟𝑡𝑖+𝛼2𝑦𝑖2 
𝑃𝑟(𝑌𝑖4 = 1|𝑇𝑟𝑡𝑖 ,𝑦𝑖3) = 𝑒𝛾0+𝛾1𝑇𝑟𝑡𝑖+𝛾2𝑦𝑖31 + 𝑒𝛾0+𝛾1𝑇𝑟𝑡𝑖+𝛾2𝑦𝑖3 
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We assume that the probability of a positive response at a given time point is entirely 
determined by the available responses observed at the previous time point. The estimated 
parameters are used to predict the probability of positive response for missing observations.  
For illustration, we demonstrate how to apply this approach to assign scores to the vectors 
with missing data. Here we empirically calculate the probabilities in (3.6) by using the available 
observations from the dataset. As we considered the first row of 𝑴, 𝑴1 = (1 1 1 •),  we estimate 
the probability that 𝑴1 is equal to 𝑪1 = (1 1 1 1) or 𝑪2 = (1 1 1 0) which is the probability that the 
last observation is 1 or 0. We estimate this probability by fitting the logistic regression model 
mentioned above and substitute into the following equation  
𝑅{𝑴1} = 𝑃𝑟[ 𝑴1=(1 1 1 1) ]𝑅{𝑪1}+𝑃𝑟[𝑴1=(1 1 1 0)]𝑅{𝑪2} 
Similarly, we estimate the probabilities of positive response at each time point where the 
observation was not obtained by fitting logistic regression models at each time point to assign 
scores to the other vectors with missing data.  
This approach differs from the ‘crude substitution approach’ in Section 3.2.1.1 since the 
assigned scores to the vectors with missing data depend on the empirical frequency distributions 
of known outcomes. We refer to this approach as “logistic regression substitution approach”. 
It should be noted that the reasons of missingness are not known and we assume that we do 
not have any information about reasons of occurrence of dropouts.  
3.2.2 Nonstochastic Approach 
The strategies considered here are not required to assume or estimate probabilities as in Section 
3.2.1. Some vectors with missing data can still be partially ranked because its relative score 
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compared to another vector does not change regardless of the ‘true’ outcomes for the missing 
data. Also in some clinical trials, subjects may drop out of the study without completing all 
schedules visits. If reasons for withdrawals are known, the information about withdrawals can be 
incorporated in the analysis.  
3.2.2.1  Modification of Gehan’s Wilcoxon Test  
In clinical trials where the primary outcome is time to occurrence of an event (e.g., death), some 
subjects are censored before completing the study. To incorporate subjects who were censored 
into the analysis of data, Gehan (1965) proposed a method for integrating information about 
dropping out of the study. The Gehan-Wilcoxon test is formulated on the basis of comparisons of 
all pairs of subjects where each pair contains one individual from each group. Even with 
incomplete data the relative rank of some pairs can be determined. For example, in a clinical trial 
comparing two treatment groups in terms of time to the occurrence of a death, if censored time of 
a subject X is greater than the time of death for a subject Y, X is ranked higher than Y because it 
is known that the time of death for subject X is greater than that for subject Y.  We can modify 
Gehan’s Wilcoxon test to apply the proposed method for analyzing longitudinal binary data. 
Consider a situation where binary response is measured over four time points. A subject X 
dropped out of the study after the second time point and [1, 1, •, •] denotes the profile for subject 
X. Another subject Y completed the study and the observed profile of this subject is [1, 0, 0, 0]. 
A subject X is ranked lower than a subject Y regardless of missing values because it is known 
that X would have worse outcome than Y even those missing values were assumed to be disease 
free.  
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3.2.2.2 Modification of Gould’s Method 
When we have information about reasons for discontinuing the trial, we can incorporate this 
information in the ranking. Follow-up measurements which are scheduled to be observed after 
the initiation of treatment may be missing for some subjects due to treatment-related reasons or 
the progression of the disease. Some subjects withdraw from the study as a result of an adverse 
effect, lack of efficacy of the treatment, recovery, and external reasons irrelevant to the progress 
of the disease or unwillingness to continue the study. For example, in placebo-controlled trials, 
subjects in the placebo group who experience little or no improvement may drop out from the 
study to look for better treatment or subjects in the drug group who recover considerably may 
withdraw from the study because they think that it is not necessary to continue the study. Such 
subjects with missing observations can be included in the analysis of the data by assigning a rank 
that represents a better or worse score relative to those actually observed based on the reason of 
withdrawal or the time of leaving the study.  
One method for analysis of data with missing observations proposed by Gould (1980) is 
to incorporate the information about reasons of withdrawals into a rank ordering of subjects. 
Gould proposed an approach for analyzing longitudinal data with continuous responses when the 
outcomes observed at the last time point are used to make comparisons between two treatment 
groups without using the previous observations. If subjects prematurely withdraw from the study 
due to outcome related reasons (i.e., lack of improvement, adverse experiences, and beneficial 
effect of treatment), informatively missing observations occur and so, a pre-scheduled outcome 
at the end of the study cannot be measured for these subjects. Gould (1980) suggested ordering 
these withdrawals by the drop-out reasons and using rank tests to compare the treatment groups 
based on the rank scores produced by incorporating subjects with missing data.  
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If it is known that subjects who did not complete the study have better or worse responses 
than those who completed the study (e.g. cured subjects or lack of treatment effect), relevant 
scores that may be used in an analysis are assigned to such subjects.  
We can modify Gould’s idea to account for missing data in the analysis of longitudinal 
binary responses by ranking withdrawals based on the reasons such as treatment-related adverse 
events and a satisfactory effect of treatment Subjects who have withdrawn from the study due to 
treatment-related reasons can be ranked as better/worse values based on their missing data 
information and reasons for withdrawals.  
Non-completers can be considered as ‘poor’ outcomes if they withdraw from the study 
due to an adverse side effect or treatment failure or they can be regarded as ‘good’ outcomes if 
reasons of leaving the study are satisfactory effect of treatment or cure. Subjects withdrawn from 
the study at the same time point might receive the same score if their withdrawal reasons are 
same. Thus, these subjects share the same tied rank value. These tied ranks can be broken by 
ordering these vectors on the basis of the responses obtained prior to withdrawal. Moreover, 
another variable measured at baseline or during the study can be used to break the ties. 
3.3 PROPOSED METHOD OF ANALYSIS 
Define  
𝛿𝑖 = Rank�𝒁(𝑟)�    if  𝑿𝑖 = �𝑿𝑖𝑂(𝑡−1),𝑿𝑖𝑀(𝑡) � ≡ 𝒁(𝑟) ,     𝑖 =  1,2, . . . ,  𝑛𝐴; 𝑟 =  1,2, … , 2𝑘+1 −  2 
𝜉𝑗 = Rank�𝒁(𝑠)�    if   𝒀j = (𝒀jO(t−1),𝒀jM(t) ) ≡ 𝒁(s) ,     𝑗 =  1, 2, . . . ,𝑛𝐵; 𝑠 =  1,2, … ,  2𝑘+1 −  2 
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Hence, 𝛿1, … , 𝛿𝑛𝐴 are values of the subjects in Trt-A and 𝜉1, … , 𝜉𝑛𝐵 are values of the subjects in 
Trt-B.  
We can compare each of the 𝑛𝐴 subjects in Trt-A with each of the 𝑛𝐵 subjects in Trt-B 
using the relative order of the two vectors of outcomes in the presence of missing data. The 
assigned score comparing subject 𝑖 in Trt-A with subject 𝑗 in Trt-B is denoted as 𝑈𝑖𝑗. Thus, the 
comparison of the two treatment groups can be defined by a series of scores 𝑈𝑖𝑗, 𝑖 = 1,2, … ,𝑛𝐴, 
𝑗 = 1,2, … ,𝑛𝐵. We assume that 𝑈𝑖𝑗 takes the values 0, 0.5 or 1 if the 𝑖𝑡ℎ subject is worse, the 
same or better than the 𝑗𝑡ℎ  subject, respectively. It can be defined as  
𝑈𝑖𝑗 =
⎩
⎪
⎨
⎪
⎧       0     𝑖𝑓 (𝑿𝑖𝑂(𝑡−1),𝑿𝑖𝑀(𝑡)) < (𝒀𝑗𝑂(𝑡−1),𝒀𝑗𝑀(𝑡)) 𝑜𝑟 𝛿𝑖 < 𝜉𝑗   0.5     𝑖𝑓 (𝑿𝑖𝑂(𝑡−1),𝑿𝑖𝑀(𝑡)) = (𝒀𝑗𝑂(𝑡−1),𝒀𝑗𝑀(𝑡)) 𝑜𝑟 𝛿𝑖 = 𝜉𝑗      1      𝑖𝑓 (𝑿𝑖𝑂(𝑡−1),𝑿𝑖𝑀(𝑡)) > (𝒀𝑗𝑂(𝑡−1),𝒀𝑗𝑀(𝑡)) 𝑜𝑟 𝛿𝑖 > 𝜉𝑗
  
We compare two treatment groups by applying a Wilcoxon rank-sum test to the ranked 
scores, 𝛿1, … , 𝛿𝑛𝐴 , 𝜉1, … , 𝜉𝑛𝐵. Rank scores can be ordered from lowest to highest score and the 
Wilcoxon statistic 𝑊 is the sum of the ranks of the 𝛿’s in the combined ordered arrangement of 
𝛿’s and 𝜉’s. When ties are present, ties can be replaced by the average of ranks that the set of tied 
values would have been assigned if the values were distinct.  
W = �𝑅𝑎𝑛𝑘(𝛿𝑖) = ����𝐼�𝛿𝑖>𝜉𝑗� + 0.5 𝐼�𝛿𝑖=𝜉𝑗��𝑛𝐵
𝑗=1
+ ��𝐼�𝛿𝑖>𝛿𝑗� + 0.5 𝐼�𝛿𝑖=𝛿𝒋��𝑛𝐴
𝑗=1
�
𝑛𝐴
𝑖=1
𝑛𝐴
𝑖=1
 
The Mann-Whitney (1947) statistic, 𝑈, is the number of times a 𝜉𝑗 (1 ≤ j  ≤  nB) in the Trt-
B precedes a 𝛿𝑖 (1 ≤  i  ≤  nA) in the Trt-A in the combined ranking of the two treatment groups. 
𝑈 = ��𝑈𝑖𝑗𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
= ���𝐼�𝛿𝑖>𝜉𝑗� + 0.5𝐼�𝛿𝑖=𝜉𝑗��𝑛𝐵
𝑗=1
𝑛𝐴
𝑖=1
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where 𝐼{𝑣<0} is a set indicator with 𝐼{𝑣<0} = 1 if 𝑣 < 0 and 0 otherwise. 
Large values of 𝑈 indicate that there is a difference between treatment groups 
3.4 SIMULATION STUDY 
We conducted a simulation study comparing the performance of the proposed method and the 
frequently applied three standard methods using simulated data sets with various primary 
assumptions about the complete data sets and missing data mechanisms. Statistical models 
corresponding to each method of analysis were described in Section 2.2.1. For the t-test 
comparing the average proportions of positive responses between two treatment groups, 
proportions for each subject in both treatment groups were calculated based on the observed 
responses in which the number of positive responses was divided by the number of observed 
measurements, not the number of time points. The methods were compared with respect to type I 
error rates and power. 
3.4.1 Simulation Design 
The simulation study consisted of two different phases: (1) the data-generating phase and (2) 
analysis phase. In the first step, repeated binary responses were generated for each treatment 
group (placebo and drug) separately and missing values were imposed on these binary 
measurements. In the second step, data with missing values were analyzed by our proposed 
method and other commonly used methods under a wide range of scenarios and different missing 
data assumptions.  
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3.4.2 Data Generation 
We assumed that measurements were collected at four time points (𝑡1, 𝑡2, 𝑡3, and 𝑡4). We 
simulated correlated binary responses given the marginal probabilities of positive (disease) 
responses and independent correlation structures, exchangeable correlation structures with 
correlation coefficient being 0.3, and AR(1), correlation structures with correlation coefficient 
being 0.6 (i.e., 𝐶𝑜𝑟𝑟 (𝑌𝑗 ,  𝑌𝑘)  =  0.6, 𝐶𝑜𝑟𝑟(𝑌𝑗 , 𝑌𝑘)  =  0.36, and 𝐶𝑜𝑟𝑟(𝑌𝑗 ,𝑌𝑘)  =  0.216 for |𝑗 −
𝑘|  =  1,2,3, respectively)  using the method of Park et al. (1996) as mentioned in Section 2.2.3. 
The response at each time point was either positive (= 1) or negative (= 0) if it was observed. 
The same sets of marginal expectations and correlation structures for the association among the 
measurements were considered as we used in Section 2.2.3.  
We assumed that the treatment indicator (A indicates placebo group and B indicates drug 
group) is completely measured and that dropout could occur at the 2𝑛𝑑, 3𝑟𝑑, or 4𝑡ℎ time points. 
When a measurement is missing from any subject at any given time point, all subsequent 
measurements for that subject are assumed to be missing (monotone missing data pattern). 2000 
simulated data sets of 60 subjects per treatment group for four time points were generated for 
each setting and a missingness mechanism imposed to the generated data. We applied all 
methods to the same simulated dataset.  
We subjected each simulated data set to various missing data patterns and proportion of 
withdrawals. After simulating full longitudinal binary responses for each treatment group, we 
randomly deleted responses (MCAR) at specified rates and deleted stochastically on the basis of 
the value of the covariate (treatment group) or on the basis of previously observed response 
(MAR) after the first time point to create an incomplete data set. We assumed that measurements 
from each subject were obtained at the first assessment. We first imposed missing values on 
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measurements at the second time point (𝑌2), then imposed missing values on those at the third 
time point (𝑌3) for the remaining subjects and then imposed missing values on those at the last 
time point (𝑌4) for the subjects who stayed in the study separately for each treatment group. Two 
separate scenarios were used for the MAR mechanism: The likelihood of missing values on the 
response is related to the treatment group for the first scenario and is correlated with the previous 
response prior to dropping out for the second scenario.  
For MCAR, the probability of drop-out at time 𝑡 = 2,3,4 did not depend on any variables 
or responses. After generating a complete data set, data were randomly deleted at rates of 10%, 
15%, and 25% for the 2𝑛𝑑, 3𝑟𝑑, and 4𝑡ℎ time points, respectively. The subjects were equally 
likely to drop out of the study for both treatment groups.  
Let 𝑌𝑖𝑡  be the observed binary response for subject 𝑖 =  1, … ,𝑁 and occasion 𝑡 = 1, 2, 3, 4. 𝑀𝑖𝑡 = 0 denotes a missing response and 𝑀𝑖𝑡 = 1 denotes an observed response.  
𝑃𝑟(𝑀𝑖2  =  0|𝑀𝑖1  =  1)  =  0.10     
𝑃𝑟(𝑀𝑖3  =  0|𝑀𝑖2  =  1)  =  0.15   
𝑃𝑟(𝑀𝑖4  =  0|𝑀𝑖3  =  1)  =  0.25 
For the first scenario of MAR (MAR-1), rates of missingness are different for each 
treatment group at the 2𝑛𝑑, 3𝑟𝑑, and 4𝑡ℎ time points. Unequal drop-out rates in treatment and 
placebo groups were assumed. This MAR situation represents a reasonable scenario where 
missing data might predominantly occur in one treatment group relative to other group. It 
illustrates that more subjects in the placebo group than the treatment group drop out the study 
due to a lack of efficacy of the treatment. It results in different rates of missingness between the 
treatment groups. Thus, we assumed that proportions of withdrawals are higher in Trt-A than 
Trt-B at each time point. Rates of missigness of 10%, 15%, and 25% for the placebo group and 
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6%, 10%, and 16% for the treatment group at the 2𝑛𝑑, 3𝑟𝑑, and 4𝑡ℎ time points, respectively 
were considered. 
𝑃𝑟(𝑀𝑖2  =  0|𝑀𝑖1  =  1)  =  �0.10,      𝑝𝑙𝑎𝑐𝑒𝑏𝑜        0.06,      𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡      
𝑃𝑟(𝑀𝑖3  =  0|𝑀𝑖2  =  1)  =  �0.15,        𝑝𝑙𝑎𝑐𝑒𝑏𝑜          0.10,       𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡       
𝑃𝑟(𝑀𝑖4  =  0|𝑀𝑖3  =  1)  =  �0.25,      𝑝𝑙𝑎𝑐𝑒𝑏𝑜         0.16,      𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡       
For the second scenario of MAR (MAR-2), the likelihood of missingness occurring at a 
given time point was dependent on the previous response. The same dropout probabilities are 
used for both groups. The probability of drop-out at each time points after the first time point 
were gradually increased by 10%, 15%, and 25%, respectively. The marginal probabilities at 
four time points are 𝑝𝐴 = (𝑝𝐴1,𝑝𝐴2,𝑝𝐴3,𝑝𝐴4) and 𝑝𝐵 = (𝑝𝐵1,𝑝𝐵2,𝑝𝐵3,𝑝𝐵4) for Trt-A and Trt-B, 
respectively. The dropout model was specified as the probability of withdrawal at time point 𝑗 
given the response at the previous time point 𝑗 − 1 is modeled using a logistic regression in the 
form of 
𝑙𝑜𝑔𝑖𝑡�𝑃𝑟�𝑀𝑖𝑗  =  0�𝑀𝑖,𝑗−1  =  1�� =   𝜏𝑗−1  +  𝜏𝑦𝑌𝑖,𝑗−1  𝑓𝑜𝑟 𝑗 =  2, 3, 4 
From the above model, we calculated the intercept given the dependency of the missing 
value (𝜏𝑦) and the probability of positive response at the previous time point for 𝑗 = 2, 3, 4.  
𝜏𝑗−1  =  𝑙𝑜𝑔𝑖𝑡�𝑃𝑟�𝑀𝑖𝑗  =  0�𝑀𝑖,𝑗−1  =  1�� − 𝜏𝑦𝑌𝑖,𝑗−1   
We set the equal rates of dropout at the 2𝑛𝑑, 3𝑟𝑑, and 4𝑡ℎ time points for both treatment 
groups at 10%, 15%, and 25%, respectively. The missing pattern follows from the equations.   
𝑙𝑜𝑔𝑖𝑡[𝑃𝑟(𝑀𝑖2  =  0|𝑀𝑖1  =  1)]  =  �−2.197 + 𝜏𝑦𝑝𝐴1,        𝑝𝑙𝑎𝑐𝑒𝑏𝑜             −2.197 +  𝜏𝑦𝑝𝐵1,         𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡         
𝑙𝑜𝑔𝑖𝑡[𝑃𝑟(𝑀𝑖3  =  0|𝑀𝑖2  =  1)]  =  �−1.735 +  𝜏𝑦𝑝𝐴2,         𝑝𝑙𝑎𝑐𝑒𝑏𝑜         −1.735 +  𝜏𝑦𝑝𝐵2,        𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡      
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𝑙𝑜𝑔𝑖𝑡[𝑃𝑟(𝑀𝑖4  =  0|𝑀𝑖3  =  1)]  =  �−1.099 +  𝜏𝑦𝑝𝐴3,          𝑝𝑙𝑎𝑐𝑒𝑏𝑜       −1.099 +  𝜏𝑦𝑝𝐵3,         𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡    
𝜏𝑦 = 0.8 was chosen for strong dependency of drop-out on the previous response in our 
simulation runs. Non-response rates for each treatment group were calculated from the missing 
data pattern above given the dependence of responses to missingness (𝜏𝑦) and marginal 
probabilities 𝑝𝐴 and 𝑝𝐵 to impose missing data mechanism on the complete data. 
3.4.3 Assigning Scores to the Vectors with Missing Data 
We considered the same strategies for ordering the observed vectors without missing data as 
shown in Table 2.1 in Section 2.2.4. We used these two strategies to assign scores to the vectors 
with missing data. Details regarding the score assignment to the vectors with missing data were 
given in Section 3.2.1.1. Assigned scores to the possible vectors with missing data, which are 
rows of matrix 𝑴 in (3.5), based on strategy I and strategy II are shown in Table 3.1.  
3.4.4 Simulation Results 
The simulation results for the Type I error rate are reported in Table 3.2, Table 3.3, and Table 3.4 
and the simulation results for the power are reported in Table 3.5, Table 3.6, and Table 3.7 when 
the missing data mechanism is MCAR, MAR-1, and MAR-2, respectively. Results comparing 
the proposed method with GEE and MERI methods in terms of power are presented in Table 3.8 
when the time by treatment interaction term was included under the assumption of MAR-2 
missing data mechanism and the assumption of AR(1) correlation structure. 
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Table 3.1: Assigned scores to the vectors with missing data 
 
 
 
 
 
 
 
 
 
 
 
 
(1 = positive, 0 = negative, and • = missing) 
 
 
Type I Error Rate  
The type I error rates of the proposed method and the competing methods are given in Table 3.2 
under different selection scenarios of marginal expectations at four time points and using three 
different correlation structures when the missing data mechanism was assumed to be MCAR. 
Under a variety of scenarios using different correlation structures, none of the methods differed 
substantially from the type I error rate except the proposed logistic regression substitution 
approach which noticeably inflated the type I error rate in all cases regardless of the missing data 
mechanism. When we use this approach to estimate the probability that an outcome is positive at 
a given time point, conditional logistic regression model excludes subjects missing the 
observation at that point and is likely to produce biased estimates of treatment effects. Therefore, 
the probabilities in equations (3.6) and (3.7) may not properly estimated and the type I error rates 
 
Rank Score 
Strategy 
Profile I II 
[ 1 1 1 • ] 1.4 2.6 
[ 1 1 0 • ] 4.5 7.5 
[ 1 0 1 • ] 5.5 6.5 
[ 1 0 0 • ] 10.4 12.2 
[ 0 1 1 • ] 6.6 4.8 
[ 0 1 0 • ] 11.5 10.5 
[ 0 0 1 • ] 12.5 9.5 
[ 0 0 0 • ] 15.6 14.4 
[ 1 1 • • ] 2.64 4.56 
[ 1 0 • • ] 7.95 9.35 
[ 0 1 • • ] 9.05 7.65 
[ 0 0 • • ] 14.36 12.44 
[ 1 • • • ] 5.3 6.96 
[ 0 • • • ] 11.71 10.1 
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produced by this approach are greatly inflated. Since the logistic regression substitution approach 
did not control the type I error rate at the nominal level of 0.05, we excluded this approach in the 
comparison of the methods, therefore, when we use the term “proposed method”, it will refer to 
“crude substitution approach”.  
The type I error rates for the proposed approach with the two different strategies (I and II) 
are close to or around the nominal 5 percent level regardless of the different correlation 
structures. The type I error rates for MERI are inflated when exchangeable or AR(1) correlation 
structure was assumed. In some cases, GEE with unstructured correlation structure yielded 
slightly higher type I error rate than the nominal level of 0.05. When compared to other methods, 
the proposed method (using both strategies) produced lower type I error rate in almost all cases.   
Under MAR-1, all methods produced desirable type I error rate around the nominal level 
when independent correlation structure was assumed, as reported in Table 3.3. Similar to the 
MCAR mechanism, the type I error rate for MERI was inflated when an exchangeable or AR(1) 
correlation structure was assumed. As explained in Section 2.2.3, MERI produces higher type I 
error rate as correlation among the observations within subject increases. GEE produced a 
slightly higher type I error rate in the scenario of pA = pB = (.6, .4, .6, .4) when the correlation 
structures were assumed to be exchangeable and AR(1). The proposed method exhibit inflation 
of the type I error rates for pA = pB = (.6, .7, .8, .9) under the all three correlation structure.     
Under MAR-2, as shown in Table 3.4, simulation results demonstrated that all methods 
controlled the type I error rate at the nominal level, even the MERI method which inflated the 
type I error rate under MCAR and MAR-1. The type I error rates for all methods were lower 
when MAR-2 was assumed compared to MAR-1 and MCAR. The type I error rate for the 
proposed method with strategy II was slightly lower than that for the other methods in all 
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scenarios. The type I error rates for the proposed method with strategy I and other methods were 
comparable.  
For the scenario of pA = pB = (.6, .7, .8, .9), a high type I error rate was produced by the 
proposed method (strategy I and especially strategy II) in the situation where the missing data 
mechanism was assumed to be MAR-1 while much lower type I error rate was produced under 
MCAR and MAR-2. 
Based on these results, we can conclude that the proposed method with crude substitution 
approach controlled the type I error rate around nominal level for almost all scenarios in the 
presence of missing data. 
Statistical Power 
The logistic substitution approach artificially yielded high power under the alternative hypothesis 
at the price of a largely inflated type I error rate under the null hypothesis in all scenarios 
(different marginal probabilities and different correlation structures) regardless of the missing 
data mechanism. Therefore, this method was excluded when the methods were further discussed 
in terms of power. 
The statistical powers of the methods under MCAR are presented in Table 3.5. In the 
situation where pA = (.3, .5, .6, .8) and pB = (.8, .6, .5, .3) and different correlation structures 
were assumed, the proposed method with strategy II dramatically reduced power while the other 
methods especially the t-test and the proposed method with strategy I, which yielded the highest 
power compared to other methods, Under MCAR, the t-test tended to reduce power more than 
the other methods for almost all scenarios except those where pA = (.7, .7, .7, .7) and  
pB = (.5, .5, .5, .5), pA = (.5, .5, .5, .5) and pB = (.3, .3, .3, .3), and pA = (.7, .6, .5, .4) and   
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Table 3.2: Type I Error (%): Simualtion results for comparing the methods with missing data. MCAR, 
missingness with equal dropout rates for both groups 
Dropout rates are equal for both groups: (0, 10%, 15%, 25%)         n = ( 60, 54, 46, 34 )  
 Placebo Drug Crude  Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 4.8 4.2 9.2 20.2 5.0 5.4 5.4 5.2 5.9 5.0 
2 .4 .4 .4 .4 .4 .4 .4 .4 5.6 5.1 10.0 19.1 5.0 5.9 6.1 6.2 6.6 5.4 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.6 4.1 8.6 18.4 4.6 4.6 4.6 4.6 5.0 4.0 
4 .7 .7 .7 .7 .7 .7 .7 .7 4.6 4.2 10.5 20.9 4.6 6.2 6.0 6.2 6.5 5.5 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.0 4.6 9.7 18.6 5.8 5.3 5.4 5.3 6.0 4.4 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.6 4.3 9.8 18.8 5.5 5.6 5.7 5.7 6.4 5.2 
7 .6 .7 .8 .9 .6 .7 .8 .9 4.2 2.4 6.8 15.1 4.8 4.6 4.8 4.6 5.2 4.5 
8 .7 .6 .5 .4 .7 .6 .5 .4 4.6 5.2 8.8 17.6 4.2 4.8 4.8 4.8 5.2 4.4 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.6 4.4 9.4 18.0 5.6 5.6 5.4 5.6 5.8 4.9 
Exchangeable Correlation Structure 
1 .3 .3 .3 .3 .3 .3 .3 .3 4.6 4.6 9.4 14.8 5.1 5.8 5.8 5.8 6.2 6.8 
2 .4 .4 .4 .4 .4 .4 .4 .4 5.9 5.8 9.9 14.8 5.8 6.4 6.0 6.0 6.3 7.0 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.7 4.8 9.4 13.6 4.6 5.6 5.0 5.2 5.4 6.2 
4 .7 .7 .7 .7 .7 .7 .7 .7 3.4 2.4 8.4 15.6 4.7 5.2 4.6 4.8 5.4 5.6 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.3 4.6 9.1 12.0 5.3 5.0 5.2 5.2 5.8 6.1 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.9 4.6 9.4 13.6 4.9 5.8 5.2 5.3 6.4 6.6 
7 .6 .7 .8 .9 .6 .7 .8 .9 3.6 2.5 6.2 11.4 4.7 5.0 5.2 5.4 5.6 6.4 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.1 5.4 9.6 14.7 5.2 5.6 5.3 5.4 5.6 6.4 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.8 4.4 9.2 14.4 4.8 5.1 5.0 5.0 5.2 6.1 
Auto-Regressive Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 3.8 3.6 8.2 13.8 4.8 5.3 5.2 5.4 5.6 6.2 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.4 4.8 8.8 14.0 4.9 5.4 5.0 4.6 5.0 6.3 
3 .5 .5 .5 .5 .5 .5 .5 .5 5.5 4.8 8.5 13.7 5.5 5.6 5.0 5.3 5.7 6.3 
4 .7 .7 .7 .7 .7 .7 .7 .7 5.2 4.4 8.2 12.8 5.2 5.4 5.6 5.4 6.0 6.8 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.7 5.0 8.6 12.6 4.5 4.8 4.9 4.9 5.2 5.9 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.2 5.1 8.6 12.6 5.3 5.4 5.6 5.8 6.2 7.0 
7 .6 .7 .8 .9 .6 .7 .8 .9 3.6 2.2 6.0 8.8 4.4 4.0 4.2 4.5 5.1 5.0 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.6 5.1 10.6 13.6 5.4 5.6 5.6 5.8 6.2 7.2 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.0 4.4 8.8 13.9 3.9 4.1 4.6 4.4 4.7 5.1 
Abbreviations: Crude, proposed method by applying “crude substitution approach” for score assignment to 
the vectors with missing data based on the ordering of strategies I and II in Table 2.1; Logistic, proposed 
method by applying “logistic regression approach” for score assignment to the vectors with missing data 
based on the ordering of strategies I and II in Table 2.1; t-test, t-test comparing the means of the proportions 
of positive responses between the two groups; GEE, logistic regression model using GEE; MERI, mixed 
effects logistic regression model with random intercept; IND, independent correlation structure; EX, 
exchangeable correlation structure; AR(1), first-order auto-regressive correlation structure; UN, unstructured 
correlation structure; pt, marginal probability of positive response at time t, t = 1, 2, 3, 4. 
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Table 3.3: Type I Error Rate (%): Simulation results for comparing the methods with missing data. MAR-1, 
missingness with different dropout rates for each group 
Dropout rates:   Placebo: (0, 10%, 15%, 25%)               n = (60,  54,  46,  34)  
                             Drug   :  (0,  6%, 10%, 1                      n = (60,  56,  50,  42)  
 Placebo Drug Crude  Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 5.4 5.4 8.5 15.2 5.6 5.5 5.4 5.5 5.9 5.0 
2 .4 .4 .4 .4 .4 .4 .4 .4 5.0 5.9 8.6 16.1 4.8 5.2 5.2 5.2 5.9 4.6 
3 .5 .5 .5 .5 .5 .5 .5 .5 5.0 4.5 8.2 14.5 4.9 4.8 4.8 5.0 5.1 4.4 
4 .7 .7 .7 .7 .7 .7 .7 .7 5.1 5.6 7.8 17.0 4.8 4.7 4.8 4.8 5.2 4.2 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.5 5.0 7.6 14.2 4.8 4.8 4.8 5.0 5.1 4.4 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.6 4.8 7.8 14.3 4.0 4.4 4.2 4.4 5.0 4.2 
7 .6 .7 .8 .9 .6 .7 .8 .9 6.4 7.2 7.0 13.2 6.0 5.6 5.6 5.7 5.8 5.3 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.4 5.4 9.0 14.4 5.0 5.3 5.4 5.4 6.0 4.9 
9 .6 .6 .4 .4 .6 .6 .4 .4 5.4 5.2 8.2 15.4 5.6 5.5 5.4 5.6 6.0 5.4 
Exchangeable Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 4.6 5.2 7.8 10.6 4.7 4.2 4.8 4.0 5.4 5.5 
2 .4 .4 .4 .4 .4 .4 .4 .4 5.0 4.7 7.8 11.6 5.2 5.2 5.1 4.9 5.7 6.2 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.6 4.4 7.9 11.8 4.6 4.6 4.3 4.5 5.0 5.6 
4 .7 .7 .7 .7 .7 .7 .7 .7 5.9 6.2 9.0 14.2 5.6 6.4 6.0 6.4 6.5 7.0 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.8 5.6 9.2 13.2 6.0 6.2 6.1 6.2 6.6 7.2 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.0 5.2 8.0 10.6 4.5 5.0 4.6 4.8 5.2 5.6 
7 .6 .7 .8 .9 .6 .7 .8 .9 6.4 6.9 7.6 10.9 4.8 5.5 5.8 5.8 6.0 6.6 
8 .7 .6 .5 .4 .7 .6 .5 .4 4.8 5.0 8.2 11.4 5.5 4.8 5.0 5.2 5.5 5.8 
9 .6 .6 .4 .4 .6 .6 .4 .4 5.2 4.9 8.4 11.0 5.3 5.0 5.4 5.2 6.2 6.4 
Auto-Regressive Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 6.0 5.8 7.8 12.2 4.5 5.6 5.1 5.0 5.4 6.2 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.8 4.4 6.8 10.0 4.7 4.6 4.7 4.4 5.2 5.8 
3 .5 .5 .5 .5 .5 .5 .5 .5 5.8 5.2 8.0 11.2 5.4 5.6 5.6 5.2 5.8 6.8 
4 .7 .7 .7 .7 .7 .7 .7 .7 5.5 5.2 8.2 10.9 4.8 5.1 5.0 5.2 5.5 6.5 
5 .6 .4 .6 .4 .6 .4 .6 .4 5.6 5.5 8.6 12.2 5.6 6.4 6.2 6.0 6.5 7.5 
6 .4 .5 .6 .7 .4. 5 .6 .7 5.2 5.6 7.8 10.4 5.4 5.4 5.2 5.5 6.2 6.6 
7 .6 .7 .8 .9 .6 .7 .8 .9 6.6 7.8 8.1 9.8 6.2 5.3 5.4 5.8 6.6 7.2 
8 .7 .6 .5 .4 .7 .6 .5 .4 5.4 5.6 8.8 11.2 5.0 5.3 5.3 5.2 6.3 6.5 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.4 5.2 7.2 11.6 4.7 4.8 4.5 4.6 5.0 5.4 
Abbreviations are same as in Table 3.2 
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Table 3.4: Type I Error Rate (%): Simulation results for comparing the methods with missing data. MAR-2, 
missingness with same dropout rates for each group 
Dropout rates are equal for both groups:  (0, 10%, 15%, 25%)             n = ( 60,  54,  46,  34 )  
 Placebo Drug Crude Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 3.0 2.0 7.8 15.0 4.1 3.2 3.2 3.2 3.6 2.8 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.4 3.4 8.4 14.2 4.5 4.0 4.1 4.1 4.0 3.6 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.2 3.0 7.4 14.6 4.2 3.5 3.6 3.6 3.7 3.2 
4 .7 .7 .7 .7 .7 .7 .7 .7 3.0 2.9 7.2 16.0 3.8 3.6 3.6 3.6 3.7 3.2 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.4 3.2 8.4 14.0 4.2 4.4 4.4 4.4 4.4 3.4 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.8 3.2 10.0 16.9 4.6 4.5 4.4 4.3 4.6 3.5 
7 .6 .7 .8 .9 .6 .7 .8 .9 2.9 1.0 6.8 14.2 4.1 4.5 4.8 4.8 4.9 4.4 
8 .7 .6 .5 .4 .7 .6 .5 .4 4.0 3.4 8.4 13.6 3.6 4.0 4.0 3.9 3.9 3.6 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.0 3.0 9.0 14.4 4.2 3.6 4.0 3.6 4.2 3.3 
Exchangeable Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 3.5 3.4 7.0 11.0 5.0 3.8 4.2 4.2 4.4 5.0 
2 .4 .4 .4 .4 .4 .4 .4 .4 4.2 4.0 8.0 10.2 4.6 4.4 5.0 4.9 5.4 6.0 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.6 4.3 9.0 10.8 5.4 4.7 5.2 4.8 5.4 6.0 
4 .7 .7 .7 .7 .7 .7 .7 .7 3.0 2.4 8.6 14.4 5.2 5.2 5.2 5.2 5.4 5.6 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.4 3.5 8.1 11.6 4.7 4.0 4.4 4.0 4.5 5.4 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.8 3.5 9.2 11.9 4.5 5.0 4.8 4.8 5.2 6.0 
7 .6 .7 .8 .9 .6 .7 .8 .9 3.5 1.6 7.2 12.0 4.8 5.6 5.7 5.3 6.0 6.8 
8 .7 .6 .5 .4 .7 .6 .5 .4 3.5 3.2 8.2 10.0 4.8 3.6 4.4 4.2 4.8 5.2 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.2 3.0 8.2 10.0 4.0 3.3 4.4 3.8 4.4 4.9 
Auto-Regressive Correlation Structure  
1 .3 .3 .3 .3 .3 .3 .3 .3 3.2 3.0 6.3 10.0 4.3 3.4 3.9 4.2 4.2 4.6 
2 .4 .4 .4 .4 .4 .4 .4 .4 3.4 2.8 6.8 10.6 4.4 3.4 4.2 4.1 4.6 5.2 
3 .5 .5 .5 .5 .5 .5 .5 .5 4.0 3.6 7.0 10.2 3.8 3.9 4.1 4.2 4.4 4.8 
4 .7 .7 .7 .7 .7 .7 .7 .7 4.0 3.6 7.4 10.4 5.6 4.6 5.2 4.8 5.8 6.2 
5 .6 .4 .6 .4 .6 .4 .6 .4 4.4 4.2 6.8 9.8 4.8 4.2 4.2 4.0 4.4 5.2 
6 .4 .5 .6 .7 .4. 5 .6 .7 4.3 3.6 7.0 11.4 4.4 4.2 4.3 4.4 4.6 5.3 
7 .6 .7 .8 .9 .6 .7 .8 .9 3.4 1.9 6.8 8.7 4.9 4.2 4.5 4.4 5.0 5.9 
8 .7 .6 .5 .4 .7 .6 .5 .4 4.0 3.7 8.3 9.4 4.8 4.1 4.8 4.8 5.1 5.4 
9 .6 .6 .4 .4 .6 .6 .4 .4 4.2 3.3 8.0 10.6 3.8 4.4 4.1 4.1 4.6 5.0 
Abbreviations are same as in Table 3.2. 
 
pB = (.4, .4, .4, .4)  regardless of assumption of correlation structures when compared to the 
results in Table 2.2.   
When the marginal probabilities were pA = (.4, .4, .4, .4) and pB = (.3, .3, .3, .3) with  
AR(1) correlation structure and the marginal probabilities were pA = (.8, .8, .8, .8) and 
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pB = (.7, .7, .7, .7) assuming both exchangeable and AR(1) correlation structures, the proposed 
approach with strategy II had slightly lower power than the other methods whereas it yielded 
statistical power comparable to other procedures in the absence of missing data (Table 2.2). In 
view of the results on Table 2.2, the results produced under MCAR (Table 3.5) were parallel in 
terms of comparisons of the power of the methods and the decrease in power for the proposed 
method with strategy II was less than the decrease in power for other methods. 
The results are reported in Table 3.6 when the dropout rates were different in each 
treatment group (MAR-1). We compared the results under MAR-1 (Table 3.6) to those under 
MCAR (Table 3.5). There were some scenarios where the results under MCAR were different 
than those under MAR-1.  
For the scenario of pA = (.6, .7, .8, .9) and pB = (.6, .6, .6, .6) assuming independent and 
AR(1) correlation structures, the power of the proposed method with strategy II reduced while 
GEE and MERI methods increased power under MAR-1 compared with MCAR and hence, the 
proposed method with strategy II, GEE, and MERI are comparable in terms of power. For the 
same scenario with the assumption of exchangeable correlation structure, the proposed method 
with strategy II demonstrated lower power than GEE and MERI under MAR-1 whereas it had 
higher power than other methods under MCAR. For the scenario where pA = (.7, .7, .8, .9) and 
pB = (.7, .7, .6, .5), the proposed method with strategy II yielded lower power when independent 
correlation structure was assumed and it yielded similar or slightly higher power compared with  
GEE and MERI methods when exchangeable and AR(1) correlation structure were 
employed under MAR-1. The proposed method with strategies I and II produced higher power 
when the marginal probabilities were pA = (.4, .4, .4, .4) and pB = (.3, .3, .3, .3) and produced 
lower power when the marginal probabilities were pA = (.8, .8, .8, .8) and pB = (.7, .7, .7, .7) 
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compared with other methods regardless of correlation structures. In other scenarios, results 
under MAR-1 were similar to those under MCAR. t-test tended to produce similar or higher 
power under MAR-1 compared to MCAR in all scenarios except pA = (.3, .5, .6, .8) and 
pB = (.8, .6, .5, .3) in which it produced lower power.  
The results are demonstrated in Table 3.7 when the missing data mechanism was assumed 
to be MAR-2. The results under MAR-2 were very similar to those under MCAR. All methods 
produced very close statistical power in detecting the treatment difference under the alternative 
hypothesis when both missing data mechanism of MCAR and MAR-2 were considered.   
Table 3.8 reported the simulation results to compare the proposed method with GEE and 
MERI approaches when the treatment by time interaction term is included for applying these 
methods. As expected and observed in Section 2.2.5, GEE and MERI methods achieved more 
power in some scenarios (i.e., pA= (.3, .5, .6, .8) and pB = (.8, .6, .5, .3), pA= (.4, .5, .6, .7) and 
pB = (.4, .4, .4, .4), pA= (.6, .6, .6, .6) and pB = (.6, .5, .4, .3)) compared to results in Table 3.7. 
Under these scenarios, powers of these methods are comparable with the proposed method when 
independent correlation structure is used and are higher than that of the proposed method in the 
presence of correlation among observations. For some scenarios (i.e., pA= (.4, .4, .4, .4) and 
pB = (.3, .3, .3, .3), pA= (.8, .8, .8, .8) and pB = (.7, .7, .7, .7), pA= (.7, .7, .7, .7) and 
pB = (.5, .5, .5, .5)), there is a decrease in power for GEE and MERI methods compared to results 
in Table 3.7. 
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Table 3.5: Power (%): Simulation results for comparing the methods with missing data. MCAR, missingness 
with same dropout rates for each group 
 Placebo Drug Crude  Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 85.4 6.0 60.0 72.2 64.2 31.4 29.4 32.0 36.2 28.0 
2 .4 .6 .7. 8 .4 .4 .4 .4 86.1 99.6 96.5 100 86.5 97.6 97.6 97.6 97.1 97.1 
3 .4 .5 .6 .7 .4 .4 .4 .4 47.0 82.5 70.4 96.3 50.9 71.4 71.6 71.4 71.0 69.2 
4 .7 .6 .5 .4 .4 .4 .4 .4 96.6 78.1 96.3 77.2 92.4 92.8 93.0 92.6 92.4 92.7 
5 .6 .7 .8 .9 .6 .6 .6 .6 47.2 87.4 71.8 98.3 53.8 76.6 76.8 76.4 77.2 74.7 
6 .8 .7 .7. 6 .8 .6 .5 .4 33.4 51.6 53.4 79.4 32.9 45.8 45.7 45.9 46.6 44.3 
7 .5 .6 .6. 7 .5 .4 .4 .3 75.7 97.4 92.1 100 77.0 93.1 93.0 93.1 93.0 92.7 
8 .7 .7 .8 .9 .7 .7 .6 .5 23.6 53.2 44.4 86.6 28.4 42.0 42.2 41.9 43.4 40.5 
9 .6 .6 .6 .6 .6 .5 .4. 3 46.6 83.1 70.8 97.2 50.2 70.2 70.6 70.2 70.6 68.4 
10 .4 .4 .4 .4 .3 .3 .3 .3 49.3 47.0 62.6 68.2 46.9 55.1 55.3 55.4 55.6 53.8 
11 .8 .8 .8 .8 .7 .7 .7 .7 52.6 47.6 69.2 75.9 53.3 61.4 61.7 61.6 62.4 60.4 
12 .7 .7 .7 .7 .5 .5 .5 .5 96.9 96.4 98.6 98.6 95.4 98.0 97.9 98.0 97.8 97.8 
13 .5 .5 .5 .5 .3 .3 .3 .3 97.0 96.4 99.0 8.6 94.9 98.4 98.4 98.5 98.1 98.4 
Exchangeable Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 65.2 5.8 39.9 48.8 46.8 20.4 27.6 27.3 37.2 29.4 
2 .4 .6 .7. 8 .4 .4 .4 .4 69.2 93.6 86.2 98.9 75.5 87.4 84.8 84.0 84.4 87.7 
3 .4 .5 .6 .7 .4 .4 .4 .4 34.0 62.2 53.0 83.8 39.8 51.0 48.1 50.2 50.5 52.6 
4 .7 .6 .5 .4 .4 .4 .4 .4 84.0 54.0 83.0 55.6 81.8 75.1 79.9 78.4 80.4 82.2 
5 .6 .7 .8 .9 .6 .6 .6 .6 34.2 66.8 57.4 92.8 42.6 57.6 50.1 53.9 52.4 59.0 
6 .8 .7 .7. 6 .8 .6 .5 .4 38.6 55.5 56.2 76.7 34.8 42.0 44.2 41.1 44.2 43.9 
7 .5 .6 .6. 7 .5 .4 .4 .3 54.7 84.8 74.1 96.2 59.7 71.8 69.4 68.2 70.0 72.1 
8 .7 .7 .8 .9 .7 .7 .6 .5 27.2 67.8 54.0 94.8 32.8 47.4 42.6 49.2 49.4 48.2 
9 .6 .6 .6 .6 .6 .5 .4. 3 38.5 67.3 57.2 85.8 38.3 49.2 46.0 47.1 47.9 48.3 
10 .4 .4 .4 .4 .3 .3 .3 .3 31.1 30.4 40.6 46.1 31.7 33.6 33.8 32.8 34.2 36.3 
11 .8 .8 .8 .8 .7 .7 .7 .7 39.4 33.8 54.8 60.1 39.4 40.1 40.6 40.2 42.0 46.0 
12 .7 .7 .7 .7 .5 .5 .5 .5 87.8 85.5 92.0 92.0 84.4 86.0 87.2 85.8 87.2 89.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 85.0 83.8 89.8 89.6 85.6 86.1 86.9 86.7 87.7 88.3 
Auto Regressive Correlation Structure 
1 .3 .5 .6 .8 .8 .6 .5 .3 70.8 7.0 46.1 52.4 50.9 20.6 31.4 28.6 35.6 33.0 
2 .4 .6 .7. 8 .4 .4 .4 .4 47.6 86.7 71.2 97.2 53.2 69.2 65.6 68.6 68.9 68.2 
3 .4 .5 .6 .7 .4 .4 .4 .4 19.2 49.8 35.3 78.0 22.0 31.4 29.5 32.8 33.1 31.6 
4 .7 .6 .5 .4 .4 .4 .4 .4 73.3 39.4 70.0 44.0 68.3 60.3 67.1 67.2 70.6 68.9 
5 .6 .7 .8 .9 .6 .6 .6 .6 19.2 50.0 36.1 78.6 24.7 34.8 28.8 36.2 37.3 35.7 
6 .8 .7 .7. 6 .8 .6 .5 .4 50.9 65.4 66.5 80.6 46.4 55.4 57.6 52.2 55.9 57.8 
7 .5 .6 .6. 7 .5 .4 .4 .3 53.5 87.8 74.4 97.2 60.2 74.6 70.0 71.4 72.5 73.6 
8 .7 .7 .8 .9 .7 .7 .6 .5 24.4 64.4 49.7 91.4 31.4 44.4 40.8 49.7 52.2 44.4 
9 .6 .6 .6 .6 .6 .5 .4. 3 48.2 77.1 68.0 92.0 50.6 63.2 59.4 57.4 59.0 63.4 
10 .4 .4 .4 .4 .3 .3 .3 .3 31.8 28.6 41.8 47.2 33.0 34.0 34.6 34.6 35.7 38.3 
11 .8 .8 .8 .8 .7 .7 .7 .7 37.6 34.2 50.0 52.6 39.0 40.4 40.8 40.0 41.8 45.4 
12 .7 .7 .7 .7 .5 .5 .5 .5 85.5 83.0 90.2 90.2 85.6 85.6 86.6 85.4 86.8 88.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 83.6 81.9 89.9 89.8 83.9 85.2 85.6 85.6 86.8 87.9 
Abbreviations are same as in Table 3.2. 
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Table 3.6: Power (%): Simulation results for comparing the methods with missing data. MAR-1, missingness 
with different dropout rates for each group 
Dropout rates:   Placebo: (0, 10%, 15%, 25%)             Drug   : (0, 6%, 10%, 16%)  
 Placebo Drug Crude  Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 83.8 10.2 60.4 70.2 50.8 23.5 21.3 24.2 28.5 20.0 
2 .4 .6 .7. 8 .4 .4 .4 .4 88.8 96.4 97.2 100 89.8 98.7 98.8 98.8 98.3 98.4 
3 .4 .5 .6 .7 .4 .4 .4 .4 51.0 86.7 71.8 96.8 54.4 77.0 76.8 76.8 77.0 75.0 
4 .7 .6 .5 .4 .4 .4 .4 .4 97.4 78.0 97.2 74.4 93.8 93.3 93.2 93.5 93.0 93.0 
5 .6 .7 .8 .9 .6 .6 .6 .6 41.2 80.0 71.1 99.0 56.0 82.0 82.0 81.8 81.5 80.0 
6 .8 .7 .7. 6 .8 .6 .5 .4 32.8 52.8 49.2 76.2 46.0 48.0 47.9 47.8 49.2 46.0 
7 .5 .6 .6. 7 .5 .4 .4 .3 78.9 98.5 91.8 99.8 83.6 94.6 94.4 94.5 94.2 94.2 
8 .7 .7 .8 .9 .7 .7 .6 .5 17.6 42.2 41.4 83.6 33.1 47.4 48.0 47.6 48.1 45.4 
9 .6 .6 .6 .6 .6 .5 .4. 3 52.8 87.6 71.4 96.0 61.6 76.6 76.8 76.5 76.0 75.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 58.2 59.2 63.4 68.2 48.8 55.3 55.6 55.6 95.8 54.4 
11 .8 .8 .8 .8 .7 .7 .7 .7 42.0 29.4 65.7 69.6 57.2 65.0 64.9 65.2 65.2 63.5 
12 .7 .7 .7 .7 .5 .5 .5 .5 96.2 94.9 98.7 98.5 95.8 98.4 98.3 98.4 98.4 98.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 97.9 98.0 98.9 98.7 95.8 98.4 98.4 98.4 98.4 98.3 
Exchangeable Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 61.7 6.4 40.0 47.2 35.6 16.0 22.0 20.5 29.4 23.4 
2 .4 .6 .7. 8 .4 .4 .4 .4 68.2 91.8 83.4 98.4 75.0 87.6 85.8 84.7 86.0 88.0 
3 .4 .5 .6 .7 .4 .4 .4 .4 38.0 62.6 53.2 83.2 43.4 54.8 52.7 53.2 54.1 56.3 
4 .7 .6 .5 .4 .4 .4 .4 .4 84.3 53.8 82.8 54.0 81.2 74.9 78.4 76.7 79.6 81.2 
5 .6 .7 .8 .9 .6 .6 .6 .6 26.5 51.4 49.3 88.2 43.6 59.7 52.7 56.9 56.0 61.4 
6 .8 .7 .7. 6 .8 .6 .5 .4 34.2 52.0 50.3 72.6 43.2 43.1 45.6 40.9 45.7 45.0 
7 .5 .6 .6. 7 .5 .4 .4 .3 56.9 86.2 71.9 95.2 63.8 74.0 71.2 70.8 73.1 74.6 
8 .7 .7 .8 .9 .7 .7 .6 .5 21.4 56.4 47.5 91.8 40.2 53.4 49.2 56.0 55.4 54.0 
9 .6 .6 .6 .6 .6 .5 .4. 3 38.0 71.4 54.4 85.2 43.0 50.7 47.8 48.0 48.6 50.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 41.8 41.7 47.7 50.0 35.8 35.4 36.8 36.2 38.3 40.0 
11 .8 .8 .8 .8 .7 .7 .7 .7 25.0 16.2 43.6 48.8 39.6 41.8 41.6 41.2 43.2 46.8 
12 .7 .7 .7 .7 .5 .5 .5 .5 84.0 80.0 91.0 90.0 86.2 86.2 87.6 86.4 88.0 89.7 
13 .5 .5 .5 .5 .3 .3 .3 .3 87.1 87.0 90.6 89.8 84.8 85.6 86.7 85.8 87.3 87.8 
Auto Regressive Correlation Structure 
1 .3 .5 .6 .8 .8 .6 .5 .3 64.2 11.0 46.0 52.4 39.4 17.3 25.0 23.6 30.7 26.6 
2 .4 .6 .7. 8 .4 .4 .4 .4 50.0 87.6 69.8 97.6 53.5 71.0 68.3 69.6 69.8 70.3 
3 .4 .5 .6 .7 .4 .4 .4 .4 25.4 56.4 39.2 80.4 24.8 36.0 34.0 37.6 36.8 36.6 
4 .7 .6 .5 .4 .4 .4 .4 .4 78.6 49.2 74.8 46.8 71.6 61.0 66.8 67.1 70.2 69.1 
5 .6 .7 .8 .9 .6 .6 .6 .6 18.4 43.4 34.2 73.9 30.1 42.6 37.4 43.0 43.1 42.4 
6 .8 .7 .7. 6 .8 .6 .5 .4 51.0 67.2 62.4 78.7 56.2 56.0 56.6 51.1 56.2 57.4 
7 .5 .6 .6. 7 .5 .4 .4 .3 59.6 91.8 74.0 97.8 64.8 75.6 71.5 71.6 73.0 75.0 
8 .7 .7 .8 .9 .7 .7 .6 .5 19.8 58.0 41.4 87.7 36.2 48.2 44.2 53.6 55.2 47.0 
9 .6 .6 .6 .6 .6 .5 .4. 3 53.4 82.0 67.4 91.3 59.2 65.0 61.9 59.3 62.2 65.6 
10 .4 .4 .4 .4 .3 .3 .3 .3 41.4 42.2 46.0 49.6 33.0 33.4 33.3 31.6 35.1 36.8 
11 .8 .8 .8 .8 .7 .7 .7 .7 26.4 19.6 39.3 41.7 41.1 41.6 41.5 40.9 42.6 47.9 
12 .7 .7 .7 .7 .5 .5 .5 .5 85.0 81.6 89.4 89.4 86.6 86.3 87.4 86.0 87.8 89.1 
13 .5 .5 .5 .5 .3 .3 .3 .3 89.2 88.2 91.8 91.2 85.4 85.6 85.7 85.0 86.5 88.4 
Abbreviations are same as in Table 3.2. 
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Table 3.7: Power (%): Simulation results for comparing the methods with missing data. MAR-2, missingness 
with same dropout rates for each group 
Dropout rates are equal for both groups :  (0, 10%, 15%, 25%)                     n = ( 60,  54,  46,  34 )  
 Placebo Drug Crude  Logistic t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 86.9 5.0 61.6 73.6 68.3 33.3 29.6 33.8 38.0 28.8 
2 .4 .6 .7. 8 .4 .4 .4 .4 86.6 99.6 97.4 100 85.2 98.0 98.0 98.0 97.4 97.5 
3 .4 .5 .6 .7 .4 .4 .4 .4 46.6 85.1 72.8 99.0 47.6 71.0 71.6 71.2 71.4 69.5 
4 .7 .6 .5 .4 .4 .4 .4 .4 97.4 78.8 97.7 80.6 94.0 95.3 95.1 95.2 94.8 95.0 
5 .6 .7 .8 .9 .6 .6 .6 .6 47.6 88.2 75.8 99.6 53.2 79.3 79.4 79.2 78.5 77.4 
6 .8 .7 .7. 6 .8 .6 .5 .4 50.4 74.8 54.6 79.4 54.0 67.5 67.4 67.4 67.6 65.8 
7 .5 .6 .6. 7 .5 .4 .4 .3 77.5 98.4 93.4 100 79.0 94.4 94.5 94.4 94.0 94.0 
8 .7 .7 .8 .9 .7 .7 .6 .5 40.8 90.7 47.7 89.4 51.6 76.1 76.2 76.0 77.3 74.1 
9 .6 .6 .6 .6 .6 .5 .4. 3 51.9 85.9 73.0 98.3 55.2 72.8 73.2 73.0 73.0 71.6 
10 .4 .4 .4 .4 .3 .3 .3 .3 51.0 49.6 65.4 72.0 48.4 55.4 55.8 55.2 56.2 54.6 
11 .8 .8 .8 .8 .7 .7 .7 .7 52.8 49.4 72.4 77.4 56.3 64.0 64.0 64.1 63.6 62.5 
12 .7 .7 .7 .7 .5 .5 .5 .5 97.4 97.8 99.3 99.3 96.2 98.6 98.6 98.6 98.8 98.6 
13 .5 .5 .5 .5 .3 .3 .3 .3 97.6 97.2 99.0 99.3 95.4 98.4 98.3 98.4 98.4 98.2 
Exchangeable Correlation Structure 
1 .3 .5 .6 .8 .8 .6 .5 .3 66.2 4.7 38.6 53.0 47.6 18.4 27.7 26.0 38.9 29.5 
2 .4 .6 .7. 8 .4 .4 .4 .4 67.2 93.6 87.5 99.2 71.8 87.8 84.4 84.0 84.0 86.8 
3 .4 .5 .6 .7 .4 .4 .4 .4 31.9 58.8 53.4 86.0 36.0 48.6 45.4 46.8 47.0 50.0 
4 .7 .6 .5 .4 .4 .4 .4 .4 84.6 52.9 84.5 57.4 80.4 76.6 80.8 78.8 81.3 83.0 
5 .6 .7 .8 .9 .6 .6 .6 .6 30.8 61.7 57.0 93.8 42.1 56.5 49.6 53.4 50.0 57.2 
6 .8 .7 .7. 6 .8 .6 .5 .4 38.8 57.8 56.4 79.0 38.6 42.9 46.7 41.6 46.6 45.1 
7 .5 .6 .6. 7 .5 .4 .4 .3 54.0 85.8 73.7 96.8 56.9 71.5 68.4 67.9 70.0 70.8 
8 .7 .7 .8 .9 .7 .7 .6 .5 28.2 69.2 57.7 97.2 37.5 51.4 47.8 54.0 52.6 51.9 
9 .6 .6 .6 .6 .6 .5 .4. 3 36.0 69.6 56.7 87.8 38.1 46.5 44.8 45.0 46.0 47.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 31.8 30.2 40.2 45.9 32.1 32.1 33.4 32.5 34.3 36.2 
11 .8 .8 .8 .8 .7 .7 .7 .7 38.6 33.2 58.1 64.1 41.2 42.9 43.8 43.2 44.4 48.6 
12 .7 .7 .7 .7 .5 .5 .5 .5 86.8 85.2 93.2 93.4 85.1 85.8 87.2 85.8 86.8 89.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 87.3 87.1 91.8 93.0 86.7 88.0 88.9 87.8 89.0 90.3 
Auto Regressive Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 68.9 6.4 41.9 54.0 46.8 19.6 30.2 27.4 33.0 31.0 
2 .4 .6 .7. 8 .4 .4 .4 .4 48.6 87.4 72.5 98.2 51.8 69.4 64.4 67.6 67.4 67.5 
3 .4 .5 .6 .7 .4 .4 .4 .4 19.2 52.1 37.0 84.2 21.0 29.6 28.0 32.0 31.4 31.2 
4 .7 .6 .5 .4 .4 .4 .4 .4 72.2 39.3 70.7 42.2 68.0 61.2 68.9 68.0 70.0 69.9 
5 .6 .7 .8 .9 .6 .6 .6 .6 20.0 50.8 40.0 84.0 27.2 38.4 32.1 39.2 39.1 37.8 
6 .8 .7 .7. 6 .8 .6 .5 .4 50.9 67.0 67.4 81.8 48.4 55.3 58.2 52.8 56.2 57.8 
7 .5 .6 .6. 7 .5 .4 .4 .3 54.0 89.8 74.0 97.3 59.0 73.6 68.0 69.0 70.4 72.3 
8 .7 .7 .8 .9 .7 .7 .6 .5 22.0 66.4 49.8 93.2 31.2 46.2 42.4 52.4 54.3 45.0 
9 .6 .6 .6 .6 .6 .5 .4. 3 49.3 77.8 66.5 92.0 52.6 62.2 58.4 56.9 58.6 62.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 31.2 28.1 40.1 46.1 31.6 32.6 33.4 33.2 33.8 37.1 
11 .8 .8 .8 .8 .7 .7 .7 .7 34.8 32.1 48.8 52.8 39.4 38.5 40.2 39.8 41.7 45.2 
12 .7 .7 .7 .7 .5 .5 .5 .5 87.6 85.9 92.2 91.4 87.4 87.9 88.4 87.6 88.6 89.7 
13 .5 .5 .5 .5 .3 .3 .3 .3 83.3 82.2 88.8 90.0 82.7 84.6 85.4 84.8 85.6 87.4 
Abbreviations are same as in Table 3.2. 
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Table 3.8: Power (%): Simulation results for comparing the methods with missing data and treatment by 
time interaction. MAR-2, missingness with same dropout rates for each group 
Dropout rates are equal for both groups : (0, 10%, 15%, 25%)     n = ( 60,  54,  46,  34 )  
 Placebo Drug PROPOSED t-test GEE MERI 
 p1 p2 p3 p4 p1 p2 p3 p4 I II  IND EX AR(1) UN  
Independent Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 87.4 4.0 65.0 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 87.5 99.4 87.2 99.8 99.8 99.8 99.6 99.8 
3 .4 .5 .6 .7 .4 .4 .4 .4 47.6 85.5 45.4 87.6 87.8 87.8 88.5 87.4 
4 .7 .6 .5 .4 .4 .4 .4 .4 97.0 78.6 93.2 95.6 95.6 95.6 95.6 95.7 
5 .6 .7 .8 .9 .6 .6 .6 .6 49.8 88.1 55.4 95.7 95.8 95.8 96.0 95.8 
6 .8 .7 .7. 6 .8 .6 .5 .4 50.7 73.8 53.7 70.2 70.5 70.2 71.2 70.4 
7 .5 .6 .6. 7 .5 .4 .4 .3 77.2 97.8 78.4 98.7 98.6 98.6 98.7 98.6 
8 .7 .7 .8 .9 .7 .7 .6 .5 37.5 89.7 51.2 98.4 98.4 98.4 98.4 98.2 
9 .6 .6 .6 .6 .6 .5 .4. 3 48.9 85.4 52.7 88.2 88.0 88.0 88.0 87.7 
10 .4 .4 .4 .4 .3 .3 .3 .3 50.8 48.2 45.8 42.8 42.8 43.0 44.0 41.2 
11 .8 .8 .8 .8 .7 .7 .7 .7 55.1 48.6 56.4 53.2 53.1 53.0 53.4 51.8 
12 .7 .7 .7 .7 .5 .5 .5 .5 97.6 96.9 95.8 96.6 96.6 96.6 96.4 96.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 97.1 97.6 95.4 96.2 96.1 96.0 96.0 95.8 
Exchangeable Correlation Structure 
1 .3 .5 .6 .8 .8 .6 .5 .3 65.0 4.6 47.8 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 66.8 93.6 70.6 98.2 98.8 98.5 98.9 89.3 
3 .4 .5 .6 .7 .4 .4 .4 .4 33.6 60.1 38.6 77.4 80.1 78.8 81.6 82.1 
4 .7 .6 .5 .4 .4 .4 .4 .4 82.6 54.2 79.4 90.4 90.4 89.6 90.4 91.6 
5 .6 .7 .8 .9 .6 .6 .6 .6 30.4 63.8 40.8 89.4 90.0 89.2 90.4 91.9 
6 .8 .7 .7. 6 .8 .6 .5 .4 39.2 57.4 39.3 55.3 60.3 54.9 60.5 60.3 
7 .5 .6 .6. 7 .5 .4 .4 .3 54.8 86.3 59.0 94.2 95.3 95.8 95.3 95.6 
8 .7 .7 .8 .9 .7 .7 .6 .5 25.2 65.9 34.5 95.4 96.0 95.4 96.0 96.4 
9 .6 .6 .6 .6 .6 .5 .4. 3 38.0 69.4 38.8 77.3 80.4 78.6 80.2 81.0 
10 .4 .4 .4 .4 .3 .3 .3 .3 32.0 30.0 32.6 22.6 24.6 23.8 26.0 26.8 
11 .8 .8 .8 .8 .7 .7 .7 .7 37.9 31.6 39.6 29.8 30.9 29.4 31.8 36.2 
12 .7 .7 .7 .7 .5 .5 .5 .5 87.7 85.6 85.4 77.0 78.1 77.2 79.5 82.2 
13 .5 .5 .5 .5 .3 .3 .3 .3 86.1 85.2 85.4 76.9 79.0 77.1 79.2 81.0 
Auto Regressive Correlation Structure  
1 .3 .5 .6 .8 .8 .6 .5 .3 70.2 6.7 50.2 100 100 100 100 100 
2 .4 .6 .7. 8 .4 .4 .4 .4 47.8 88.4 51.4 97.5 97.6 97.4 97.2 99.2 
3 .4 .5 .6 .7 .4 .4 .4 .4 17.8 51.6 20.0 74.7 76.4 71.7 72.8 84.0 
4 .7 .6 .5 .4 .4 .4 .4 .4 71.4 38.2 66.8 84.0 83.8 86.1 84.8 88.4 
5 .6 .7 .8 .9 .6 .6 .6 .6 19.2 51.1 25.8 89.3 88.6 86.0 86.2 92.3 
6 .8 .7 .7. 6 .8 .6 .5 .4 49.8 66.4 48.2 60.4 67.0 62.4 66.2 72.8 
7 .5 .6 .6. 7 .5 .4 .4 .3 51.5 88.2 57.4 96.1 96.8 96.6 96.8 98.0 
8 .7 .7 .8 .9 .7 .7 .6 .5 22.4 66.8 30.8 98.6 98.6 97.6 97.4 99.0 
9 .6 .6 .6 .6 .6 .5 .4. 3 48.0 78.4 50.8 83.6 85.8 85.8 86.2 90.2 
10 .4 .4 .4 .4 .3 .3 .3 .3 30.4 28.3 31.5 21.8 23.4 23.9 24.9 29.3 
11 .8 .8 .8 .8 .7 .7 .7 .7 39.8 36.4 43.8 32.7 34.1 32.6 35.4 41.3 
12 .7 .7 .7 .7 .5 .5 .5 .5 87.0 85.4 85.8 76.9 78.2 77.8 79.2 82.6 
13 .5 .5 .5 .5 .3 .3 .3 .3 85.6 83.6 83.5 77.2 76.8 76.8 78.4 81.7 
Abbreviations are same as in Table 3.2 except that Proposed, proposed method by applying “crude substitution 
approach” for score assignment to the vectors with missing data based on the ordering of strategies I and II. 
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3.5 CONCLUSION 
We compared the performance of our proposed method to other methods for analysis of 
longitudinal binary data in the presence of missing data via simulation study. The type I error 
rate of the proposed method with logistic regression substitution was considerably inflated so 
this method is not preferable. The type I error rate for MERI method was slightly inflated when 
the correlation structure is assumed to be exchangeable or AR(1). Other methods produced type I 
error rate reasonably close to the nominal value of 0.05.  
Under MCAR, MAR-1, and MAR-2 missing data mechanisms, simulation studies 
comparing the proposed method with other methods demonstrated that none of the approaches 
are uniformly better than the others in terms of power. All methods yielded very similar results 
for all scenarios under MCAR and MAR-2. Results obtained under MAR-1 were different for 
some scenarios. All method lost power in the presence of missing data but the lost in power is 
greater for t-test than other methods. Our proposed approach performs better/worse than the 
other approaches for some situations depending on strategies of ordering vectors and assigning 
scores to the vectors with missing data. The proposed method with crude substitution may be 
preferred method for some scenarios in which the proposed method gives higher empirical power 
and maintains control over the type I error rate.  
In most situations, our proposed method is competitive with other methods when data are 
not complete. We believe that our approach will be adaptable to multiple outcomes (intervention 
with other treatments, adverse side effects, and therapy with multiple effects).  
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4.0  METHODS OF RANKING VECTORS OF OBSERVATIONS 
Our proposed method is based on applying the Wilcoxon test statistic to vectors of repeated 
binary observations and events. The main requirement of applying the proposed method is to 
order vectors of observations in terms of meaningful importance. The ordering is determined by 
‘clinical relevance’. For some scenarios, clinically meaningful ordering of the vectors may be 
defined by a ‘natural algorithm’; while for other scenarios, the ordering could be obtained from a 
group of clinicians.  
If an agreement among clinicians with respect to ordering of the vectors of repeated 
observations is reached, it is reasonable to apply the proposed approach to the data to be 
analyzed. If there is no consensus among clinicians about orderings of vectors due to differences 
in opinion among clinicians, it might not be easy to interpret the results and to employ the 
proposed method in the analysis of the data (Follmann et al. 1992). On the other hand, it might 
be beneficial to obtain different rankings produced by a group of experts who have diverse 
backgrounds. In this case, data can be analyzed in different ways and a proper perspective can be 
obtained on the impact of variability of clinician assessment on study conclusions.  
In this chapter, we discuss natural algorithm and clinicians’ orderings with respect to 
obtaining the rankings of vectors of repeated observations. We apply the ordering algorithms to a 
clinical trial of the efficacy of treatment for children with acute otitis media (AOM). We measure 
the variability of orderings among clinicians and examine the effects of this heterogeneity in the 
analysis of the otitis media clinical trial data.  
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4.1 NATURAL ALGORITHM  
To demonstrate achievement of ordering vectors of observations, we present an illustration with 
a clinical trial comparing two treatment groups (e.g. drug versus placebo) to evaluate the effect 
of antibiotic treatment for children with acute otitis media to prevent AOM and to clear Middle 
Ear Effusion (MEE). Binary outcomes (1 = AOM or MEE, 0 = Disease-free) are obtained from 
each child for four time points which result in 16 possible profiles over time.  
We first rank the vectors according to the number of disease-free time points. A vector 
with 4 disease-free time points ranks higher than the one with 3 disease-free time points which 
ranks higher than a vector with 2 disease-free time points and so on. We assume, without loss of 
generality, that the lower rank score indicates poorer outcome. After applying the first criteria, 4 
vectors with one disease-free time points, 6 vectors with two disease-free time points, and 4 
vectors with three disease-free time points share separately the same tied rank scores. These tied 
ranks can be broken on the basis of time to occurrence of disease. We follow two different 
strategies to break ties.  
 Some trials expect to observe a rapid effect of antibiotic treatment and successful initial 
effect of therapy is important for these trials. Therefore, we break ties by considering earlier 
disease as a poorer outcome. Among the subjects who have the same number of time points with 
diseases, if the disease occurred earlier for the subject, then this subject has lower rank score than 
the one who had disease later (Table 4.1). For some trials, it can be important to examine 
subjects without disease at or near the end of the study so we can break ties by considering later 
diseases as poorer outcome. In this case, a subject who has disease earlier is assigned higher rank 
score than the one who has disease later (Table 4.2).  
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Table 4.1: Nested criteria for ordering of 16 possible outcomes, R=Rank 
Number of disease-free time points 
0 1 2 3 4 
R Profile R Profile R Profile R Profile R Profile 
1 [1 1 1 1] 2 [1 1 1 0] 6 [1 1 0 0] 12 [1 0 0 0] 16 [0 0 0 0] 
  3 [1 1 0 1] 7 [1 0 1 0] 13 [0 1 0 0]   
  4 [1 0 1 1] 8 [1 0 0 1] 14 [0 0 1 0]   
  5 [0 1 1 1] 9 [0 1 1 0] 15 [0 0 0 1]   
    10 [0 1 0 1]     
    11 [0 0 1 1]     
Algorithm: 
1. Rank first by number of disease-free time points 
2. Break ties by considering earlier disease as poorer outcome  
Lower rank is poorer outcome.  
 
  
 
Table 4.2: Nested criteria for ordering of 16 possible outcomes, R: Rank 
Number of disease-free time points 
0 1 2 3 4 
R Profile R Profile R Profile R Profile R Profile 
1 [1 1 1 1] 5 [1 1 1 0] 11 [1 1 0 0] 15 [1 0 0 0] 16 [0 0 0 0] 
  4 [1 1 0 1] 10 [1 0 1 0] 14 [0 1 0 0]   
  3 [1 0 1 1] 9 [1 0 0 1] 13 [0 0 1 0]   
  2 [0 1 1 1] 8 [0 1 1 0] 12 [0 0 0 1]   
    7 [0 1 0 1]     
    6 [0 0 1 1]     
Algorithm: 
1. Rank first by number of disease-free time points 
2. Break ties by considering later disease as poorer outcome  
Note: Lower rank is poorer outcome.   
 
Such a nested set of criteria should be very robust in assigning vector ranks and permits a 
priority to be assigned as to what type of differences are most important. Applying different 
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criteria generates different orderings. Note that a vector with 4 disease-free time points ranks as 
the best outcome and a vector with 4 disease episodes ranks as the worst outcome based on the 
both ordering criteria. Table 4.1 and Table 4.2 present ordering of possible outcomes based on 
the two different principles. 
  
4.2 CLINICIANS’ RANKINGS 
While ordering the vectors of repeated binary observations can be obtained by natural algorithm 
as the one just described, another approach to rank the outcomes is to ask a group of people who 
are expert in the area of study to order the vectors. Experts’ opinion and knowledge play an 
important role in the application of our proposed method. Experts can rank the vectors in order 
of clinically meaningful and relevant importance.  
4.2.1 Guidelines for Clinicians 
We collaborated with three clinicians who are knowledgeable about otitis media at Children’s 
Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC). We asked them 3 
scenarios related to otitis media. The following instructions were provided to them and each 
clinician independently ranked the outcomes: 
We are developing a statistical test to use in randomized clinical trials that will give more 
weight to clinical considerations. It is based on ranking a set of outcomes from lowest to highest 
in regard to which is “clinically the least or most desirable”. We are giving you a scenario and 
we would like you to answer the given questions. Note that there is no correct answer and “ties” 
are allowed in ranking your set of outcomes i.e. two different outcomes might be considered as 
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clinically equivalent. This will be asked to a number of clinicians because the extent of clinical 
variability is one of the important issues for us. 
Scenario 1: Children entering the study with MEE are given a treatment and followed for 
a period of time. Four measurements, one measurement/month, are taken for each patient over 
the four months. A determination is made at each visit whether child has effusion (“1”) in either 
ear or no effusion (“0”). For example, [1 0 0 1] would indicate effusion at the 1st and 4th visit and 
no effusion at visit 2 and 3 for a patient. We have the following 16 possible outcomes for the 4 
months of measurements which can be obtained from each patient at the end of the study. We 
would like you to rank these outcomes from 1 (the least desirable or worst) to 16 (the most 
desirable or best). Some of the outcomes might be clinically equivalent so that they might have 
the same ranking score. Is there any “algorithm” you used to rank outcomes? 
 
Table 4.3: Possible outcomes with 4 time points 
1 [1 1 1 1] 5 [0 1 1 1] 9 [0 1 1 0] 13 [0 1 0 0] 
2 [1 1 1 0] 6 [1 1 0 0] 10 [0 1 0 1] 14 [0 0 1 0] 
3 [1 1 0 1] 7 [1 0 1 0] 11 [0 0 1 1] 15 [0 0 0 1] 
4 [1 0 1 1] 8 [1 0 0 1] 12 [1 0 0 0] 16 [0 0 0 0] 
Thank you for your help. 
4.2.2 Clinicians’ Responses 
All three clinicians responded to questions and returned their answers to us. We present the 
responses of clinicians. Table 4.4 demonstrates the considerations clinicians applied to order the 
16 vectors for 4 measurements. They ordered the vectors based on these criteria. Scores assigned 
to the vectors by clinicians are shown in Table 4.5. 
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Table 4.4: Considerations applied by three clinicians for ordering the vectors 
Clinician A 
1. The longer time without relapse the better. 
2. An ideal treatment should prevent relapse.  
3. Consecutive months of MEE worse than MEE for the same number of months but 
separated by no MEE. 
Clinician B 
1. More visits with MEE worse. 
2. Those with MEE at the last visit would be worse than those without MEE at the 
last visit within each number of visits with MEE. 
Clinician C 
1. The more “0” the better. 
2. The less continuous the period of “1” the better. 
3. Prefer to see resolution at last visit. 
 
As presented in Table 4.4, they reached an agreement that more time points with diseases 
are worse outcome. They first ordered the vectors based on the number of time points with 
diseases. For example, all clinicians assigned the highest score to the vector with no disease and 
the lowest score to the vector with diseases over four time points if higher score is better. They 
followed different strategies to break ties for vectors which have the same number of time points 
with diseases. While clinician B and C ordered the vectors with three diseases (profiles 2-5) 
similarly, clinician A ordered them in a different way as shown in Table 4.5. For ordering 
vectors with one disease (profiles 12-15), clinician B and C considered later diseases as poorer 
outcome and ordered the vectors almost identical  while clinician A regarded vectors with earlier 
disease as poorer outcome and ordered the vectors opposite way. Clinicians assigned the same 
scores to the vectors when they considered that they are indeterminate. For example, Clinician C 
assigned the same score to some of the vectors with 2 diseases (profiles 6, 8, 9, and 10).          
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Table 4.5: Rank scores assigned by clinicians 
 
 
 
 
 
 
 
 
4.2.3 Clinicians Agreement  
The degree of agreement between each pair of clinicians can be measured using Spearman’s rank 
correlation. Table 4.6 shows correlations between the pairs of clinicians for rankings of 16 
vectors.  
High degree of agreement between clinicians was observed. Correlations between pairs 
of clinicians range from 0.887 to 0.936. The reason of observing high correlations among the 
clinicians is partly because they considered the more time points with diseases as worse 
outcome. For example, all three clinicians agreed that a child with 4 visits of disease ranks lower 
than the one with 3 visits of disease. All clinicians did not follow the same criteria for breaking 
ties so the reduction in correlation coefficients may have been due to this disagreement. For 
example, one of them preferred to see resolution at the earlier visits while two of them to see 
  Clinician (original) Clinician (adjusted) 
 Profile A B C A B C 
1 [1 1 1 1] 1 1 1 1 1 1 
2 [1 1 1 0] 2 4 5 2 5 5 
3 [1 1 0 1] 3 3 4 4 3.5 4 
4 [1 0 1 1] 3 3 3 4 3.5 3 
5 [0 1 1 1] 3 2 2 4 2 2 
6 [1 1 0 0] 4 6 7 6 7 8.5 
7 [1 0 1 0] 5 5 8 8 6 11 
8 [1 0 0 1] 5 8 7 8 10 8.5 
9 [0 1 1 0] 5 9 7 8 11 8.5 
10 [0 1 0 1] 6 7 7 10 8.5 8.5 
11 [0 0 1 1] 7 7 6 11 8.5 6 
12 [1 0 0 0] 8 13 11 12 15 15 
13 [0 1 0 0] 9 12 10 13 14 13.5 
14 [0 0 1 0] 10 11 10 14 13 13.5 
15 [0 0 0 1] 11 10 9 15 12 12 
16 [0 0 0 0] 12 14 12 16 16 16 
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resolution at the later visits within the same number of diseases, therefore, they broke ties by 
using different rules. In some instances, they could not clearly rank some of the profiles which 
led them to assign the same rank to the some vectors. 
 
Table 4.6: Correlations (Spearman) among clinicians 
Clinician A B C 
A 1   
B .911 1  
C .887 .936 1 
4.3 APPLICATION TO A CLINICAL STUDY 
We illustrate an application of our proposed method in the analysis of otitis media clinical trial 
data in which repeated observations were obtained at 5 unequally spaced time points over a 
period of time. We evaluate the ordering strategies consisting of a natural algorithm based on 
two different criteria and experts’ rankings produced by three clinicians. We also compare our 
proposed approach with the other three standard methods. 
4.3.1 Data Description 
The motivating data of this study come from a randomized trial evaluating the effect of a 
treatment of acute otitis media for children between 7 months and 12 years of age. The trial, 
reported by Mandel, et al. (1995), compared 20 days of antimicrobial treatment versus the 
standard 10 days of amoxicillin treatment for children with AOM to prevent recurrences of AOM 
and to resolve the occurrence of middle ear effusion and also to determine if it is beneficial to 
change the antimicrobial agent after initial 10-day treatment with amoxicillin.  
  77 
The study was designed as a placebo-controlled, double-blinded, randomized clinical 
trial. Patients were stratified according to their age (7-23 months, 2-6 years, and 7-12 years), 
laterality of effusion (unilateral or bilateral), and history of AOM during the previous year (0, 1-
2, 3+ episodes). In the first 10 days of the trial, all patients were given an initial dose of 
amoxicillin. In the second 10 days of the study (days 11 through 20), available two hundred and 
sixty seven children with AOM at entry were randomly assigned to receive one of the three 
treatment medications: 1) 88 children continued taking amoxicillin, 2) 86 children received 
amoxicillin-clavulanete (Augmentin), and 3) 93 children received a placebo. Follow-up 
assessments of examination of the ears, nose, and throat of each patient were scheduled at 10, 20, 
30, 60, and 90 days after entry. Since all subjects were given the same treatment in the first 10 
days, we assumed that the 20-day assessment time point was considered as the first time point so 
that there are 4 follow-up time points included in the analysis. 
Of the patients lost to follow up prior to the 10-day assessment (2 in the Amoxicillin 
group, 4 in the Augmentin group, and 4 in the placebo group), 3 patients discontinued the study 
with unknown reasons and 7 patients were released from the study due to recurrence of 
symptoms of acute infection before the end of the initial 10-day course of amoxicillin. 3 patients 
were withdrawn before the 20-day assessment, one in each treatment group. A total of 13 
patients were excluded from the analysis. Table 4.7 displays the overview of the missing data 
patterns by treatment group. Although the total number of patients in this trial was 267, the 
number of subjects who had complete data at all time points was 201. In addition to 13 patients 
excluded from the study, 30 patients were lost to follow-up after the 20-day assessment: 6 of 
them before 30-day, 16 of them before 60-day, and 8 of them before 90-day assessments. 23 
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patients missed only one of four visits during the period of the trial: 8 missed at the 20-day, 9 
missed at the 30-day, and 6 missed at the 60-day assessments.  
 
Table 4.7: Overview of missing data: Number of subjects in each missing data pattern 
Assessment (days) Number of Subjects by Treatment Group  
20 30 60 90 Amoxicillin Augmentin Placebo Total 
Completers     
O O O O 68 67 66 201 
Dropouts  
O O O M 1 3 4 8 
O O M M 6 3 7 16 
O M M M 2 2 2 6 
M M M M 1 1 1 3 
Intermittent  
M O O O 5 2 1 8 
O M O O 1 2 6 9 
O O M O 2 2 2 6 
(O: Observed, M: Missing) 
 
Table 4.8 summarizes frequency of the observed profiles for four time points in the 
dataset. Of the 74 patients who completed all scheduled visits without any diseases, 37%, 35%, 
and 28% of them were in the Amoxicillin, Augmentin, and Placebo groups, respectively. Among 
the 61 patients whose measurements at all time points were observed and who had only one visit 
with disease, the proportion of patients in Amoxicillin, Augmentin, and Placebo groups were  
31%, 39%, and 30%, respectively. Of the 31 patients who had 2 visits with disease and 2 visits 
without disease, the proportion of patients in Placebo (48%) was higher than the proportions of 
patients in Amoxicillin (29%) and Augmentin (23%) groups. The more patients were observed in 
Placebo (39%) and Amoxicillin (35%) groups compared to those in Augmentin group (26%) 
among the patients who had only one visit without disease over four time points.  
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Table 4.8: Frequencies: Observed profiles by treatment groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 1 = Disease; 0 = Disease-free; • = Missing 
 
 Assessment (days) Frequency  
 20 30 60 90 Treatment Groups  
 Profile Amoxicillin Augmentin Placebo Total 
1 0 0 0 0 27 26 21 74 
2 0 0 0 1 5 6 7 18 
3 0 0 1 0 7 8 4 19 
4 0 1 0 0 3 8 0 11 
5 1 0 0 0 4 2 7 3 
6 0 0 1 1 3 2 2 7 
7 0 1 0 1 2 1 0 3 
8 0 1 1 0 1 0 1 2 
9 1 0 0 1 1 3 1 5 
10 1 0 1 0 0 0 3 3 
11 1 1 0 0 2 1 8 11 
12 0 1 1 1 1 3 2 6 
13 1 0 1 1 1 0 0 1 
14 1 1 0 1 2 0 3 5 
15 1 1 1 0 4 3 4 11 
16 1 1 1 1 5 4 3 12 
17 0 0 1 • 0 0 1 1 
18 0 1 1 • 0 3 0 3 
19 1 0 1 • 0 0 3 3 
20 1 1 1 • 1 0 0 1 
21 0 0 • • 0 2 0 2 
22 0 1 • • 4 0 3 7 
23 1 0 • • 1 0 0 1 
24 1 1 • • 1 1 3 5 
25 0 • • • 0 2 1 3 
26 1 • • • 2 0 1 3 
27 • 0 0 0 2 1 1 4 
28 • 0 1 1 1 1 0 2 
29 • 1 1 1 2 0 0 2 
30 0 • 0 0 1 2 1 4 
31 0 • 1 1 0 0 1 1 
32 1 • 0 0 0 0 2 2 
33 1 • 0 1 0 0 1 1 
34 1 • 1 1 0 0 1 1 
35 0 0 • 0 2 0 1 3 
36 0 1 • 0 0 1 0 1 
37 1 0 • 0 0 1 0 1 
38 1 1 • 0 0 0 1 1 
39 • 1 • • 0 0 1 1 
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All possible profiles with missing values were not observed in this dataset (e.g., [1 • 1 •] was not 
observed) and there was no particular profile with missing values that occurred mainly over 
groups. 
4.3.2 Data Analysis Results 
Since our purpose is to illustrate the application of the proposed method in analyzing data, we 
restrict attention to the comparison of two treatment groups (Augmentin versus Placebo). We 
considered the rankings produced by natural algorithm and clinicians’ opinion to order to the 
vectors and employed the proposed method to the data using each of these orderings.  
We applied the approach given in Section 3.2.2.1 to assign scores to the vectors with 
missing observations using the scores assigned to the complete vectors presented in Table 4.1, 
Table 4.2, and Table 4.3. We used the fact that missing response value would have been 1 
(disease) or 0 (no disease) if it was measured. We assumed that the probability of observing 
disease and that of observing no disease are equal if that missing value had been obtained. For 
example, to assign a score to the vector [0 0 1 •], the probability of obtaining [0 0 1 1] is equal to 
that of obtaining [0 0 1 0] and thus, simple average of the scores of [0 0 1 1] and [0 0 1 0] is 
assigned to [0 0 1 •]. In other words, the probabilities in equations (3.6) and (3.7) are chosen as 
0.5. Table 4.9 demonstrates the scores assigned to the vectors with missing values using the 
scores in Table 4.1, Table 4.2, and Table 4.3.      
The analyses present the results of comparing the treatment effect using the proposed 
method with different ordering strategies achieved by natural algorithm and clinicians’ opinion 
and the t-test comparing the proportions of diseases between the two treatment groups are 
presented in Table 4.10. Table 4.11 shows the analyses results from the GEE and Mixed Effects 
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Table 4.9: Scores assigned to the profiles with missing values 
Observed  Natural Algorithm Clinicians 
Profile  Possibilities 1 2 A B C 
[1 1 1 •] { R(1111) + R(1110) }  / 2 1.5 1.5 1.5 2.5 3 
[1 1 0 •] { R(1101) + R(1100) }  / 2 4.5 7.5 3.5 4.5 5.5 
[1 0 1 •] { R(1011) + R(1010) }  / 2 5.5 6.5 4 4 5.5 
[1 0 0 •] { R(1001) + R(1000) }  / 2 10 11.5 6.5 10.5 9 
[0 1 1 •] { R(0111) + R(0110) }  / 2 7 5.5 4 5.5 4.5 
[0 1 0 •] { R(0101) + R(0100) }  / 2 11.5 10.5 7.5 9.5 8.5 
[0 0 1 •] { R(0011) + R(0010) }  / 2 12.5 9.5 8.5 9 8 
[0 0 0 •] { R(0001) + R(0000) }  / 2 15.5 14 11.5 12 10.5 
[1 1 • •] { R(111 •) + R(110 •) } / 2 3 4.5 2.5 3.5 4.25 
[1 0 • •] { R(101 •) + R(100 •) } / 2 7.75 9.25 5.25 7.25 7.25 
[0 1 • •] { R(011 •) + R(010 •) } / 2 9.25 8 5.75 7.5 6.5 
[0 0 • •] { R(001 •) + R(000 •) } / 2 14 11.75 10 10.5 9.25 
[• 1 • •] { R(11 • •) + R(01 • •) }/ 2 6.125 6.25 4.125 5.5 5.375 
[1 • • •] { R(11 • •) + R(10 • •) }/ 2 5.375 6.875 3.875 5.375 5.75 
[0 • • •] { R(01 • •) + R(00 • •) }/ 2 11.625 9.875 7.875 9 7.875 
[• 1 1 1] { R(1111) +  R(0111) } / 2 3 1.5 2 1.5 1.5 
[• 0 1 1] { R(1011) +  R(0011) } / 2 7.5 4.5 5 5 4.5 
[• 0 0 0] { R(1000) +  R(0000) } / 2 14 15.5 10 13.5 11.5 
[1 • 1 1] { R(1111) +  R(1011) } / 2 2.5 2 2 2 2 
[1 • 0 0] { R(1100) +  R(1000) } / 2 9 13 6 9.5 9 
[0 • 1 1] { R(0111) +  R(0011) } / 2 8 4 5 4.5 4 
[0 • 0 0] { R(0100) +  R(0000) } / 2 14.5 15 10.5 13 11 
[1 • 0 1] { R(1101) +  R(1001) } / 2  5.5 6 4 5.5 5.5 
[1 1 • 0] { R(1110) +  R(1100) } / 2 4 8 3 5 6 
[1 0 • 0] { R(1010) +  R(1000) } / 2 9.5 12.5 6.5 9 9.5 
[0 1 • 0] { R(0110) +  R(0100) } / 2 11 11.5 7 10.5 8.5 
[0 0 • 0] { R(0010) +  R(0000) } / 2 15 14.5 11 12.5 11 
R ([]): rank score of the vector [] 
 
Model using the available data. While Wilcoxon tests produced significant treatment differences 
based on the ranking of natural algorithm 1, clinician A, and clinician B, the treatment 
comparison was not significant from the analysis when the ordering was achieved by natural 
algorithm 2. A borderline statistically significant difference (𝜒12 =3.22, p=0.0725) was found 
between the two treatment groups when the analysis was performed based on the ordering of 
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clinician C. A two-sample t-test comparing the average of the proportion of disease over time 
yielded a significant treatment difference with p=0.0369.  
 
Table 4.10: Data analysis results from the proposed method and two sample t-test 
 Method of Analysis 
 Proposed Method t-test 
 Natural Algorithm Clinician  
1 2 A B C  
Test Statistic 5.29 2.73 4.76 4.72 3.22 2.10 
p value 0.0215 0.0987 0.0292 0.0299 0.0725 0.0369 
 
 
Based on the main effects models testing the overall treatment effect over time, GEE and 
mixed effects logistic regression with random intercept methods yielded statistically significant 
treatment effect with p=0.0273 and p=0.0477, respectively. GEE and mixed effects logistic 
regression approaches produced significant treatment by time interaction effect (Table 4.11). 
The results based on the rankings of clinician A and B were similar because the rankings 
of these two clinicians are highly correlated. While the proposed method produced significant 
treatment difference based on the ordering of clinician A, the result was not significant based on 
the ordering of clinician C. The reason may be because clinician A and clinician B applied 
different algorithm to break ties. Even though high correlation between the rankings of clinician 
B and C is observed, the treatment difference was significant based on the rankings of clinician 
B but not clinician C. The reason of obtaining different results from clinician B and clinician C 
can be explained by the fact that they broke the ties for vectors with 2 diseases in a different way. 
Different ordering strategies produced different results as the proposed method yielded different 
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results based on the natural algorithm 1 and 2. As a summary, the levels of statistical significance 
of the proposed method were competitive at least with those of the other standard methods.  
 
Table 4.11: Data analysis results from GEE and mixed effects logistic regression model 
Main Effects Model 
 Marginal Model GEE Mixed Effects Model 
 Estimate SE p value Estimate SE p value 
Treatment (Augmentin) -0.48 0.2191 0.0273 -0.56 0.2801 0.0477 
Time (days) -0.003 0.0032 0.2924 -0.004 0.0036 0.2432 
Main and Interaction Effects Model 
 Marginal Model GEE Mixed Effects Model 
Treatment (Augmentin) -1.17 0.3795 0.0021 -1.41 0.4584 0.0024 
Time (days) -0.01 0.0046 0.0338 -0.013 0.0051 0.0148 
Treatment*Time   0.014 0.0062 0.0242   0.018 0.0074 0.0174 
4.4 CONCLUSION 
We presented several methods of ordering the vectors of observations. Ordering strategies 
obtained by natural algorithm and from a group of clinicians were applied to the otitis media 
clinical trial. We compared the results obtained from the proposed method using natural 
algorithm and clinicians’ ordering schemes with those produced by other methods. Results of the 
analysis show that the proposed method provides results similar to those obtained from other 
methods. We can conclude that our proposed method is competitive with other methods. Also, 
our proposed approach is adaptable to missing data.   
As shown in Table 4.1 and Table 4.5, clinician A ranked the vectors very similar to the 
natural algorithm 1 which orders the vectors by the number of time points with disease and the 
earlier time to occurrence of disease. As presented in Table 4.10, the proposed method using 
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these two orderings produced very similar results. If clinician B and C had followed the same 
strategies as clinician A to order the vectors, one general algorithm would be created (i.e., natural 
algorithm 1) and this algorithm would be used for the analysis. In other words, when a good 
agreement among the clinicians with respect to ordering of the vectors is attained, general 
algorithm can be developed based on the clinicians’ ordering (Bjorling et al. 1997). This 
established algorithm can be used as a reference for similar studies. 
The feasibility of our proposed method depends on the degree of agreement among 
clinicians with respect to the ordering of the vectors of repeated binary observations. When 
clinicians’ rankings are inconsistent with each other, it might be difficult to apply the proposed 
approach. One could use a specific ordering algorithm to evaluate the treatment effect, draw 
conclusion about treatment use, and interpret the results based on this ordering scheme. In this 
situation, consensus among the clinicians is not important (Brittain et al. 1997).  
In clinical trials, some subjects withdraw the study and the reasons for dropping out can 
be available for these subjects. For example, subjects leave the study due to a lack of treatment 
effect or adverse effects. Even though we did not incorporate the reasons of withdrawal in the 
analysis of otitis media trial, these informative missing data can be easily incorporated into our 
approach by ranking the vectors with missing data according to the reasons of withdrawal 
(Modification of Gould’s Method, Section 3.2.2.2). Our approach can handle this type of missing 
data while incorporating informative missing data into the analysis may be sophisticated for 
other methods (GEE, MERI).  
Even though all methods had similar results for this one dataset, it may not be the case in 
general. The simulation results showed that depending on the pattern of differences our proposed 
method can be a lot worse or a lot better than conventional methods. Present dataset had 
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interactions over time. Therefore we believe that for some diseases and some situations, there 
will be differences where our method will have an advantage because clinically important 
differences are being targeted.  
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5.0  REPEATED BINARY MEASURES WITH MULTIPLE OUTCOMES 
Clinical trials are often planned to compare two treatments (e.g., drug compared with a placebo) 
using repeated binary measurements over time and in general, a treatment effect is evaluated 
based on one response variable of interest. Additionally, several outcomes can be observed in 
such studies and these outcomes may cause different clinical influences on subjects. It may not 
be appropriate to evaluate the overall treatment effect without accounting for these occurrences. 
Using analyses based on single outcome may not capture all aspects of outcome to assess the 
overall effects of therapies under study and it may increase the risk of drawing improper 
conclusions. This chapter focuses on the proposed method in evaluating a treatment effect from 
longitudinal binary data with multiple outcomes.  
5.1 MULTIPLE OUTCOMES AND EVENTS 
In clinical studies, multiple outcomes may arise (e.g., AOM, MEE, or none in otitis media trial) 
and many symptoms may occur due to the progression of the disease in addition to single 
primary outcome (1=disease, 0=disease-free). Moreover, some undesirable effects of the therapy 
which could have an impact on patients’ quality of life may occur besides the benefits of the 
treatment. In some studies in which the effect of treatment declines over time or patients are 
unresponsive to the assigned therapy, it might be necessary to change the therapy. Also, some 
subjects prematurely withdraw the study and comparison of treatments may be affected if the 
patterns or circumstance of dropouts are different between the treatment groups. To effectively 
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evaluate a treatment effect, it is important to incorporate occurrences developing during the study 
such as different responses, serious side-effects, and ‘need for clinical intervention’ which can 
influence outcomes.  
In the presence of such occurrences, an overall evaluation of the treatment effect is not 
adequately determined by examining individual response because the related information about 
the treatment effect from various events is not considered (Gray and Brookmeyer 1998). While 
treatment groups are statistically compared in terms of main outcome, examination of qualitative 
findings and other possible responses that might reveal clinically meaningful difference must be 
included in the analyses. The proposed method allows the assessment of overall treatment effect 
in presence of these occurrences. It has the flexibility to integrate information across multiple 
events. The objective of this chapter is to discuss the proposed method for analyzing this type of 
longitudinal data and to demonstrate how to adapt the proposed method in distinguishing 
“clinically relevant difference”. We illustrate adjustment of the proposed method with an 
example using data from otitis media clinical trial.  
5.1.1 Adverse Effects and Need for Clinical Intervention  
In clinical trials, patients may experience several occurrences during the course of the trial such 
as serious adverse effects, insufficient effectiveness of treatment, and allergic reaction to the 
therapy. Although a treatment has a positive effect on a primary outcome, it can have a severe 
negative effect on another body system. It may be required to give a non-protocol clinical 
intervention or another treatment to the patients who experience serious side effects or are 
unresponsive to the medical treatment. The requirement of giving another therapy or intervention 
may result in a drastic change in the primary outcome and interfere with the study results. On the 
  88 
other hand, a therapy, for example, may cause side effects yet has generally positive effect. If 
subjects who drop out due to adverse effects of therapy are not included in the analysis, 
favorable information about the effectiveness of the treatment may be ignored.       
When treatment and placebo are being compared, it is not uncommon that the placebo 
group has a lower rate of improvement of progression of disease than the treatment group. 
Therefore, non-protocol intervention may be necessary for subjects receiving placebo. Different 
rates of interventions in the treatment groups may result in the improper comparison of treatment 
groups and an incorrect conclusion that treatment is not preferable to placebo may be reached. 
For example, in a clinical trial of otitis media comparing the effect of antibiotic in children with 
acute otitis media, children in placebo group are more likely to need tube insertion than those in 
the treatment group to prevent fluid in their ears due to insufficient therapeutic effect. If a 
considerable number of children in the placebo group receives tube, effusion will not be 
observed and a desirable response will be obtained for these children. Ignoring a large number of 
tube insertions in the placebo group can lead to a misleading conclusion that treatment is not 
effective. Nevertheless, tube placement clinically is not regarded as a good outcome. 
In placebo-controlled studies, it is not unexpected that subjects in the treatment group 
may have lack of therapeutic effects or intolerable side effects. It might be required to give 
another therapy to the subjects who have experienced adverse effects of study treatment. 
Responses from subjects who had been randomly assigned to treatment group but received 
different therapy because of unpleasant side effects would not be similar to the responses from 
the subjects who did not change the assigned therapy. This results in difficulties in comparing 
treatment groups.  
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In such trials, it is important to accommodate these occurrences and qualitative measures, 
which are observed during the trial, to draw proper inferences and results. The relative benefits 
and side-effects of treatment must be weighed to evaluate the overall effect of the therapy. It 
would be useful to incorporate such events into the analysis in a way that preserves the clinical 
relevance of the outcomes. The proposed approach can be adaptable to such occurrences. 
5.1.2 Clustered Data 
In some studies, clustering of observational units arises and this induces dependence among the 
responses of the same cluster. For example, the left and right eyes of individual patients are 
evaluated for the examination of eye illnesses in the ophthalmology studies. In otitis media 
clinical trials where patients are followed over time after the initiation of antimicrobial treatment, 
measurements are obtained separately from each ear of a subject to assess the symptoms of acute 
infection. Since ears are clustered within subjects, the data are doubly nested. In this situation, 
two types of correlation are inherent: the correlation between ears or eyes of the same subject 
and the correlation between the measurements taken on each subject at different time points. 
Type I error rate is inflated or biased results may be obtained if an analysis ignores the 
correlation between the ears clustered within the same subjects (Hedeker and Gibbons 2006). 
Methods must account for the correlations that exist between measurements taken from each 
subject both at the same time and across time. 
Analyzing this type of data would be a challenge for some of the standard methods. For 
example, applying the GEE procedure to this kind of dataset could be appropriate however, this 
method would require a complicated correlation structure (Lefkopoulou et al. 1989). Even though 
the GEE method is robust against misspecification of correlation structure, it is important to 
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choose an appropriate correlation structure before performing GEE as incorrect choice of 
correlation structure causes a reduction in efficiency (Hedeker and Gibbons 2006). Our proposed 
method is a simpler approach and adaptable to handle this sort of data nested twice.  
For example, in a clinical trial for assessing the efficacy of antibiotic in children with 
AOM, a child who has experienced unsatisfactory treatment effects and has had bilateral 
effusion is more likely to have hearing loss which may damage language and cognitive 
development during early childhood than the one who has unilateral effusion because unaffected 
ear can prevent complete hearing loss (Bluestone and Klein 2001).  
Furthermore, otitis media with effusion (OME) is defined as an inflammation of the 
middle ear with fluid without signs or symptoms of acute infection. Bilateral OME for 3 months 
or more may result in tube placement regardless of hearing loss. If a child with unilateral OME 
for 6 months or more has significant hearing loss, language and learning problems, or middle ear 
abnormalities, placement of a tube would be appropriate to prevent OME and to improve hearing 
to reduce the risk for language and learning problems (Alper et al. 2004). Since tube placement, 
which is clinically considered a poor outcome, is required for children with long standing 
bilateral OME more than for those with unilateral OME, bilateral effusion is a different and 
worse outcome than the unilateral effusion, thus, they should be considered as separate 
outcomes. The proposed method has the ability to differentiate the difference between these two 
outcomes so that it accounts for correlation that occurs between observations within subject.      
5.1.3 Categorical Data 
Even though clinical trials are designed to measure the effect of the treatment on a single 
outcome, treatments have different impacts on patients. It is of importance to distinguish the 
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possible outcomes a patient may have in such trials. The effect of treatment is sometimes 
evaluated on each separate outcome using standard approaches. For example, in a trial of 
treatments for otitis media, therapy is given to subjects to improve several different outcomes 
such as prevention of AOM and resolution of MEE in the middle ear. Treatment effect is 
evaluated based on each individual response variable. One could count separately the total 
number of AOM and MEE episodes over time for each subject and compare the proportions of 
time with AOM and MEE between the two treatment groups to test the null hypothesis of no 
treatment effect on each outcome. Even though evaluating individual responses gives useful 
information about the treatment effect, it does not provide a single overall evaluation of the 
treatment effect. This crude analysis also results in the inflation of the experimentwise error rate.  
Since AOM is a worse outcome than MEE, one could consider treating outcome as 
ordinal data and apply GEE or mixed effects models to analyze longitudinal ordinal data. 
However, these analyses may not have enough statistical power to detect the effects of interest 
between two treatment groups if adequate frequencies of AOM or MEE are not observed. 
Infrequent sparse cells can be collapsed into one category due to the rare occurrence of AOM 
and MEE but collapsing categories can result in a loss of information. The proposed method does 
not suffer from such limitations. We can adapt our approach to analyze data with this type of 
outcome to detect clinically meaningful treatment effect without sacrificing information.    
5.2 ADAPTATION OF THE PROPOSED METHOD 
In the previous section, we discussed the possible outcomes which can occur in clinical studies 
besides a main outcome. Our proposed method can be adapted to accommodate these 
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occurrences as long as vectors of binary observations with multiple outcomes and adverse effects 
can be clinically ranked. If clinicians can order the vectors in a clinically relevant manner and 
consensus among clinicians about rankings is obtained, the proposed method can be easily 
applied to the data. In the absence of agreement among clinicians, interpretation of the results 
may not be easy and the proposed method may not be beneficially applied. However, a method 
could be employed incorporating the variability among clinicians (e.g. bootsraping clinical 
response) or enough weight might be obtained to develop an empirical algorithm for ranking 
outcomes (e.g. the disagreements might be considered as ties)  We present clinicians’ responses 
for complex situations and use the information from them to employ the proposed method to the 
otitis media data. 
5.2.1 Clinicians’ Opinion 
As discussed in the previous chapter, we obtained input from clinicians about ordering binary 
outcomes in Scenario 1, Section 4.2.1. We asked them to order vectors of observations for more 
complex scenarios. We present the rest of the instructions provided to three clinicians to order 
the vectors with multiple outcomes. 
5.2.1.1 Guidelines for Clinicians  
Scenario 2: Consider Scenario 1 with two modifications: 
1) The trial is six months  
2) If the treatment is not effective, the child receives tubes.   
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Thus we could have outcomes like [1 1 1 1 T T] which would indicate effusion at the first 
four visits and tube is inserted by visit five. How would you incorporate tubes into the ranking 
process?  What are the clinical criteria you use to place tubes? 
Scenario 3: We now address a more complicated algorithm. Specifically, we incorporate AOM 
into Scenario 1. We address this more complicated scenario in two steps:   
Step 1 – For a fixed pattern in Scenario 1, e.g. [1101], is there a simple way to order the 
outcomes with AOM superimposed within this MEE pattern? Thus, order 
1 [1  1   0   1] 
2 [A 1   0   1] 
3 [1  A  0   1] 
4 [1  1   0  A] 
5 [A A  0   1] 
6 [A 1   0  A] 
7 [1  A  0  A] 
8 [A A  0  A] 
where A indicates AOM. 
Is there a general algorithm you are applying?   
Step 2 – Are there any suggestions you have for ordering AOM superimposed on 
different patterns?  
e.g.  Pattern 1111 and 1110 
         1111 ↔   A1A0    less MEE but more AOM 
Any insight you have as to a general algorithm for these types of comparisons would be 
useful. 
Thank you for your help. We believe this could eventually result in a better procedure to 
analyze studies of patients with MEE. 
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5.2.1.2 Clinicians’ Responses 
Table 5.1 presents the responses from three clinicians for Scenario 2 about tube intervention. All 
clinicians agreed fairly well with each other regarding the tube insertion. It can be interpreted as 
tube placement is considered a poor outcome because patients who are unresponsive to medical 
treatment are likely to be given a tube. Also, it is worth noting that bilateral effusion is a different 
outcome than unilateral effusion since one of the criteria for placing tube for patients is to have 
3-6 months of effusion depending on the bilateral or unilateral. Therefore, it is important to 
account for this distinction between bilateral and unilateral effusion in the analysis. 
 
Table 5.1: Responses from 3 clinicians for Scenario 2 
Clinician A 
Tube would be worse than 6 months of effusion. 
Clinician B 
Functionally, [1111-11] would be (or may be) worse than [1111-TT], as hearing would most likely 
be within the normal range with tubes but may not be with effusion. The minimum criteria for 
undergoing tympanostomy tube insertion for OME is >3 months of bilateral effusion or >6 months 
unilateral effusion, unresponsive to medical treatment and not improving. Such factors as age of the 
child, hearing status, season, presence of developmental/school problems, also enter into the 
decision of whether or not to recommend tube placement. 
Clinician C 
1. ≥ 3-6 months continuous effusion especially if bilateral not improving and especially if 
significant hearing deficit 
2. Might also lean more about tubes if there was apparent and relevant patient discomfort. In 
reality, clinically this is more likely to occur in the presence of superimposed recurrent AOM. 
 
 
Table 5.2 illustrates the ordering of outcomes with AOM superimposed to MEE by three 
clinicians. Considerations suggested by them for ordering 8 vectors are given in Table 5.3. They 
reached a consensus about comparing AOM and MEE. They preferred MEE to AOM and agreed 
that AOM is worse outcome than MEE. All clinicians first order the vectors according to the 
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number of AOM which shows a high degree of consensus about importance of observing AOM 
or MEE. 
Based on clinicians’ considerations, a vector with 3 AOM is the worst outcome and a 
vector without AOM is the best outcome among these 8 trajectories. While Clinicians A and B 
did not break the ties in terms of time to occurrence of AOM, Clinician C considered the time to 
occurrence of AOM in the ordering and broke the ties based on this criterion. It is stated that 
other factors such as age and period of language development influence ordering the vectors with 
AOM and MEE. 
 
Table 5.2: Rank scores for Scenario 3 by clinicians 
  Clinician 
 Profile A B C 
1 [A A  0 A] 1 1 1 
2 [1  A  0 A] 3 3 2 
3 [A 1   0 A] 3 3 4 
4 [A A  0  1] 3 3 3 
5 [1  1   0 A] 6 6 7 
6 [1  A  0  1] 6 6 6 
7 [A 1   0  1] 6 6 5 
8 [1  1   0  1] 8 8 8 
 
 
A consensus may not be achieved when comparing a vector including one type of 
outcome with a vector including another type of outcome when there are different numbers of 
points of diseases. For example, it might be difficult to order vectors [1100] and [A000] as 
clinician C addressed in Table 5.3. One question to ask clinicians would be how many time 
points with MEE would be better, worse or equal to how many time points with AOM. For 
example, three time points with MEE over four time points ([1110]) is worse outcome than the 1 
time point with AOM ([A000]) based on the evaluation of clinician C. As a result, consensus 
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among clinicians may not be reached if rankings are applied to different type of outcomes. In this 
situation, the same scores are assigned to some vectors in the absence of agreement. 
 
Table 5.3: Responses from clinicians for Scenario 3 and Step 2 
Clinician A 
AOM is worse than MEE. It’s painful. I would rather have a child with OME for many months 
before opting for AOM. The age of the child also matters. If it is during language development and 
if the MEE is bilateral, it is worse. 
Clinician B 
AOM is more disruptive to the family and child than OME (in most cases), so the more the episodes 
of AOM, the worse the course. 
Clinician C 
A1A0 is worse than 1110. 
What about A000 vs. 1100? i.e. is any acute worse by diffusion? How much effusion? 
A000 vs. 1100 is difficult but feel A000 is worse because it requires antibiotic with attendant costs, 
potential adverse effects, etc patient discomfort to AOM. But I would consider 1110 worse than 
A000 because of continuous effusion. 
5.3 AN ILLUSTRATION: OTITIS MEDIA TRIAL 
Algorithms can be developed to take into account simultaneously whether disease status was 
none, fluid (MEE), infection (AOM); unilateral or bilateral disease; number of time points of 
disease and early disease versus late disease. Some hierarchy including all possible outcomes is 
defined and the outcomes are considered from top to bottom to assign scores to the subjects. We 
create a set of criteria for ranking vectors of observations with multiple outcomes for otitis media 
trial based on the clinicians’ responses presented above. We illustrate how our proposed method 
can be adjusted to the complex scenarios using this information. Table 5.4 depicts a set of 
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criteria. Based on the criteria given in Table 5.4, Bilateral AOM would be the worst outcome 
which can be observed at any time point. 
 
Table 5.4: Criteria for ranking outcomes 
1. AOM is worse outcome than MEE 
2. Bilateral AOM (MEE) is worse than unilateral AOM (MEE) 
3. Tube placement is considered as poor outcome 
 
 
Children with AOM entering the otitis media trial where subjects are assessed over 4 time 
points may have one of the three possible outcomes at any time point: AOM, MEE, or none in 
their one or both ears. Seven possible outcomes which can be observed in the otitis media trial 
are given in Table 5.5. If multiple outcomes were not considered and only one response is 
evaluated as disease (1 = AOM, MEE, unilateral or bilateral) or not disease (0 = none), patients 
1-4 and patients 5-7 would seperately share the same tied rank value. However, these tied ranks 
are broken on the basis of distinguishing these possible outcomes. For example, patient 2 who 
had bilateral effusion for the first two time points but remained effusion free for the last two 
time points would be considered as having worse outcome than patient 1 who had unilateral 
effusion for the first two points and stayed effusion free for the last two time points. Therefore, 
patient 2 is assigned a lower rank score than patient 1 when higher rank score is better. In the 
same manner, patient 4 is assigned a lower score than patient 3 because bilateral AOM are 
observed for patient 4 while unilateral AOM are observed for patient 3 in the first two time 
points. Therefore, a child with bilateral effusion ranks lower than a child with unilateral 
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effusion. These rank scores reflect relative ordering of the outcomes. Patients can be assigned 
different scores with respect to unilateral or bilateral outcome. 
Even though patient 1 and 3 did not have disease-free observations for the first two time 
points, patient 3 experienced 2 AOM while patient 1 experienced 2 MEE. Since AOM is 
regarded as worse outcome than MEE, patient 3 has a lower rank score than patient 1. Our 
proposed method can incorporate categorical outcomes in the analysis. Among the first four 
patients, patient 4 is assigned the lowest rank score due to the both AOM and bilateral. 
Comparing patient 3 and 6 may be indeterminate. The reason is that clinicians might not agree 
that 2 AOM is worse than 3 MEE although 2 AOM is worse outcome than 2 MEE. Comparing 
patient 4 and 7 may be uncertain due to the same reason. Therefore, the same score can be 
assigned to the vectors if they are not precisely ordered. Patient 5 would have the lowest score 
among these 7 trajectories because the tube was placed after the 3rd time points. The reason of 
observing no disease at the 4th time point for patient 5 is tube insertion which interferes with 
outcome.     
 
Table 5.5: Representation of trajectories from 7 patients form otitis media trial 
Patient ID Trajectories Score 
1     [MEE             MEE                 0                       0] 4 
2     [MEE-b          MEE-b             0                       0] 3 
3     [AOM            AOM                0                       0] 2 
4     [AOM-b         AOM-b            0                       0] 1 
5     [MEE             MEE-b          MEE-b      T        0] 0 
6     [MEE             MEE             MEE                    0] 2 
7     [MEE-b         MEE-b          MEE                    0] 1 
MEE-b denotes bilateral MEE, AOM-b denotes bilateral AOM, and T denotes tube insertion. 
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5.4 CONCLUSION 
We discussed how to adapt our proposed method in studies where several outcomes and 
occurrences are observed in addition to main outcome. The proposed method has the flexibility 
to incorporate these occurrences in the analysis but it might be difficult to employ the proposed 
method for some situations where there are different numbers of points of diseases and different 
type of outcomes because ordering vectors can be burdensome for clinicians. Even though 
clinicians rank the vectors in clinical relevant manner, there may not be a consensus among 
clinicians. However, the proposed method can still be applied by using specific individual 
ordering and in this case; interpretation is made based on this particular ordering. In some 
situations, enough weight might be calculated for each vector from clinicians’ ranking to develop 
an algorithm or tied values are assigned in the absence of agreement. 
On the other hand, the proposed method can be adjusted to extremely complex situations 
if a ‘hierarchy’ of criteria of ordering vectors can be applied. If vectors can be ordered in 
reasonable way, the proposed method can be easily applied. Also it can be readily adapted to 
accommodate non-protocol ‘outcomes’ (tube insertion in the otitis media trial).    
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6.0  DISCUSSION 
The purpose of this study is to develop a family of statistical tests based on the Wilcoxon test 
statistic which orders the vectors of repeated binary observations and events where the ordering 
is determined by “clinical relevance”. Our simulation studies indicate that the proposed method 
has statistical power competitive with and, for some scenarios, is preferable to conventional 
methods in the absence and presence of missing data. The real data analysis (otitis media trial) 
also shows that the proposed method and other methods give similar results indicating that the 
proposed method is appropriate and adaptable to missing data. 
Although the proposed method is not applicable to every situation, we believe that for 
some diseases and scenarios, this easy-to-apply, simple method is noteworthy in the sense that it 
can be adjusted to extremely complex situations if vectors can be hierarchically ordered in a 
reasonable fashion, it can be focused on alternatives that have high clinical relevance, and it can 
be readily adapted to accommodate non-protocol “outcomes” and missing data. Another 
advantage of the proposed approach is that no distributional assumptions are made and no 
assumptions are required regarding correlation among the observations.   
While the proposed method has advantages, there are a few limitations. Some outcomes 
may be difficult to order or clinicians order the vectors in different ways which result in 
disagreement among clinicians. However, same scores might be assigned to the vectors which 
are not easily ordered or disagreement among clinicians can be considered as ties. Another 
disadvantage of the proposed method might be that for long term follow-up, ranking of all 
possible ‘theoretical’ outcomes may not be feasible or may be burdensome for clinicians. For 
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example, there are 28 = 256 possible outcomes if the number of time points is 8. However, in 
real life, all possible outcomes may not be observed (e.g. Section 4.3.1 otitis media clinical trial).  
The proposed method with crude substitution approach was found to have statistical 
power comparable to other methods and to control the type I error rate reasonably close the 
nominal value of 0.05 depending on the ordering strategies in the presence of missing data in our 
simulation studies. However, simulation studies suggest that the proposed method with logistic 
regression substitution approach is not preferable due to the inflation of type I error rate. We 
believe that the logistic regression substitution approach can be improved by further 
investigations to control the type I error rate. 
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